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Background: People with multimorbidity experience impaired quality of life, poor health and a burden
from treatment. Their care is often disease-focused rather than patient-centred and tailored to their
individual needs.
Objective: To implement and evaluate a patient-centred intervention to improve the management of
patients with multimorbidity in general practice.
Design: Pragmatic, cluster randomised controlled trial with parallel process and economic evaluations. Practices
were centrally randomised by a statistician blind to practice identifiers, using a computer-generated algorithm.
Setting: Thirty-three general practices in three areas of England and Scotland.
Participants: Practices had at least 4500 patients and two general practitioners (GPs) and used the EMIS
(Egton Medical Information Systems) computer system. Patients were aged ≥ 18 years with three or more
long-term conditions.
Interventions: The 3D (Dimensions of health, Depression and Drugs) intervention was designed to offer
patients continuity of care with a named GP, replacing separate reviews of each long-term condition with
comprehensive reviews every 6 months. These focused on individualising care to address patients’ main
problems, attention to quality of life, depression and polypharmacy and on disease control and agreeing
treatment plans. Control practices provided usual care.
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Outcome measures: Primary outcome – health-related quality of life (assessed using the EuroQol-5
Dimensions, five-level version) after 15 months. Secondary outcomes – measures of illness burden,
treatment burden and patient-centred care. We assessed cost-effectiveness from a NHS and a social
care perspective.
Results: Thirty-three practices (1546 patients) were randomised from May to December 2015 [16 practices
(797 patients) to the 3D intervention, 17 practices (749 patients) to usual care]. All participants were
included in the primary outcome analysis by imputing missing data. There was no evidence of difference
between trial arms in health-related quality of life {adjusted difference in means 0.00 [95% confidence
interval (CI) –0.02 to 0.02]; p = 0.93}, illness burden or treatment burden. However, patients reported
significant benefits from the 3D intervention in all measures of patient-centred care. Qualitative data
suggested that both patients and staff welcomed having more time, continuity of care and the patient-
centred approach. The economic analysis found no meaningful differences between the intervention and
usual care in either quality-adjusted life-years [(QALYs) adjusted mean QALY difference 0.007, 95% CI
–0.009 to 0.023] or costs (adjusted mean difference £126, 95% CI –£739 to £991), with wide uncertainty
around point estimates. The cost-effectiveness acceptability curve suggested that the intervention was
unlikely to be either more or less cost-effective than usual care. Seventy-eight patients died (46 in the
intervention arm and 32 in the usual-care arm), with no evidence of difference between trial arms; no
deaths appeared to be associated with the intervention.
Limitations: In this pragmatic trial, the implementation of the intervention was incomplete: 49% of
patients received two 3D reviews over 15 months, whereas 75% received at least one review.
Conclusions: The 3D approach reflected international consensus about how to improve care for multimorbidity.
Although it achieved the aim of providing more patient-centred care, this was not associated with benefits
in quality of life, illness burden or treatment burden. The intervention was no more or less cost-effective
than usual care. Modifications to the 3D approach might improve its effectiveness. Evaluation is needed
based on whole-system change over a longer period of time.
Trial registration: Current Controlled Trials ISRCTN06180958.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Services and
Delivery Research programme and will be published in full in Health Services and Delivery Research; Vol. 7,
No. 5. See the NIHR Journals Library website for further project information.
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Plain English summary
Some people have several long-term health conditions (called ‘multimorbidity’). They often have poorquality of life and may need to take lots of drugs and attend numerous medical appointments.
These patients say that their care is not joined up and that they may not be treated as a whole person.
We tried to improve care by designing the 3D (Dimensions of health, Depression and Drugs) approach.
Instead of separate appointments for each health condition, patients got a 6-monthly review to consider
all their problems together, with one general practitioner taking responsibility for their care. The review
focused on patients’ needs, their quality of life and their mental as well as their physical health, and tried
to simplify their medication. Patients were also given an agreed written plan for their future care.
We tested this approach in 33 general practices. Sixteen practices picked at random were trained to provide
the 3D approach and the other 17 continued with usual care. In these practices, 1546 adult patients with
three or more long-term health conditions took part. We looked at the costs and benefits of the 3D approach
compared with usual care over 15 months. We also interviewed patients and staff to find out how the
approach worked in practice.
The 3D approach puts into practice many ideas that are currently recommended to improve care for patients
with multimorbidity. Patients and staff liked the approach, although practices struggled to introduce these
new ways of working. The 3D approach did not lead to improved quality of life or health or reduce the
number of drugs prescribed or appointments attended. However, patients did say that care was more joined
up and better at treating them as a whole person, and 3D was provided at little additional cost. Providing
care in a way that patients prefer could be sufficient justification for rolling out the 3D approach more widely.
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Scientific summary
Background
Health-care systems internationally have sought to improve care for patients with long-term conditions
using guidelines for each condition. However, many patients have multiple long-term conditions
(‘multimorbidity’), and a different approach may be needed for these patients.
Patients with multimorbidity have poor quality of life owing to the impact of their health conditions (‘illness
burden’). They are more likely to have poor mental health, which is not always recognised. In general practice,
patients with multimorbidity are repeatedly invited for reviews of their health conditions, prescribed large
numbers of drugs and expected to make lifestyle changes, meaning that treatment itself is burdensome.
Patients with multimorbidity also report a lack of patient-centred care. They see different health professionals,
with poor continuity and co-ordination of care. Clinicians tend to focus on biomedical topics rather than
addressing the problems that matter most to patients.
The number of people with multimorbidity is a major challenge to health systems worldwide, as they
account for a high proportion of health and social care expenditure.
Policy documents from many different countries have recommended a new approach to care for people
with multimorbidity. There is consensus that care should be based on a patient-centred model. This should
incorporate an individualised approach that addresses patient needs, continuity of care, attention to quality
of life and mental health as well as disease control, and a reduction in inappropriate polypharmacy. There
should be greater partnership with patients to help them self-manage their conditions based on sharing
information and agreeing goals and actions in a written care plan. Although these ideas are broadly
accepted, there is little evidence to show their effectiveness, either as individual strategies or when used
in combination to improve care for patients with multimorbidity. A recent systematic review highlighted
the need for further trials of interventions in multimorbidity (Smith SM, Wallace E, O’Dowd T, Fortin M.
Interventions for improving outcomes in patients with multimorbidity in primary care and community
settings. Cochrane Database Syst Rev 2016;3:CD006560).
Aim and hypothesis
Our aim was to optimise, implement and evaluate an intervention to improve the management of patients
with multimorbidity in general practice. We hypothesised that this intervention would improve patient
health-related quality of life, reduce the burden of illness and treatment and improve patient-centred care,
while being more cost-effective than current usual care.
Methods
Design
Pragmatic, cluster randomised controlled trial comparing the 3D (Dimensions of health, Depression and
Drugs) approach with usual care in general practice.
We conducted a parallel mixed-methods process evaluation and an economic evaluation from the
perspectives of (1) the NHS and Personal Social Services (PSS) and (2) patients.
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Setting
Thirty-three general practices in three areas of England and Scotland to maximise generalisability.
Participants
Practices used the EMIS (Egton Medical Information Systems) computer system and had a minimum of
4500 patients and two general practitioners (GPs). Eligible patients were aged ≥ 18 years with three
or more long-term conditions. We kept exclusion criteria to a minimum.
Patient recruitment and practice randomisation
The target sample size was 1382 participants. We used MIQUEST (Morbidity Information Query and Export
Syntax) to identify eligible patients. After screening by GPs, we invited a random sample of 150 patients
per practice. The statistician used a bespoke computerised algorithm to randomly assign practices to the
3D intervention or usual care, blind to practice identifiers, with block randomisation stratified by area and
minimised by practice deprivation and list size. Patients were informed of their allocation after recruitment
and practice randomisation.
Intervention and comparison
Intervention design was informed by previous research, consultation with patients, clinicians and policy-
makers, and international recommendations about how to organise improved care for multimorbidity.
We used a logic model outlining problems experienced by patients with multimorbidity and recommended
strategies to address those problems and how to operationalise those strategies in practices.
The 3D intervention was based on a patient-centred care model. This sought to improve continuity,
co-ordination and efficiency of care by replacing disease-focused reviews of each health condition with
one 6-monthly comprehensive review with a named GP. Each 3D review consisted of two appointments
(with a nurse and then a GP) and a remote review of medication by a pharmacist. The nurse consultation
focused on addressing the health problems that were most important to the patient, giving attention to
quality of life and screening patients for depression. The pharmacist reviewed medication from medical
records, aiming to simplify and optimise the treatment. The aim of the GP consultation was to agree a
health plan with the patient, a printed copy of which was given to the patient. The 3D review used a
computer template, which reinforced the patient-centred structure and was interactive, including different
questions depending on a patient’s combination of health conditions.
We used strategies to encourage implementation, including training, monthly feedback about
implementation and financial incentives for completed reviews.
Practices in the control arm continued to provide care as usual. Patients’ reviews mainly focused on
meeting the requirements of the Quality and Outcomes Framework (QOF).
Outcome measures
Outcomes were collected at baseline and at 9 and 15 months after patient recruitment. The primary
outcome was health-related quality of life measured by the Euroqol-5 Dimensions, five-level version
(EQ-5D-5L) at 15 months. Secondary outcomes included measures of illness burden, treatment burden
and patient-centred care. Key measures of the process of care, such as continuity, were included as
intermediate outcomes. We also collected quantitative data about implementation of the intervention.
We investigated the cause and expectedness of deaths and any possible association with the intervention.
Outcomes were collected and analysed blind to allocation when possible.
Analysis
Patients were analysed in the groups in which their participating practices were allocated (‘intention to treat’).
For analysis of the primary outcome, deceased patients were given an EQ-5D-5L value of zero and missing data
were imputed. All outcomes were analysed in multilevel regression models, which included adjustment for
baseline measures of the outcome, stratification and minimisation variables and practice as a random effect.
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Economic analysis
In a cost–consequences analysis we related the cost of the intervention or usual care to changes in a range
of outcomes; the cost-effectiveness analysis from the NHS and PSS perspective estimated the incremental
cost per quality-adjusted life-year (QALY) gain and the net mean benefit at a threshold of £20,000 per
QALY. Uncertainty was addressed in sensitivity analyses.
Process evaluation
Our process evaluation explored the initial response of the practices to the training, the delivery of the
intervention to patients, patient and professional perceptions of the intervention, the maintenance of
the intervention over time and how practice context influenced these issues. We combined quantitative
data about intervention delivery with qualitative data from various sources, including patients (and carers),
health professionals and administrative staff, and commissioners. We undertook a case study design to
understand how the intervention was delivered at five practices, as well as more focused qualitative data
collection at five additional practices. We undertook postal and telephone surveys of all practices to
understand usual care at baseline.
Patient and public involvement
An active group of up to 14 patients and carers provided a service user perspective, contributing to the
refinement of the research questions, the design of the intervention, the design of outcome measures,
the analysis of qualitative data, patient newsletters, the study website and the interpretation of findings.
Results
Recruitment and baseline characteristics
Between May and December 2015, 33 practices (1546 patients) were randomised [16 practices
(797 patients) to the 3D intervention, 17 practices (749 patients) to usual care].
Primary outcome
Primary outcome data were provided by 1346 (88%) participants at 15 months. There was no evidence
of difference between trial arms in health-related quality of life [adjusted difference in means 0.00, 95%
confidence interval (CI) –0.02 to 0.02; p-value = 0.93]. This finding was robust to a range of sensitivity
analyses. In a complier-average causal effect analysis we found no evidence that the intervention was more
effective in patients who received two 3D reviews as planned. We found no evidence that the effect was
moderated by patient age, deprivation, baseline quality of life or number of long-term conditions.
Illness burden
There was no evidence of difference between intervention and usual-care arms in respect of self-rated
health, anxiety or depression, or illness burden.
Treatment burden
Using a new measure of treatment burden developed for this study, we found no evidence that the
intervention reduced treatment burden. There was no evidence of difference in medication adherence,
the number of drugs prescribed or the number of indicators of potentially inappropriate prescribing.
Patient-centred care
All measures of patient-centred care showed benefits from the intervention after 15 months. These benefits
included the Patient Assessment of Chronic Illness Care Scale (PACIC) measure (adjusted mean difference
0.29, 95% CI 0.16 to 0.41; p < 0.001), the Consultation and Relational Empathy (CARE) measure of
relational empathy (adjusted mean difference 1.44, 95% CI 0.47 to 2.41; p = 0.01 for GP and adjusted
mean difference 1.11, 95% CI 0.03 to 2.19; p = 0.043 for nurse), the proportion of patients reporting care
related to their priorities [odds ratio (OR) 1.85, 95% CI 1.44 to 2.38; p < 0.001], those reporting care as
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joined up (OR 1.48, 95% CI 1.18 to 1.85; p = 0.001), those reporting a written care plan (OR 1.97, 95% CI
1.32 to 2.95; p = 0.001) and overall satisfaction with care (OR 1.57, 95% CI 1.19 to 2.08; p = 0.001).
Process measures
There was an improvement in continuity of care in the intervention arm compared with in the usual-care
arm, which was statistically significant using the Continuity of Care index (adjusted mean difference 0.08,
95% CI 0.02 to 0.13; p = 0.004) but not using the newer Visit Entropy measure (p = 0.065). There was no
evidence of difference between intervention and usual care in QOF indicators.
Patients in the intervention arm had more nurse consultations and slightly more GP consultations over
15 months than patients in the usual-care arm (incident rate ratios – nurse 1.37, 95% CI 1.17 to 1.61,
p < 0.001; and GP 1.13, 95% CI 1.02 to 1.21, p = 0.021). There was no evidence of difference in the
number of hospital admissions or outpatient attendances.
Carers
We recruited 145 carers of patients participating in the trial and explored the impact of the intervention on
carers’ quality of life, experience and treatment burden. In this small substudy (which had limited power to
detect differences between trial arms), no differences were observed in respect of carers’ quality of life or
treatment burden. However, carers in the 3D intervention arm reported improved experience of caring
using a scale that measures topics such as feeling supported with caring, feeling in control and fulfilment
from caring.
Patient safety
During the trial 5.0% (78/1546) of patients died. There was no evidence of difference in the number of
deaths between the intervention and usual-care arms and none of the deaths appeared to be related to
the intervention.
Implementation of the intervention
Implementation of the intervention was incomplete. Half (49%) of the patients received two complete
3D reviews over 15 months as intended, whereas another 26% had one review. Three-quarters (76%)
of patients had a review of medication and 77% of those who had a GP review were given a printed
health plan.
Economic analysis
The economic evaluation confirmed that patients with multimorbidity require considerable expenditure
from the NHS and social services. There were small and not meaningful or statistically significant increases
in both cost and QALYs in the intervention arm compared with the usual-care arm [mean cost £6140
intervention, £6014 usual care; adjusted mean difference £126 (95% CI £–739 to £991); adjusted mean
QALY difference 0.007 (95% CI –0.009 to 0.023)]. The incremental cost-effectiveness ratio was £18,499
with a 50.8% probability that the intervention was cost-effective at a threshold of £20,000 per QALY. This
provides evidence that the intervention was unlikely to be either more or less cost-effective than usual care
at this cost-effectiveness threshold.
There was no significant difference in the costs incurred by patients from the intervention compared with
usual care (mean difference £33, 95% CI –£35 to £101).
Process evaluation
Patients and practice staff were generally supportive of the 3D intervention. Qualitative data suggested that
both patients and staff welcomed the patient-centred approach. However, practices found it difficult to
organise the paired doctor and nurse consultations. Some patients received 3D reviews as well as, rather
than instead of, usual disease-focused reviews. Patients strongly appreciated continuity of care, and practice
staff agreed in principle but found this difficult to organise. Staff also questioned the appropriateness and
feasibility of offering more time to multimorbid patients. Patients valued the comprehensive 3D reviews,
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although practice staff had mixed views, particularly nurses who had training only in specific long-term
conditions. Many nurses felt uncomfortable screening for depression. The pharmacist review was valued by
patients and doctors, although pharmacists tended to ensure that treatment followed guidelines rather than
simplifying medication as intended. Agreeing health plans was unfamiliar for both patients and doctors, and
plans tended to be driven by a GP’s agenda. Practice staff found it difficult to adjust to the 3D template and
the need to concentrate on the computer tended to mitigate against a patient-centred consultation. Several
doctors and nurses questioned the need for a 3D review every 6 months.
Conclusions
This is the largest trial conducted of an intervention to improve the management of multimorbidity in
general practice. The 3D intervention is based on patient-centred principles that are widely recommended
in international guidelines. Our rigorous, pragmatic trial provides robust evidence about effectiveness.
The 3D trial achieved the aim of delivering more patient-centred care, but this was not associated with
improvements in health-related quality of life, illness burden or treatment burden. However, it was
delivered at no significant increase in cost and was similarly cost-effective to usual care.
The 3D intervention was not fully implemented, with only about half of the participants receiving two 3D
reviews as intended. Some problems with implementation were caused by a new approach being delivered
to a small number of patients in each practice for a limited time within the context of a trial. To assess fully
the benefits of 3D may require a whole-practice organisational change sustained over several years.
Implications for health care
The 3D intervention was designed to implement a range of strategies that are widely advocated to improve
the management of multimorbidity. In conjunction with findings from earlier studies, we can conclude that
these approaches are likely to have little impact on health-related quality of life in the short term, although
they do improve patient-centred care. Some have argued that providing patient-centred care in a way that
patients prefer, and which addresses the problems that matter to them most, should be a priority on ethical
grounds, and we have shown that this approach can be delivered at little additional cost. The effectiveness
of 3D could probably be improved through refinement of the intervention, better training for practice staff
and better patient targeting. Effectiveness in terms of quality of life may also become apparent over time,
as changes in treatment and self-management have an impact.
Recommendations for research
1. Future studies to determine the impact of new systems of care for multimorbidity should be based on
whole-system change and long-term patient follow-up.
2. Interventions to effectively simplify drug regimes in patients with polypharmacy need to be developed
and evaluated.
3. Research is needed to test the effectiveness of interventions to reduce treatment burden.
4. There is a need for new measures of benefit from improved management in primary care, which reflect
outcomes that are important to patients and sensitive to change.
5. Evidence synthesis is needed to understand the features of organisational interventions to improve
primary health care that are associated with an impact on quality of life.
6. Research is needed to understand the extent to which patients value concepts, such as patient-centred
care compared with quality of life, and the trade-offs they are prepared to make between them.
Trial registration
This trial is registered as ISRCTN06180958.
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Chapter 1 Introduction
Background
In an attempt to improve the quality of care of long-term conditions in general practice, care has become
increasingly driven by standardised protocols, which are delivered using computerised templates by practice
nurses. These nurses often have extra training in specific diseases and provide care within disease-specific
clinics (e.g. diabetic clinics), which focus on one disease at a time. Primary care clinicians in the UK are
incentivised through the NHS Quality and Outcomes Framework (QOF) to achieve targets relating to a
limited number of specific long-term conditions. Disease pathways for a range of long-term conditions have
been developed to improve vertical integration across primary and secondary care.
These developments fail to take account of the fact that many people have multiple long-term conditions
(multimorbidity).1,2 Sometimes these comorbid conditions have a bigger impact on the patient’s quality of
life than any single condition being addressed at a nurse-led chronic disease management clinic. The
priorities and incentives for the health professionals dealing with a specific disease may or may not align
with the priorities of the patient.3 Treating patients along care pathways for each disease can mean that one
patient is under the care of multiple clinical teams, with little co-ordination between them, and is issued
with several different care plans, which can cause confusion, especially if they contain conflicting advice.
Prevalence
The prevalence of multimorbidity depends on how the concept is defined and measured.4 Multimorbidity is
usually defined as the presence of two or more long-term conditions in the same individual, but prevalence
will depend on the conditions that are included. Recent UK studies have found that 16% of adults in
England had two or more diagnoses from a list of 17 major conditions,2 whereas 23% of people in Scotland
had two or more from a list of 40 conditions.1 A consistent (and unsurprising) finding in all studies is that
multimorbidity is much more common in older people,1,2 so this issue is increasingly important owing to the
ageing population. The number of people with at least one long-term condition is expected to increase
from 15 million in 2009 to 18 million by 2025,5 and the number with multimorbidity is expected to increase
from 1.9 million in 2008 to 2.9 million in 2018 at an additional cost to the NHS in England and Wales of £5B.6
Illness burden
Multimorbidity is important because people affected carry a substantial burden of illness. Patients with
multimorbidity are more likely to have poor quality of life7,8 and this is sometimes associated with chronic
pain, functional impairment and frailty. They also have a reduced life-expectancy.9
As well as having an impact on physical health, multimorbidity is also associated with an increased
prevalence of depression.10 The King’s Fund has estimated that at least 30% of people with a long-term
physical condition also have a mental health problem, and 46% of people with a mental health problem
also have a physical health problem.11 The relationship between physical and mental health in both
directions is reciprocal: people with chronic illnesses are more likely to be depressed and those who are
depressed are less likely to manage their long-term conditions well, leading to worse disease control and
poorer health outcomes.12 The association between poor physical health and poor mental health is
particularly strong in people with multimorbidity. Gunn et al.10 have shown that the number of long-term
conditions is more predictive of the prevalence of depression than any particular individual condition.
People with multimorbidity and depression are also more likely to have unplanned hospital admissions.13
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Treatment burden
Having multimorbidity generates work for the patient to manage their multiple conditions, a phenomenon
described as ‘treatment burden’.14 For patients with multimorbidity, the single-disease approach is inconvenient
and inefficient, because they are repeatedly invited to different disease-focused appointments in general
practice, where they are asked the same questions and given the same advice (or sometimes conflicting advice,
which can be confusing).3,15–17 Patients may receive inferior quality of care if the specialist nurse is not aware
of the impact of the treatment of one disease on other diseases, which can be a particular problem with
drug interactions. Alternatively, the disease-focused nurse or doctor may slavishly follow guidelines without
recognising that the evidence underlying those guidelines is not necessarily applicable to the individual patient
in front of them with multimorbidity (because most guidelines are based on research that excluded patients
with multimorbidity).18,19 If all the recommendations for each long-term condition are considered in isolation
and followed, patients with multimorbidity are likely to have numerous investigations and to be prescribed
large numbers of drugs.20,21 This polypharmacy can be burdensome for patients, increases the likelihood
of interactions and adverse effects (including those causing hospital admissions) and may reduce
medication adherence.19,22–24
Lack of patient-centred care
As well as an increased illness burden and treatment burden, patients with multimorbidity experience a lack
of holistic patient-centred care. Patients with multimorbidity can feel that no one treats them as a ‘whole
person’ but rather as ‘a patient with a disease’.3 Many patients say that they want to have a relationship
with one health professional that they can trust and who listens to them, helping them make appropriate
decisions in the context of their life circumstances and values.3 Given the large number of health problems
that these patients face and the number of potentially relevant investigations and treatments, they may
want to set priorities and make trade-offs so that they are not overinvestigated and medication regimes are
not excessively burdensome. For patients, improving quality of life (which might include not spending too
much time in contact with the health service or suffering side-effects of medication) might be a higher
priority than achieving improved indicators of disease control with a view to greater longevity.
Inequalities in health
Failing to address the problems of patients with multimorbidity will also lead to increased inequalities in
health. Multimorbidity is more common in deprived areas,1 and patients with fewer material and personal
resources are particularly disadvantaged by having to attend multiple appointments for each of their
long-term conditions, and being expected to follow a series of different care plans.17,25 Their care is also
more likely to be complicated by other medical and social factors, such as poor mental health, poor
housing and smoking.26 The prevalence of comorbid depression and physical health problems is much
higher in deprived areas than affluent areas.1 Therefore, improving mental health as well as physical health
in people with multimorbidity is a priority.
Importance of multimorbidity for the health service
Patients with multimorbidity are a priority for the health service because they account for a high proportion
of resource use in both primary and secondary care (including having high rates of hospital admissions).13,27,28
The consequences of a single-disease approach for the health service potentially include both duplication
and gaps in services (e.g. conditions included in the QOF are prioritised but others are neglected),29
inefficiency (because the same topics are addressed repeatedly by different specialist practice nurses) and
waste (because of non-adherence to medication and non-attended appointments).30 If taken to its logical
conclusion, the disease pathways approach would mean that one patient with multimorbidity would have
their care managed by several specialist services (each crossing primary and secondary care), but there would
be little co-ordination between these specialist services and no one professional who has an overview and
takes responsibility for the patient as a whole.
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Summary of the problem
In summary, patients with multimorbidity experience problems of illness burden (poor quality of life, depression),
treatment burden (multiple unco-ordinated appointments, polypharmacy) and lack of person-centred care
(low continuity, little attention paid to patients’ priorities). This research is designed to test the hypothesis that
an intervention in general practice designed to address the needs of patients with multimorbidity will improve
their health-related quality of life (primary outcome), reduce their burden of illness and treatment and improve
their experience of care, while being more cost-effective than conventional service models. This was tested
using a cluster randomised controlled trial (RCT), with economic evaluation and mixed-methods process
evaluation.
Rationale
The design of the intervention builds on several sources of evidence. First, it takes account of the existing
research on the scale and adverse consequences of multimorbidity, as described previously.1,2,19,21,26,30–33
A regularly updated bibliography of research on multimorbidity is maintained by Professor Martin Fortin
(Université de Sherbrooke, QC, Canada) for the virtual International Research Community on Multimorbidity.34
We reviewed this bibliography to ensure that we had a comprehensive understanding of the relevant
literature when developing the intervention and have re-reviewed it since to ensure that we take account of
recent research in reporting the findings.
Second, the intervention design takes account of a Cochrane review of interventions to improve outcomes
in people with multimorbidity in primary care.35,36 This review, originally published in 2012, identified 10
studies examining a range of complex interventions.35 A further eight trials were identified in an update
published in 2016, but the conclusions were not substantially altered.36 The review highlights the paucity
of research, with the focus to date being on specific comorbid combinations or multimorbidity in older
patients. The limited evidence available suggests that interventions to date have had little effect on clinical
health outcomes, apart from a modest effect on improving depressive symptoms. There are very limited
data about the costs of different approaches to care and none of the studies included an economic
analysis of cost-effectiveness. The authors concluded that there is a need for further pragmatic studies in
primary care settings, with clear definitions of participants and consideration of appropriate outcomes.35
Third, the intervention builds on clinical experience and professional consensus. We discussed the problems
of patients with multimorbidity and how to improve care in general practice in three workshops with
general practitioners (GPs), nurses and other practice staff, including > 250 participants at the Royal
College of General Practitioners (RCGP) Annual Conference in October 2012. These helped to generate
ideas for improvement that informed the 3D (Dimensions of health, Depression and Drugs) intervention,
which is the subject of this report, and helped to ensure that the intervention was based on a good
understanding of current practice in relation to the organisation of care for these patients.
Fourth, in the process of developing the intervention we consulted patients in two public meetings. The
participants identified a number of problems with the current organisation of long-term condition review
appointments in general practice. These included a lack of continuity of care, having to attend multiple
appointments and having difficulty in getting priorities addressed.
Fifth, the intervention builds on the research team’s experience in related trials, particularly the Whole systems
Informing Self-management Engagement (WISE) trial37 and the CARE (Consultation and Relational Empathy)
Plus feasibility study.38 The former was a trial of a patient self-management intervention, and the latter was
a study of the feasibility of an intervention in middle-aged patients in deprived areas of Scotland, which
focused on longer consultations to allow a holistic assessment of biopsychosocial needs and to provide a
self-management support pack. The CARE Plus study demonstrated feasibility and showed promising results
but it is not powered to definitively assess effectiveness (eight practices, 152 patients). The CARE Plus
approach was also very specifically focused on the needs of patients in deprived areas.
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Finally, in preparation for this trial we searched the metaregister of controlled trials in order to identify
relevant unpublished trials research or ongoing studies, but no such relevant studies were found. There is,
therefore, a pressing need for rigorous research to test interventions to improve the management of
patients with multimorbidity in general practice.
During the period of this research trial, the National Institute for Health and Care Excellence (NICE) conducted
a review of the evidence on multimorbidity and issued final guidelines in September 2016.39 Although this
guidance was being developed around the same time that we developed the 3D intervention, the strategies
incorporated in the 3D intervention are entirely consistent with the recommendations of the NICE guidance.
The key recommendations in the guidance include:
l consider how conditions and treatments interact to affect an individual’s quality of life
l tailor care to take account of each individual’s preferences, priorities and goals
l consider carefully the risks and benefits of following guidance relating to single conditions
l seek to improve quality of life by reducing treatment burden and unplanned care, and try to improve
co-ordination of care
l review medicines and other treatments, considering individual risks, benefits and harms, and outcomes
important to the individual
l agree an individualised management plan.
All of these elements are included within the 3D intervention, which is the focus of this study. The NICE
guidelines summarised previous trials of interventions to improve care for people with multimorbidity
and concluded that most of the evidence was of low to moderate quality and it was not possible to
recommend any particular approach. One of the four key recommendations in the NICE report for future
research was: ‘What is the clinical and cost-effectiveness of alternative approaches to organising primary
care compared with usual care for people with multimorbidity?’.39 This study contributes to answering
this question.
Since this study was planned, the Health Select Committee has also published its findings on the
management of patients with long-term conditions, including a section on the management of people
with multimorbidity.5 The conclusions again resonate with the aims of this research. The select committee
criticised the current single-disease approach to management, and emphasised that in its view:
The objective of the health and care system in treating people with long-term conditions should be
to improve the quality of life of the person. At a time when increasing numbers of people requiring
support and treatment from the system have multiple conditions combining physical health, mental
health, social care and other support requirements, it seems anachronistic that the Department
[of Health]’s definition of long-term conditions appears to emphasise a single-disease approach to
treatment. We recommend that the Department revise its working definition of long-term conditions
to emphasise the policy objective of treating the person, not the condition, and of treating the person
with multiple conditions as a whole.
House of Commons Health Committee. Managing the Care of People with Long–Term
Conditions, Volume 1. London: The Stationery Office Limited; 2014.5 Contains Parliamentary
information licensed under the Open Parliament Licence v3.0
The select committee strongly endorsed a person-centred approach to care, reinforced by individualised
care plans.5
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The need for evidence
Evaluating models of care for long-term conditions was identified as the top research priority by stakeholders
advising the National Institute for Health Research (NIHR) Health Services and Delivery Research programme.
NIHR highlighted the improvement of the management of multimorbidity in general practice as a priority in
a 2013 themed call for research on primary care interventions, and then followed this with a specific call for
research on multimorbidity in 2015. Commissioners, professional bodies, academics and other stakeholders
have all recognised the growing tension between the single-disease focus of medicine and the needs of
patients with multiple long-term conditions.30,40–43 This is evidenced by reports from the RCGP,44 the Royal
College of Physicians45 and NICE,39 as well as from international organisations.40,46 There is a long-term
challenge to redesign the NHS to reflect the needs of patients with multiple long-term conditions47 in light
of the ageing population. There has been considerable research on the scale of the problem and the needs
of patients with multimorbidity.3,25,32,48–51 Research is now needed to test interventions to address these
problems.43 As described previously (see Rationale), the recent Cochrane Review and the NICE multimorbidity
guidelines both highlighted the urgent need for further pragmatic studies of potential interventions for
multimorbidity in primary care settings.35,39
Some general practices have recognised the problems of providing care for their patients with multimorbidity
and, in the absence of research, have themselves innovated in the way they provide care. In particular, some
practices have begun to co-ordinate long-term condition reviews into one appointment each year, rather
than expecting the patient to attend a different appointment for each condition. However, these changes
typically focus on rationalising appointments rather than any fundamental change in the content of the
reviews. Because practices are beginning to explore ways of improving care for multimorbidity, the time is
right to test the benefits and costs of a new approach.
The intervention described in this proposal includes a number of elements that have become frequently
advocated in the management of specific diseases, including an emphasis on patient-centred care, explicit
agenda setting, self-management support, shared decision-making and care planning. These are well
captured by the House of Care model described by The King’s Fund,52 which is the basis for NHS policy
on long-term care. This is an intuitively attractive conceptual model, but it is important to recognise that
evidence of benefit from implementation of many of these ideas is limited or indirect. For example, there
are parallels between the 3D intervention described in this report and aspects of the Year of Care initiative
for diabetes mellitus, itself built on the House of Care model.53 Although the experience of pilot sites
involved in the Year of Care appears to have been positive, evaluation of the approach was mainly
qualitative, describing the process of implementation and perceived benefits from the perspective of
patients and clinicians. Only limited objective quantitative data were available, and the evaluation did
not include any control group or robust economic evaluation.53
The main focus of the 3D intervention is on improving the management of multimorbidity in general
practice. There are several reasons for this focus on general practice rather than on hospitals. General practice
provides the foundation for the organised care of most major long-term conditions, with most patients
having the vast majority of their NHS contacts and all of their prescriptions provided in general practice.
Although patients with multimorbidity have an increased rate of outpatient attendances and inpatient
admissions, one of our hypotheses is that these contacts might be reduced by improved management
in general practice. Improving the management of patients with multimorbidity in hospital is also a
challenge45 but this requires different solutions beyond the scope of this intervention. The aim of the 3D
study was to design and evaluate an intervention that is ambitious, but also achievable and likely to lead to
patient benefits in the short term.
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Study aims and objectives
Aims and hypothesis
The aim is to optimise, implement and evaluate an intervention to improve the management of patients
with multimorbidity in general practice.
The hypothesis is that an intervention in general practice designed to improve the management of
multimorbidity will improve patients’ health-related quality of life, reduce their burden of illness and
treatment and improve their experience of care, while being more cost-effective than conventional
service models.
Objectives
l To optimise an intervention to improve the management of multimorbidity in general practice through
piloting in four practices.
l To implement this intervention in a representative range of general practices.
l Through a cluster RCT and economic evaluation, to assess the impact of the intervention on health-
related quality of life, illness burden, treatment burden, patient experience, carers’ burden and quality
of life and cost-effectiveness.
l Through a mixed-methods process evaluation, to explore how and to what extent the intervention
was implemented, the advantages and disadvantages of different models of care for patients with
multimorbidity, and how and why the intervention was or was not beneficial.
l To design educational materials and commissioning guides to ensure that the intervention is delivered
consistently in practices in the trial, and that, if beneficial, it can be speedily rolled out nationally
following publication of the final report.
Most of the outcomes relate to the effect on individual patients (with allowance made in the analysis for
the cluster randomised design), although some of the implementation objectives related to practices.
INTRODUCTION
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Chapter 2 Study design and governance
Design
The research design was a pragmatic, cluster RCT comparing the 3D approach (a new approach to the
management of multimorbidity) with usual care in general practice. Figure 1 shows the original planned
study design, slightly modified later as described in Chapter 4. A cluster design was chosen, with each
general practice forming a cluster, because the intervention required organisational change in service delivery
at a practice level and because of the likelihood of contamination effects if patients were randomised
individually. The trial was designed to be as pragmatic as possible in order to assess the effects of the 3D
intervention when implemented in routine practice.
In line with the Medical Research Council (MRC) framework for the evaluation of complex interventions,54
an optimisation phase in a small number of pilot practices allowed for testing the feasibility of the
intervention, particularly the training and implementation of the intervention, as well as piloting of study
procedures prior to starting the main evaluation phase. Alongside the main trial we conducted a parallel
mixed-methods process evaluation to examine how the intervention was implemented by practices and
how and why the intervention worked (or did not work).
An economic evaluation was undertaken from the perspectives of (1) NHS and Personal Social Services
(PSS) and (2) patients. In a cost–consequences analysis we related the cost of the intervention or usual care
to changes in a range of outcomes, and in a cost-effectiveness analysis we estimated the incremental cost
per quality-adjusted life-year (QALY) gain.
Study setting
The study was conducted in general practices in three geographical areas: (1) in and around Bristol,
(2) Manchester and (3) Ayrshire and Arran. This includes a wide range of deprived and affluent areas, as well as
urban, suburban and rural areas. The patient populations from these practices will, therefore, have a wide range
of characteristics. Working in different types of area, with different commissioning groups, and in the different
health-care systems in England and Scotland, will all help to ensure the generalisability of the research.
Economic evaluation
Study design
Optimisation phase Implementation and evaluation phase
Four
practices
Training and
initial
implementation
Observation and
reflection
Revised 3D
intervention
32
practices
Cluster
allocation
3D
intervention
Usual care
6-month
follow-up
12-month
follow-up
6-month
follow-up
12-month
follow-up
Process evaluation
FIGURE 1 Original plan for study design.
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Ethics approval and research governance
This study was conducted in accordance with principles of Good Clinical Practice.
Research ethics approval was obtained from the South West (Frenchay) NHS Research Ethics Committee
(REC) (reference number 14/SW/0011). Appropriate NHS Research and Development (R&D) governance
approvals were also obtained from local Clinical Commissioning Groups (CCGs) and health boards prior to
study commencement at sites. Amendments of study protocols and documentations were reviewed and
approved by NHS REC, and NHS R&D departments.
Participants were not denied any form of care and had full access to NHS services throughout the duration
of their study participation. Any changes in medication prescribing were made by a GP in the context of
normal clinical care.
Although randomisation and delivery of the intervention were at the practice level, individual patient-level
consent was obtained to collect questionnaire follow-up data.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN06180958.
Trial oversight
The study was hosted by Bristol CCG and the sponsor was the University of Bristol. The 3D study was
managed by the Trial Management Group (TMG) consisting of the chief investigator, principal investigators
and researchers from each of the recruiting centres (Bristol, Manchester and Glasgow) and co-applicants.
Regular meetings (every 6–8 weeks) ensured that study progress, targets or any problems were monitored
and reviewed.
Additional governance oversight was provided by an independent Trial Steering Committee (TSC) and Data
Monitoring Committee (DMC). A further advisory group made up of key local and national stakeholder
organisations was also convened to provide advice about the wider context and facilitate communication
and knowledge mobilisation. Member details of these committees are provided in Appendix 1.
STUDY DESIGN AND GOVERNANCE
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Chapter 3 Intervention development and
pilot study
The intervention took account of several sources of evidence, as described in Chapter 1. It was furtherdeveloped through workshops and stakeholder events with patients, carers, health professionals and
health service managers. The description below addresses all aspects of the Template for Intervention
Description and Replication (TIDieR) framework.55
Theoretical/conceptual framework
The underlying theoretical basis for the intervention was the patient-centred care model, described by
Stewart et al.56 This is strongly valued by patients57 and there is some evidence that it is associated with
improved health outcomes.58–61 A recent report from the American Geriatric Society has also recommended
the patient-centred care model to improve care for multimorbidity.40
The concept of patient-centred care has been reviewed and developed by other authors following the
seminal work of Stewart et al.,56 but it broadly includes four key components:62,63
1. a focus on the patient’s individual disease and illness experience – exploring the main reasons for their
visit, their concerns and need for information
2. a biopsychosocial perspective – seeking an integrated understanding of the whole person, including
their emotional needs and life issues
3. finding common ground on what the problem is and mutually agreeing management plans
4. enhancing the continuing relationship between the patient and doctor (the therapeutic alliance).
The conceptual framework for our intervention draws on the existing research evidence about the main
types of problems experienced by patients with multimorbidity and their preferences for care, and uses
strategies based on the patient-centred care model to seek to address these problems. For example, there
is evidence that patients with long-term conditions particularly value relational continuity of care;64
therefore, the intervention includes strategies to improve this.
Our conceptual framework also draws on the Chronic Care model65 and experience in related initiatives,
such as the House of Care,66 which include, for example, the importance of promoting patient
engagement in self-care through care plans and improving communication between primary and
secondary care.
In Chapter 1 we described the problems experienced by patients with multimorbidity in terms of illness
burden, treatment burden and a lack of holistic patient-centred care. The intervention was designed to
address the problems within this framework.
The 3D intervention was a complex intervention with multiple interacting components at different levels.
When designing complex interventions it is important to design a clear logic model to show how specific
strategies are intended to lead to particular benefits.67 This also aids the process of selecting intermediate
and final outcomes. In the 3D trial we used this process to develop the 3D intervention and the selection
of outcomes. Figure 2 shows a logic map of how the different intervention components map on to
strategies that address specific problems. These components are described in detail in this chapter.
We later show how the logic map also informed the selection of outcome measures (see Figure 5).
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Clinicians’ conduct of reviews
• Two-part longer review with named health professionals
   to address all conditions together, using new ‘intelligent’
   3D review template
• Part 1 – identify patient’s priorities and QOL issues before
   disease checks, screen for depression, create agenda
   including patient and clinician concerns, give copy to
   patient
• Pharmacy review of medication prior to part 2
• Part 2 – address patient’s priorities and needs, review
   treatment and medication adherence, agree health plan
   with patient and provide written copy
• Involvement of secondary care physician if needed
Individual and organisational changes
• Training of clinical, reception and admin staff
• IT to facilitate identification, recall, review, monitoring
• Financial incentives
• Appointment of practice champions
• Monthly feedback of progress
Practices’ organisation of care
Patients with three or more long-term conditions identified 
and flagged on computer
• Allocated a named GP (and nurse if appropriate)
• Given a 3D card to request appointments with named
   nurse or GP
• Scheduled for 6 monthly 3D review of all conditions
   together
Intervention components to implement strategies
3D – Dimensions of health, Depression, Drugs
Strategies to address problems
Identify and prioritise patients
with multimorbidity for a
different type of care
Improve continuity of care
• Responsible GP
• Longer consultations when
   needed
Co-ordinated, holistic reviews
• Instead of disease-focused
   reviews
Lack of holistic,
patient-centred care
• Care driven by 
   single-disease targets
• Patients’ priorities
   not addressed
• Lack of continuity of
   care; no one person
   with detailed
   understanding and
   overall responsibility
High illness burden
• Poor quality of life,
   multiple symptoms
   and impairments
• Depression common
• Poor disease control
High treatment burden
• Multiple appointments
• Polypharmacy
• Poor co-ordination
   of care
• High self-management
   requirements
Integration with secondary care
• Easy access to nominated
   generalist physician
Problems for patients
with multimorbidity
Patient-centred ‘3D’ reviews to
focus on
• Dimensions of health
   • Patients’ priorities and needs
   • Quality of life and function
   • Disease management
• Depression – identify and treat
• Drugs – simplify treatment
   regimes, address adherence
• Develop explicit and written
   plans with patient
FIGURE 2 Logic model showing how problems are linked to strategies and to components of the intervention. IT, information technology.
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In summary, the intervention was designed to:
l reduce illness burden by placing greater emphasis on quality of life (including pain and activities of
daily living) and seeking to identify and address poor mental health
l reduce treatment burden by addressing polypharmacy, improving medication adherence and providing
better co-ordinated care
l improve patient-centred care through enhanced continuity of care, offering longer appointments,
identifying patients’ priorities and needs and addressing these through an individualised written
health plan.
Our approach also recognises that the successful and sustained implementation of any intervention in
health care requires a range of organisational changes to support and sustain the innovation, and this may
also require attitudinal change among clinicians. Implementation of the 3D approach therefore involved a
range of enabling and reinforcing strategies, including training of practice staff, regular feedback, financial
incentives and the appointment of local GP champions with collaborative working between practices to
share experience.
In this way, we recognise that the intervention operates at several levels and cannot be considered simply
as the new 3D review offered to patients. First, it begins at the practice level, with a range of strategies
and tools provided to practices to support organisational change. Second, it involves the training offered
to clinicians and receptionists, with the aim of influencing their attitudes to patients with multimorbidity,
training them to use the computerised 3D template and enhancing their skills in identifying patients’
priorities and negotiating care plans. Third, the intervention operates at the level of the patient, as care is
provided to them in a new way and they do or do not respond (whether through behaviour change or
improved medical treatment).
The name ‘3D’ was chosen for the intervention because it alluded to the concept of a holistic
three-dimensional perspective of care and served as a mnemonic for:
l dimensions of health – patients’ concerns and priorities for improving their quality of life were elicited,
before the collection of data about disease metrics, such as weight or blood pressure
l depression – the Patient Health Questionnaire-9 (PHQ-9) was used to screen for depression, and
management was discussed if depression was identified
l drugs – to address polypharmacy, a pharmacist reviewed patients’ medical records prior to the 3D
review and made recommendations to simplify drug regimes or discontinue low-priority medications.
As part of the 3D review, GPs reviewed the pharmacist’s comments and recommendations, explored
any problems with medication adherence and could modify a patient’s drug regime if required.
The components of the intervention operating at each level are described in more detail below.
Practice-level components relating to the organisation of care
Identification and flagging of participants
Consented participants in intervention practices were ‘flagged’ on practice computer systems to identify
that they should receive a different process of care.
Promoting continuity of care
Participants were allocated a named GP who was responsible for their care (and a named nurse when
possible, particularly in larger practices where several nurses are involved in long-term disease
management). When possible, the named GP was the patient’s usual GP. At the beginning of the study,
each participant was sent a letter informing them of their named GP and nurse and explaining why it was
important to try to see their named GP and nurse when possible.
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Named GP on a ‘3D card’
Patients were given a ‘3D card’, a credit card-sized card that stated their named responsible GP (and nurse
if appropriate). This card could be used to identify themselves with the practice and encouraged them to
book longer appointments with their named GP if needed (see Appendix 5).
‘Flagging’ for receptionists
A facility was added to Egton Medical Information Systems (EMIS) so that each time a 3D participant made
an appointment a ‘flag’ appeared on the receptionist’s computer screen. This identified the patient as a 3D
participant and asked the receptionist to encourage the patient to see their named GP.
3D reviews
A key component of the 3D approach was the reorganisation of the participants’ multiple, separate
disease-focused review appointments into paired 3D reviews during which all conditions were reviewed at
one time. These 3D reviews replaced the need for participants to attend multiple clinics for each disease,
at which they were likely to see different health professionals, who were following different computerised
disease-specific management templates, which were likely to include a high degree of duplication of
questions about topics such as blood pressure, weight and smoking. The 3D reviews were scheduled every
6 months.
Secondary care physician
Each practice was allocated a designated ‘general physician’ (usually a geriatrician) in secondary care
whose role was to act as a contact to discuss patients with complex problems and (if possible) help to
co-ordinate multiple hospital appointments and investigations.
Components relating to clinicians conduct of reviews
3D template
The 3D reviews were supported by a dynamic template, which populated automatically depending on the
relevant conditions of each individual patient. This eliminated the problem of duplication of questions and
the need to switch between single-disease templates and also provided a structure to encourage clinicians
to follow the 3D approach. Several screenshots from the 3D template are shown in Appendix 6.
The 3D review appointments
Each 3D review consisted of two appointments (every 6 months) with a nurse and then a GP, as well as a
pharmacist review (once a year).
In the UK, GPs have a minimum of 5 years’ post-graduate education after their medical degree and
provide urgent care, management of long-term conditions, health promotion, prevention and screening
activities. They have generalist training and experience across all common health conditions. Practice
nurses are fully qualified nurses and come from a range of backgrounds, including hospital or community
nursing. In many general practices they undertake most of the review and management of some long-term
condition, such as asthma and diabetes mellitus, although they are less often involved in other conditions,
particularly mental health problems. The extent and range of experience of nurses in general practice is
variable. Many nurses have further training in specific long-term conditions, with different nurses in the
same practice sometimes specialising in different conditions. Pharmacists working in general practice have
usually worked as community pharmacists and are increasingly working within general practices to support
medication review and repeat prescribing.
3D nurse appointment
The first appointment with a practice nurse included collecting information about the patient’s priorities,
aspects of quality of life, such as pain and function, screening for depression using the PHQ-9 and
organising all relevant blood tests and investigations. These were entered into the nurse consultation
INTERVENTION DEVELOPMENT AND PILOT STUDY
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section of the 3D template which summarised their assessment to produce a 3D agenda which was given
to the patient. Practices were advised to allow 30–40 minutes for the nurse appointment.
Pharmacist review
Once a year a pharmacist reviewed the participant’s medication and made recommendations to the GP.
This review was based on the medical records without the pharmacist seeing the patient and was usually
conducted remotely. Funding for the pharmacist’s time was based on an estimate of 10 minutes per
review. The pharmacist was either seconded from the local CCG/health board or was already working as
the practice pharmacist.
3D general practitioner appointment
Practices were advised to invite the patient to attend the second 3D review appointment with their named
GP approximately 1 week after the nurse appointment. The GP reviewed the test results, the pharmacist’s
recommendations and the 3D agenda following the nurse appointment to address the priorities and
identified problems. Goals were negotiated with mutually agreed actions for patients and clinicians.
Practices were advised to allow a double appointment (approximately 20 minutes) for the GP 3D review.
Care planning
At the end of the 3D nurse consultation, information about the patient’s priorities was combined with
information about test results and any problems identified by the nurse and merged into a ‘patient
agenda’ document, which was printed and given to the patient (see Appendix 7). The patient was asked
to bring this to their subsequent GP appointment. The idea was that sharing information with the patient
would help to promote self-management.
At the end of the 3D GP consultation, goals were agreed between the patient and doctor, accompanied
by actions that the patient could take and that the health professionals could take to address each goal.
These goals and actions were merged into a 3D health plan, which was printed and given to the patient,
again to promote self-management (see Appendix 8). The term ‘health plan’ was chosen to avoid
confusion with care plan. At the time of this study, ‘care plans’ were being created for the unplanned
admissions directed enhanced service and sent to patients. However, unlike the 3D health plan, these
unplanned admission ‘care plans’ mainly consisted of a synopsis of medical information to be shared
between health professionals rather than being a document including patient goals to promote
self-management.
Components relating to supporting practices to provide the intervention
We used a number of evidence-based strategies to try to ensure that the intervention was implemented in
the way intended.68
Training/researcher intervention
Practice training was delivered within practices over two sessions by at least one researcher and one
GP trainer. All clinical staff (GPs, practice nurses and research nurses) who would be delivering the 3D
review consultations were expected to attend training. The external pharmacist and hospital consultant/
geriatrician were also invited. Although the original intention was to train practices together, the pilot
study indicated a need to deliver training in each practice and be flexible over timing, for example by
running both sessions in one day or running the sessions multiple times over several practice lunch breaks.
In the first training session (session A), practice staff discussed the problems facing patients with
multimorbidity and how their practice currently managed these patients. The principles and strategies of
the 3D approach were introduced and, using a case study patient and other examples, discussion took
place around how these strategies could be applied. This session primarily focused on identifying patient
priorities, promoting patient-centred care and promoting the importance of mental health alongside
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physical health. Practice staff were encouraged to feed back concerns about implementing the study and
what they considered the positive or important aspects of the 3D model.
The second training session (session B) concentrated on more practical elements of the 3D review
consultations, including negotiating goal-setting, creating a health plan and using the 3D template.
This usually involved using one of the practice’s consented patients as a worked example.
The training materials, including slides and tasks, are included in Report Supplementary Material 1 and 2.
Administrative staff also underwent training, including discussion of the 3D cards, 3D named GP pop-ups
and the requirement to offer longer appointments with the named GP or nurse. Suggestions were made
for how to implement the last of these (e.g. by reserving an extended appointment slot for participating
3D GPs each day).
Flexibility in delivering the 3D intervention
Owing to the pragmatic nature of the study, local adaptation of the intervention was permitted to reflect
local contexts, although key elements of the conceptual framework were maintained. For example, practices
were allowed flexibility in how they integrated 3D with their existing systems for organising long-term condition
review appointments. A suggested template letter was provided, although some practices used their own
letters asking participants to call for an appointment or telephoned participants with a set appointment time.
The time allocated for nurse and GP reviews were also flexible and often based on how existing consultation
slots were timetabled.
Practices were required to provide two pairs of 3D reviews over 12 months. However, the decision to recall
participants for review was made at their discretion. For example, if the practice used a system of recalling
patients in the birthday month, or time from last review, they could choose to fit the 3D reviews into their
existing systems.
Financial incentives
Practices were reimbursed to cover the cost of staff attending 3D training sessions and setting up the
necessary patient recall systems. Practices were also given financial incentives (£30 per patient for each 3D
review consisting of both a nurse and a GP consultation). This incentive was not intended to cover the full
cost of providing care, because practices are already paid by capitation and completing the 3D review
would fulfil their requirements for chronic disease reviews under the QOF, for which they are also paid.
Rather, the modest incentive was to encourage them to implement the new form of care, particularly
given their concerns that it may generate extra work.
General practitioner practice champions
Each intervention practice nominated a practice champion to monitor and promote the 3D approach.
They acted as a direct point of contact for the research team, provided feedback from the practice and
disseminated monthly monitoring feedback and newsletters from the research group.
Nominated 3D GP champions were invited to meet other champions in their region every 4 months.
This was an opportunity to share ideas and experiences of 3D implementation and delivery within local
collaboratives. Local researchers facilitated these meetings following a semistructured format, which
included enquiries about what was going well and not so well with the 3D approach and sharing ideas
about how to overcome any difficulties. Any important issues raised at the meetings were fed back to
the TMG.
Monthly monitoring feedback
All intervention practices were requested to run a monthly purpose-designed search that extracted data on
the number of 3D reviews completed and other aspects of the intervention, such as continuity of care and
the number of health plans printed. This enabled the research team to monitor the progress of 3D review
INTERVENTION DEVELOPMENT AND PILOT STUDY
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delivery and the completeness of the reviews but also acted to encourage practices to continue to deliver
the intervention. A performance graph comparing all intervention practices was circulated to the GP
champions to encourage a sense of competition. (See Appendix 2 for a table of monitoring/feedback items
and Appendix 3 for an example of a practice feedback report.)
How the 3D intervention compares with other interventions
for multimorbidity
During the course of the 3D study we undertook a review of previous models of care for multimorbidity
in order to provide a framework by which different interventions could be compared.69 We identified
39 different models of care described in 68 research papers. Not all of these models have been subject to
the rigorous evaluation being conducted for the 3D approach. We created a framework that identifies two
foundations for these models (the theoretical basis, and defined target population) and three categories of
care elements to implement the model in practice: (1) clinical focus, (2) organisation of care delivery and
(3) support for model delivery. Figure 3 shows the percentage of models in the current literature that use each
element of the framework. All of the elements shown are included in the 3D approach, except ‘integration of
social/community care’, ‘group visits’, ‘trained lay navigator’ and ‘telehealth’. This shows that the 3D approach
is relatively comprehensive and covers most of care elements included in other interventions.
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Optimisation of the intervention and pilot study
Prior to commencing the main trial, three GP practices (two in Bristol and one in Manchester) were
recruited to pilot the trial procedures and optimise the intervention. All procedures were delivered as
intended for the trial, with additional evaluation from local researchers, the process evaluation team and
practice staff feedback. This allowed us to check that our recruitment rate estimates were feasible, training
was acceptable and information technology (IT) (computerised search routines, intervention template and
data monitoring searches) worked smoothly across a range of practices. Many useful suggestions led to
amendments and refinement of the study documentation and procedures. Because the practices were
aware of the pilot nature of the intervention, and received additional access, support and feedback from
the research team, their patient participant data were not included in the main analyses.
Unfortunately, because of delays in developing the IT, there was insufficient time to complete a full pilot
study with complete follow-up before the main study began. The pilot phase began 6 months prior to the
main trial, which allowed changes to be made to recruitment, data collection and implementation of the
intervention before the main study. The amendments made to the main study as a result of suggestions
from the pilot are summarised in Appendix 4 (see Table 37).
There were two significant changes. In the light of experience in the pilot study and the first practices
recruited to the main trial, we found that it often took several months to arrange training sessions for
intervention practice staff, to install the required IT and for practices to rearrange their appointment
systems to invite participating patients. To allow for a lag of approximately 3 months, the time point for
collecting outcome data was changed after the pilot study from 6 months and 12 months following
recruitment at the baseline time point (T0) to 9 months [9-month post-randomisation time point (T1)] and
15 months [15-month post-randomisation time point (T2)].
Second, we originally designed the trial as a whole-system change in which all patients with multimorbidity
in practices allocated to the intervention would receive the 3D approach. This would have replicated as far
as possible the organisational changes needed to implement the intervention in real life. However, this
design was rejected after the pilot study because of difficulties in recruiting practices, partly because of
their concerns that the 3D approach would create additional work, and partly because a whole-system
reorganisation required all GPs in the practice to agree to participate in the trial (in many practices, some
but not all GPs were willing to participate). Furthermore, this whole-system approach would mean that
services had to be reorganised for the large number of patients with multimorbidity, but only a minority of
them would contribute data to the research (because we required individual patient consent). This would
be a financially inefficient use of research funds. Furthermore, it would be disruptive for both patients and
practices to change care for a large number of patients just for 1 year and then to change back again once
the research was over. We, therefore, offered the 3D intervention only to patients who gave consent to
participate in the trial.
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Chapter 4 Methods
The material in this chapter is adapted from Man et al.70 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The material in the section on Process Evaluation methods is adapted from Mann et al.71 This is an
Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial
(CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Study setting
General practices serving three areas: around Bristol and Greater Manchester in England and Ayrshire and
Arran in Scotland.
Recruitment of general practices
The study was restricted to practices using the EMIS system (web or PCS versions). EMIS is the most
common clinical records system in UK general practice and the intervention template was designed for this
system only.
Practice inclusion criteria required a minimum of two GP partners and a minimum list size of 4500. We
excluded small practices to ensure an adequate patient population pool and because the intervention may
be less relevant and harder to implement in very small practices with few staff and existing high levels of
continuity of care.
Practices were approached via the Comprehensive Local Research Networks, the Scottish Primary Care
Research Network and NHS Clinical Research Network (CRN) events, and cascaded via research active
practices. Local researchers met with key practice stakeholders (practice manager, GPs and practice
nurses) to explain the study and the organisational changes required. If the practice agreed to take part,
a practice-level consent agreement form (see Report Supplementary Material 3) was signed before practices
were randomised. Practice recruitment is represented in Figure 4. Because of the variety of ways in which
practices heard about the trial, with some just receiving information as part of a newsletter informing
research-active practices about studies open to recruitment, it is difficult to define a clear denominator for
the number of practices invited to participate.
Recruitment of participants
Eligibility criteria
Participant inclusion criteria were adults, aged ≥ 18 years and having three or more long-term conditions
from a list of those included in the NHS QOF, version 31.0 (Box 1).
Patients were excluded if they had a life expectancy of < 12 months, were deemed by the GP to be at
serious suicidal risk, were known to be leaving the practice within 12 months, were unable to complete
questionnaires even with the help of carers, were actively taking part in other research involving extra visits
to primary care or other health services, lacked capacity to consent (this exclusion applied in Scotland only)
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Invitation/approached
(n = 140 GP practices approximately)
Expression of interest
(n = 68)
Initiation visit
(n = 46)
Signed practice agreement
(n = 35)
Randomised
(n = 33 practices)
Declined
(n = 21)
Declined
(n = 15)
Declined
(n = 9)
Intervention
(n = 16)
Usual care
(n = 17)
Practice withdrawal
(n = 2 prior to randomisation)
FIGURE 4 General practice recruitment flow chart.
BOX 1 Chronic conditions for inclusion
Three or more diagnoses from the following groups of chronic conditions
l Cardiovascular disease or chronic kidney disease (including coronary heart disease, hypertension, heart
failure, peripheral arterial disease, chronic kidney disease stage 3 to 5).a
l Stroke.
l Diabetes mellitus.
l Chronic obstructive pulmonary disease or asthma.a
l Epilepsy.
l Atrial fibrillation.
l Severe mental health problems (schizophrenia or psychotic illness).a
l Depression.
l Dementia.
l Learning disability.
l Rheumatoid arthritis.
a If a patient had multiple conditions within a group, this was counted only once. For example, having both
hypertension and heart failure would just count for one condition.
Reproduced from Man et al.70 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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or were considered otherwise unsuitable as determined by their GP (e.g. recently bereaved or currently
hospitalised). GPs were asked not to exclude people on the basis of being elderly or frail, having a
diagnosis of dementia or being housebound. Although these patient groups are frequently excluded from
other research studies, this study may be particularly relevant to such patients.
For sites in England, REC approval allowed the inclusion of patients who lacked capacity by obtaining a
signed declaration from the patient’s carer, legal guardian or consultee on behalf of the patient (see
Report Supplementary Material 4). In Scotland, it is not lawful to recruit patients without capacity if the
research could be conducted without them, and patients without capacity to consent were excluded there.
Identification and consent of patients
Participating practices ran a custom-built search, based on pre-defined read-codes, which identified
patients with health conditions within the inclusion criteria. The presence of three or more conditions
made the patient eligible.
If > 150 patients per practice were eligible, a simple random sample of 150 was selected. GPs screened
the resultant list for any patients meeting the exclusion criteria. The remaining patients were sent a patient
study invitation pack, containing a study invitation letter, patient information sheet, consent form, baseline
questionnaire and a freepost return addressed envelope (see Report Supplementary Material 5–7 and
Appendix 9). We estimated that selecting 150 patients would enable us to recruit at least 43 patients per
practice (the target from the sample size calculation) after allowing for GP exclusions and patients who
were subsequently found to be ineligible, declined participation or failed to respond.
In some practices, not all GPs took part. In practices with > 150 eligible patients, we selected patients with
a participating GP and then a sample of other patients where necessary to meet the recruitment target.
This was to minimise the number of patients who would be asked to see a different doctor from their
usual GP for the purpose of the study.
Patients agreeing to participate signed the consent form, completed the questionnaire and returned both
using the return envelope.
During development of the study procedures and the pilot phase, the patient and public involvement
(PPI) group reviewed the patient invitation documentation and suggested the need for an active decline
procedure (should patients wish to not take part, they were asked to return the empty questionnaire) to
ensure that reminders were not sent to people who declined.
Non-respondents were sent one postal reminder and the practice had the option of telephone reminders if
the recruitment target was not met.
Recruitment of carers
Formal or informal carers of consented patients were invited to contribute to a substudy investigating their
views and experiences. Carer information sheets, carer consent forms and carer baseline surveys were used
(see Report Supplementary Material 8–10 and Appendix 10).
Randomisation, concealment and blinding
Practices were the unit of allocation and were allocated in a 1 : 1 ratio to receive either the intervention or
continue care as usual (control group). Randomisation was stratified by area (Bristol, Greater Manchester
or Ayrshire) and minimised by practice deprivation and list size. The minimisation algorithm retained a
probabilistic element, which varied depending on the degree of imbalance between arms (see Appendix 11).
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To ensure concealment of allocation, the randomisation procedure was performed by the trial statistician
blind to the practice details, using a randomisation system run from the Bristol Randomised Trials Collaboration
(BRTC). Allocations were performed in blocks of two in each area. We waited until a pair of practices had been
recruited at any one site and then randomly allocated both practices simultaneously and released details of
the allocation at the same time to local researchers so that those recruiting practices were unaware of the next
allocation. Practice randomisation occurred only after eligible patients had been invited to participate.
After randomisation, the statistician informed the research team, which communicated the allocation to
the practice and arranged practice set-up in the intervention practices. The research team also informed
participants of their practice’s allocation by post. Participants were notified several weeks after practices
were allocated, once practices had been trained and were ready to start delivering the intervention.
Owing to the nature of the intervention, it was not possible to blind participants to their treatment arm
after allocation, nor was it possible to blind the research team to allocation when they collected data from
GP records. The primary outcome and most secondary outcomes were collected by patient self-report but
entered on to the database and analysed blind to allocation. The trial statistician became unblinded when
she presented the main results to the TSC and DMC. It was not possible for her to remain blind when
analysing the process measures.
Intervention arm
The intervention was the 3D approach to the management of multimorbidity in general practice, which is
described in the preceding chapter.
Usual-care arm
Practices allocated to the usual-care arm continued to provide their patients with care as usual. In many
practices this meant that patients would be called to different long-term condition clinics, possibly seeing
different nurses and doctors, which may focus on collecting data related to QOF targets rather than a
patient’s priorities or quality of life.
Usual care was likely to vary between practices depending on the practice size and staffing, the
demographics of the practice population, area deprivation levels and local/regional circumstances. In
addition, practice circumstances could change with staff being ill or leaving the practice, changes to
infrastructure such as practices merging or the introduction of other policies or higher-level initiatives.
The nature of usual care in both intervention and control practices was examined at the beginning and
end of the study as part of the process evaluation.
A checklist describing the content of the intervention and usual-care arms using the TIDieR framework55 is
provided as Report Supplementary Material 11.
Outcome measures
The outcome measures were chosen to reflect the problems and strategies that the intervention was
designed to address (Figure 5). Although this trial included a large number of secondary outcomes, this
reflects the complex nature of the intervention, which included a number of strategies operating at the
different levels of practice, clinician and consultation.
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• Care that is joined up (LTC6)
• PACIC measure of chronic disease management
• Overall satisfaction
• Number of hospital admissions
• Number of outpatient attendances
• Number of times hospital physician contacted
   
• Care related to patients’ priorities (LTC6)
• Bayliss measure of illness burden
• EQ-5D-5L
• Self-rated health
• Quality of disease management
• HADS Anxiety score
• HADS Depression score
• Multimorbidity Treatment Burden Questionnaire
• Medication adherence: MMAS-8
• Number of drugs prescribed
• Number of high-risk prescribing indicators
• Patient has written plan
• CARE measure
• Continuity of care – COC index
• Continuity of care – Visit Entropy
Outcome measuresStrategies to address problems
Identify and prioritise patients
with multimorbidity for a
different type of care
Improve continuity of care
• Responsible GP
• Longer consultations when
   needed
Co-ordinated, holistic reviews
• Instead of disease-focused
   reviews
Lack of holistic,
patient-centred care
• Care driven by 
   single-disease targets
• Patients’ priorities
   not addressed
• Lack of continuity of
   care; no one person
   with detailed
   understanding and
   overall responsibility
High illness burden
• Multiple symptoms
   and impairments
• Depression common
• Poor disease control
High treatment burden
• Multiple appointments
• Polypharmacy
• Poor co-ordination
   of care
• High self-management
   requirements
Improve integration with
secondary care
• Easy access to nominated
   generalist physician
Problems for patients with
multiple long-term conditions
Patient-centred ‘3D’ reviews to
focus on
• Dimensions of health
   • Patients’ priorities and needs
   • Quality of life and function
   • Disease management
• Depression – identify and treat
• Drugs – simplify treatment
   regimes, address adherence
• Develop explicit and written
   plans with patient
FIGURE 5 Relationship between strategies in 3D intervention and outcomes. COC, continuity of care; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; HADS, Hospital Anxiety
and Depression Scale; LTC6, Six-item Long-Term Conditions questionaire; MMAS-8, Morisky Medication Adherence Scale-8 item; PACIC, Patient Assessment of Chronic Illness
Care Scale.
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Outcomes were measured following recruitment (T0), at 9 months (T1) and 15 months (T2). The original plan
was to collect data after 6 months and 12 months but this was changed after the pilot study in the light of
experience that it took about 3 months for practices to be trained and set up to deliver the intervention.
The first follow-up at 9 months was conducted because it was plausible that the 3D intervention would be
effective only in the short-term, with any effects disappearing by 15 months. However, such shorter-term
effects may still warrant implementation of 3D into primary care practice. The 15-month follow-up period
was chosen as the longest duration of follow-up deemed feasible in this trial, although the effects of the
intervention may accumulate over a longer period if the intervention was continued, with regular 3D
reviews every 6 months.
Primary outcome measure
The primary outcome was health-related quality of life as measured by the EuroQol-5 Dimensions,
five-level version (EQ-5D-5L) at 15 months. This generic health status measure has five dimensions
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of which is scored
on a five-point scale from ‘no problems’ to ‘extreme problems’.
Secondary outcome measures
A series of secondary outcome measures were collected to examine health domains targeted by the
intervention and believed to be important in multimorbidity.
The patient secondary outcomes are listed in Table 1 and described below.
Consultation and Relational Empathy measure (CARE): this is a measure of relational empathy. It consists
of a 10-item questionnaire and a total score based on a summation of individual scores.72
Six-item Long-Term Conditions questionnaire (LTC6): this is a brief 6-item questionnaire designed to
measure patient perceptions of aspects of their long-term condition management. Two questions from the
LTC6 were included: ‘Did you discuss what was most important to you in managing your own health?’
and ‘Do you think the support you receive is joined up and working for you?’.
Patient Assessment of Chronic Illness Care Scale (PACIC): this is a 20-item questionnaire designed to
measure specific actions or qualities of care that reflect patient-centred care within the Chronic Care
Model, including patient activation, delivery system design, decision support, goal-setting, problem-solving
and follow-up/co-ordination of care.73
Overall satisfaction: a single question item on a five-point scale about how satisfied the participant was
with the care they received at their GP surgery or health centre.
EQ-5D-5L (at 9 months): this was the primary outcome at 15 months but treated as a secondary outcome
at 9 months.
Self-rated health: a single question item on a five-point scale about self-rated health, from ‘poor’ to ‘excellent’.
Bayliss measure of illness burden: for each of 27 long-term conditions, respondents selected those that
they experience and rated each selected condition on a five-point scale from 1 (interferes with daily
activities ‘not at all’) to 5 (interferes with daily activities ‘a lot’). Respondents were additionally allowed to
add medical conditions not already on the list. The overall score representing level of morbidity is then the
sum of conditions selected weighted by the level of interference assigned to each (i.e. the sum of the
interference scores).74
The Hospital Anxiety and Depression Score (HADS): this consists of seven questions on anxiety and
depression. Responses are summated to produce separate scores for anxiety and depression.75
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Multimorbidity Treatment Burden Questionnaire (MTBQ): this was based on a new questionnaire
developed and validated by the research team. Details of the scale development and validation are
published elsewhere.76 The measure consists of 10 items each scored from 0 to 4. The total score was
calculated by calculating the average score for each patient and then multiplying by 2.5 to get a value
from 0 to 100.
Morisky Medication Adherence Scale – 8 item (MMAS-8): this is a validated measure of adherence to
medication.77–79 Use of the © MMAS is protected by US Copyright laws. Permission for use is required.
A licence agreement is available from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue,
WA 98007, USA or from dmorisky@gmail.com.
TABLE 1 Secondary outcomes to be collected in the 3D study, to be compared between trial arms
Secondary outcome Source Scale
Time point
T0 T1 T2
Experience of holistic patient-centred care
CARE measure of relational empathy (GP) Questionnaire – 10 items 10–50 ✓ ✓ ✓
CARE measure of relational empathy (nurse) Questionnaire – 10 items 10–50 ✓ ✓ ✓
Care related to patients’ priorities (LTC6) Questionnaire – 1 item 1–4 ✓ ✓ ✓
Care that is joined up (LTC6) Questionnaire – 1 item 1–4 ✓ ✓ ✓
PACIC measure of chronic disease management Questionnaire – 20 items 1–5 ✓ ✓ ✓
Overall satisfaction Questionnaire – 1 item 1–5 ✓ ✓ ✓
Burden of illness measures
EQ-5D-5L Questionnaire – 5 items ✓ ✓ ✗a
Self-rated health Questionnaire – 1 item 1–5 ✓ ✓ ✓
Bayliss measure of illness burden Questionnaire – 27+ items 0–145 ✓ ✓ ✓
HADS Anxiety score Questionnaire – 7 items 0–21 ✓ ✓ ✓
HADS Depression score Questionnaire – 7 items 0–21 ✓ ✓ ✓
Burden of treatment
Multimorbidity Treatment Burden Questionnaire Questionnaire – 10 items 0–100 ✓ ✓ ✓
Medication adherence: MMAS-8 Questionnaire – 8 items 0–8 ✓ ✓ ✓
Number of drugs prescribed Practice records ≥ 0 ✓ ✗ ✓
Number of high risk prescribing indicators Practice records ≥ 0 ✓ ✗ ✓
Process outcomes
Continuity of care – COC index Practice records 0–1 ✓ ✗ ✓
Continuity of care – Visit Entropy Practice records 0–log2(1/k) ✓ ✗ ✓
Quality of disease management Practice records 0–100 ✓ ✗ ✓
Number of hospital admissions Practice records ≥ 0 ✓ ✗ ✓
Number of outpatient attendances Practice records ≥ 0 ✓ ✗ ✓
✓, included; ✗, not included; COC, Continuity of Care; MMAS-8, Morisky Medication Adherence Scale – 8 item.
a EQ-5D-5L is also measured at 15 months; this is the primary outcome for the study, not a secondary outcome.
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Number of drugs prescribed: this was based on the number of different drugs prescribed to each
participant in the previous 3 months, extracted from medical records. Each different drug name was
counted as one, irrespective of dosage or quantity, and multiple prescriptions of the same drug were
counted just once.
Number of high-risk prescribing indicators: this was based on a number of > 100 indicators of potentially
inappropriate prescribing developed for the Prescribing Outcomes from implementing Enhanced
Medication Summaries (POEMS) and Data-Driven Quality Improvement in Primary Care (DQIP) studies80
by one of the research team (BG). The indicators were mainly drawn from existing recognised indicators
(Beers, START/STOPP, RCGP criteria)81–83 adapted for implementation in electronic medical records. The
score represents the number of adverse warnings of potentially inappropriate prescribing triggered for
each patient.
Continuity of care: this was assessed in relation to face-to-face (home or surgery or nursing home) or
telephone consultations between participants (not family members/carers) and GPs [not nurses, health-care
assistants (HCAs) or medical students] over the 12 months before recruitment and the 15 months after
recruitment during which the participant was in the trial. Longitudinal continuity of care was measured in
two ways: first, using the well-established Continuity of Care (COC) Index84 and, second, using the Visit
Entropy measure.85 Visit Entropy is a relatively new measure, in which higher entropy indicates greater
randomness (i.e. less continuity). Visit Entropy H(X) of a discrete random variable X can be calculated as:
H(X) = −Σki=1 p(xi)log2 p(xi), (1)
and the probability of visiting the ith provider is estimated as:
p^(xi)≈
ni + 1

k
N + 1
, (2)
where ni is the number of observed visits to the ith provider, k is the total number of possible providers,
and N is the total number of observed visits. H(X) approaches its minimum value of zero when a patient
has perfect continuity of care, visiting only their primary physician, and approaches its maximum when
there is no continuity of care.
Quality of disease control: this is based on the QOF indicators and uses the ‘patient average’ method of
Reeves et al.86 It was measured as a percentage for each individual patient, whereby it represents the
percentage of QOF chronic disease management indicators that apply to that patient which were
successfully met.
Number of admissions and number of outpatient attendances: these have important consequences for
policy and will, therefore, be reported as separate outcomes. They are based on data extracted from
medical records.
Carer outcomes
The impact of the 3D intervention on carers was assessed by a self-reported carer survey as part of
the carer substudy. The carer outcome measures were collected at the same three time points as the
patient questionnaires:
l Carer experience scale87,88 – this is a 6-item questionnaire. Preference-based index values are available
to transform the six responses to a profile measure value between 0 and 100.
l Carer health-related quality of life (EQ-5D-5L).
l Multimorbidity Treatment Burden Questionnaire for Carers (adapted from the MTBQ).
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Sociodemographic measures
The following sociodemographic measures were collected from the self-reported questionnaires
at baseline:
l age
l sex
l ethnicity
l education
l work status
l number of long-term conditions, based on responses to Bayliss measure74
l deprivation status [Index of Multiple Deprivation (IMD), based on domiciliary postcode].
These baseline demographic characteristics were checked for skewness and balance between the two allocation
groups. These could form potential effect modifiers or be adjusted for accordingly in the statistical analyses.
Process measures
Patient-level process of care measures were extracted from practice records using a custom search. Data
from 12 months prior to practice randomisation and patient recruitment (T0) and through the 15-month
study period were compared between trial arms. The measures collected were:
l number of GP and nurse consultations
l mean duration of face-to-face consultations with GP and nurse
l number of different review consultations [e.g. diabetes mellitus, asthma, chronic obstructive pulmonary
disease (COPD), dementia, mental health and rheumatoid arthritis, also including 3D reviews]
l patients receiving at least one chronic disease review
l patients reporting having a written care or treatment plan.
The number of chronic disease reviews for some long-term conditions was summarised for each treatment
group [diabetes mellitus (based on diabetic foot risk assessment), asthma, COPD, dementia, mental health
and rheumatoid arthritis], in each case using the number of participants in the practice with the relevant
condition as the denominator. This list of important long-term conditions did not include all the conditions
used as inclusion criteria for the trial. However, these were the only conditions in which all practices are
incentivised to record reviews, so data were routinely available.
Additional data were collected to describe implementation of the intervention, as shown in Table 2.
These data were not relevant to the usual-care arm of the trial.
Serious adverse events/reactions and safety
Given the study population, a high frequency of new medical diagnoses, hospital admissions and deaths
was expected. It was agreed by all study oversight committees that these would not be considered
potential serious adverse events (SAEs) unless participants, practice staff or researchers notified that they
considered the event to be related to the intervention or research processes, [i.e. only serious adverse
reactions (SARs) would be investigated and reported]. However, all deaths were investigated by requesting
than the participant’s GP provide details of the cause of death, expectedness and relatedness to the study
(see Report Supplementary Material 12 for deceased reporting form).
All SARs and death reports were reviewed by the trial clinician. Any SARs thought to be related to
treatment or research and of unexpected nature were reported immediately to the TSC and funder,
and to the REC within 7 days of notification (to allow for further investigation).
Serious adverse events and deaths were monitored and reported regularly to all trial oversight committees.
DOI: 10.3310/hsdr07050 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 5
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Salisbury et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Data collection, follow-up and data management
Participant study data primarily comprised self-reported questionnaires and the extraction of primary and
secondary care usage from patient records.
Questionnaire follow-up procedures
Postal questionnaires were the primary method of data collection. (See Appendices 12 and 13 for copies of
the final patient and carer follow-up questionnaires.)
Just before follow-up questionnaires were due, the local research team checked with the participating
practice that the patient had not died or left the practice. A paper questionnaire booklet with return
envelope was posted at 9 and 15 months post recruitment. Participants who had not returned a completed
questionnaire within 14 days were sent a reminder letter and another questionnaire. Non-responders
following the first reminder were given a second reminder by telephone 14 days later and provided with
options of being sent another questionnaire, providing data by telephone or by home visit or completing
the primary outcome (EQ-5D-5L) only.
Participants were sent a £5 gift voucher for completing each questionnaire as compensation for their time.
Data extraction from patient records
Data about primary and secondary care contacts and medications were collected during notes reviews at
the end of the study. Custom-built electronic searches were installed and run in each GP practice. These
collected data about primary care appointments and contacts, any tests/investigations ordered, prescriptions
and deaths. In addition, the local researcher(s) manually collected information regarding secondary care use
TABLE 2 Patient-level process of care measures to describe implementation of the intervention
Process measure Source Scale
Time point
T0 T1 T2
Number of nurse 3D reviews Practice records 0, 1, 2 ✗ ✗ ✓
Number of GP reviews Practice records 0, 1, 2 ✗ ✗ ✓
Compliancea Practice records None, partial, full reviews ✗ ✗ ✓
Most important problem noted Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
EQ-5D-5L pain question noted Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
PHQ-9 entered Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
Medication reviewed by pharmacist
(at least one comment entered)
Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
Medication adherence noted Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
First patient goal noted Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
First plan noted (‘what patient can do’) Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
First plan noted (‘what GP can do’) Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
Patient agenda printedb Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
3D plan printedb Practice records 0 (No), 1 (Yes) ✗ ✗ ✓
Number of times hospital physician was contacted Physician records ≥ 0 ✗ ✗ ✓
a Compliance defined as: full – two GP 3D appointments and two nurse 3D appointments; ‘partial’ – at least one GP or
nurse 3D appointment; and ‘none’ – no GP 3D appointment and no nurse 3D appointment (see Components relating to
clinicians conduct of reviews).
b Not available in practices in Scotland.
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(see Report Supplementary Material 13). This included out-of-hours contacts, outpatient appointments,
secondary care tests/investigations, accident and emergency (A&E) attendances and hospital admissions.
During this manual process, local researchers also collected data about 3D reviews conducted.
Data management
The patient, carer and practice staff contact details needed for trial management were held in a database
by the Bristol Randomised Trial Collaboration (BRCT), held on secure servers at the University of Bristol.
All paper questionnaires and records data were collected and managed on the Research Electronic Data
Capture (REDCap) system, a secure, web-based application for research data capture, hosted on a central
server at the University of Bristol.89 Only anonymised questionnaire and clinical report form data were
stored on this database. At least 10% of questionnaire data at each site were subject to double data entry
to ensure reliability. In the event of a discrepancy rate of ≥ 1% for any item, these discrepancies were
resolved, where necessary by checking that item in all questionnaires.
When possible, personal identifiable details were removed from hard-copy documents and replaced with
the unique trial identification number. All data were stored securely and confidentially at all sites in
accordance with data management policies.
Sample size
The study was designed to detect an effect size of 0.274 standard deviations (SDs) in the primary outcome
of the EQ-5D-5L. At the time the study was planned, data about the variability of the new 5-level (5L) version
of the EQ-5D were more limited than for the well-established 3-level version. The SD of the EuroQol-5
Dimensions, three-level version (EQ-5D-3L) in the UK general population is 0.23, rising to 0.27 in the oldest
respondents (aged > 75 years).90 Hence, an effect size of 0.274 would equate to a detectable difference of
(0.274 × 0.27) = 0.074 on the EQ-5D-3L, previously deemed to be the minimally important difference
(MID).91 Although fewer data are available about the variability in the EQ-5D-5L than the EQ-5D-3L version,
it was decided to use this latest version of the EQ-5D as it is likely to have greater sensitivity to change.
Based on data available from our previous studies, we estimated that 2.3% of adult patients would have
multimorbidity in terms of three or more long-term conditions as defined in this study. This equates to
about 108 patients in an average sized practice of 6000 patients (i.e. 3456 potentially eligible patients
in 32 practices). We made the following assumptions: 40% of patients agreed to participate (n = 1382),
80% were followed up to 15 months and an intracluster coefficient (ICC) of 0.03 was assumed for clustering
at the practice level (based on the WISE trial).92 This would provide 1106 patients (34.6 per practice) for
analysis. We estimated the power of study using the clsampsi programme in Stata version 14 (StataCorp LP,
College Station, TX, USA),93 using the assumptions of equal numbers of patients per practice and equal ICC
in both arms. Using this programme, a sample of 1106 patients for analysis provided 87% power at a 5%
significance level to detect an effect size of 0.274 SDs in the EQ-5D measure between the intervention and
usual-care arms.
After the trial was planned we became aware of two studies that had been published determining a MID
for the EQ-5D-5L based on UK data. Nolan et al.94 published EQ-5D-5L data from 616 COPD outpatients
(mean age of 70.4 years), reporting a SD of 0.24 (consistent with the EQ-5D-3L and the above sample size
calculation). They used distribution- and anchor-based methods to determine a MID for COPD of 0.051
[95% confidence interval (CI) 0.037 to 0.063]. McClure et al.95 used a simulated approach based on
instrument-defined health transitions and identified a MID for England of 0.063 (SD 0.013). The sample size
calculation for the 3D study was determined to detect a difference of 0.074 (based on the EQ-5D-3L – the
best estimate for the EQ-5D-5L at the time). Interpretation of the findings will also include consideration of
the alternative MIDs (such as Nolan et al.94 and McClure et al.95), as the study may be underpowered to
detect a MID < 0.074.
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Statistical analyses
The aim of the statistical analyses was to assess the impact of the intervention on health-related quality of
life, illness burden, treatment burden and patient experience as well as carer’s burden and quality of life.
Stata 14.196 was used for all statistical analyses.
All analyses were conducted in accordance with a statistical analysis plan (SAP) and a health economic
analysis plan, which were written before analysis began and approved by the DMC. Any analyses not
included in the analysis plan are indicated when reporting results.
General considerations
Full analysis set
All consented patients were analysed in the groups in which their participating practices were allocated.
Missing data were imputed. Deceased patients were given an EQ-5D-5L value of zero. Protocol deviations
and non-compliance were disregarded in this and all analyses, given the pragmatic nature of the trial.
Complete cases set
In the complete-case analysis, consented patients were analysed in the randomised groups that the
practices were allocated but missing data were not imputed.
Missing data
The non-return of participants’ questionnaires resulted in missing data. It was expected that the
proportions of missing data would be similar between the two study arms. This was examined by
comparing the baseline characteristics between participants with and without 15-month follow-up data.
The primary analysis for EQ-5D-5L included the full analysis set, comprising all patients in the groups as
allocated and imputing missing data. We conducted multiple imputation chained equations (MICEs)
including baseline, 9 month, 15 month and EQ-5D-5L data as available, intervention arm, stratifying/
minimisation variables and other covariates that were informative of missingness.
The multiple imputation model included the following variables: EQ-5D-5L at baseline, 9 and 15 months,
HADS anxiety subscore at baseline and 9 months, group allocation, country (England or Scotland), practice
deprivation score (calculated differently for England and Scotland), practice list-size, practice ID (categorical
variable to account for clustering), site (Bristol, Manchester or Glasgow), whether a patient had any of the
following long-term conditions, i.e. serious mental health problems, dementia, learning disability or
depression, at baseline (yes or no), baseline age, sex, death status (not died, died before 9 months, died
before 15 months), withdrawn from the trial before 15 months (yes or no), participant baseline home
deprivation score (calculated differently for England and Scotland), and the number of long-term conditions
a patient had at baseline. In addition to this, aggregate cost variables covering all measured types of health
and social care were included. The model was run in Stata 14.2 using the mi impute chained command,
which performs imputation by chained equations. All missing data were imputed by the predictive mean
matching method using five nearest neighbours and 40 imputations.
A sensitivity analysis investigated the influence of imputing or excluding missing data on the primary analysis.
Secondary outcomes used complete-case data for analyses, with the exception of derived outcomes within
validated questionnaires, where accepted procedures for processing missing data in that questionnaire
were followed.
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Study centre effects
Randomisation was at the level of general practices. Each practice was a cluster and the effect of practice
was taken into account as a random effect in multilevel regression models.
Outliers
Each data variable was separately checked for validity and any outliers (> 3 SD of the mean) were manually
checked. Cook’s distance was used to examine influential observations and sensitivity analyses conducted
on any outliers removed.
Participants characteristics
The flow of participants through the study were summarised in a Consolidated Standards of Reporting
Trials (CONSORT) diagram.
Participant demographics
Patients’ age, sex and number of long-term conditions were reported for eligible patients and the study
population to assess external validity. For study participants, ethnicity, deprivation level, employment status
and age on leaving full-time education were compared between trial arms.
Baseline characteristics
Distributions of continuous variables were examined and, if normally distributed, were summarised as a
mean and SD. For continuous variables that were not normally distributed, median and interquartile range
(IQR) were presented. Categorical data were summarised by frequency counts and percentages. Variables
were summarised by trial arm at both the cluster level and individual level.
Baseline characteristics were described by treatment arm and differences were considered in terms of their
clinical importance. Important differences were adjusted for in sensitivity analyses.
Baseline imbalance
Baseline characteristics were compared between the treatment groups, and any potential clinically
important differences were adjusted for in sensitivity analyses.
Missing data
Complete-case analyses were conducted to explore the impact of missing data on the primary analysis.
Analysis of effectiveness
Primary analysis
The tested null hypothesis was that the mean quality of life (measured by the EQ-5D-5L) for patients
receiving the 3D intervention was the same as for those receiving usual care at 15-month follow-up.
Primary analysis involved mixed-effects multivariable linear regression, adjusted for practice (to account for
clustering), minimisation variables (practice size and practice deprivation score) and patient baseline EQ-5D-5L.
Practices/patients were analysed in the groups to which they were allocated and missing data were imputed.
Sensitivity analysis
The following sensitivity analyses were performed to check whether the conclusions drawn in the primary
analysis were sensitive to assumptions:
1. repeat of the primary analysis without imputing missing data
2. treating missing EQ-5D-5L data on account of death as missing rather than zero and without imputation
3. simple imputation using last observation carried forward
4. adjusting the model (without imputation) to account for the number of days between recruitment and
return of the 15-month questionnaire.
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All of the above sensitivity analyses were pre-specified except for (3), which was conducted as a further
check on the effect of imputing missing data using multiple imputation, given concerns that the assumption
of data being missing at random may not be valid.
Secondary analysis
All secondary outcomes were considered at 9 and 15 months and were adjusted for baseline measures of
outcome, minimisation variables and practice (as a random effect).
Distributional and assumption checks were carried out for all outcomes and the most appropriate models
of analysis were selected, namely mixed-effects ordered logistical regression for ordinal outcomes and
mixed-effects linear models for continuous outcomes.
Although the primary time point for analyses is 15 months, we also considered effectiveness at 9 months
separately for the reasons previously discussed.
Process of care measures
Patient-level process measures (apart from secondary care usage and provision of 3D reviews) were
collected at baseline and 15 months via extraction from practice records. Some were pre-specified as
secondary outcomes (see Table 1). Other measures were collected to compare the process of care in each
trial arm and, although not considered outcomes, were analysed in the same way.
Additional process of care measures (see Table 2) were collected for the intervention arm only.
These described the intervention implementation and no comparative analyses were performed.
Fidelity
Fidelity, defined as the degree to which participants received the intended intervention, was explored in
detail in the process evaluation in terms of variation in how the intervention was delivered (see Chapter 7).
Quantitative measures of fidelity to the 3D approach were assessed in the 3D intervention arm. These
reported the proportion of participants receiving each of the main elements of the intervention.
For the main statistical analyses, fidelity (at the patient level) was defined as ‘full’ (receiving two GP 3D
appointments and two nurse 3D appointments), ‘partial’ (receiving at least one GP or nurse 3D appointment,
but not full attendance) and ‘none’ (no GP or nurse 3D appointments attended).
A complier-average causal effect (CACE) analysis was then performed for the primary analysis of EQ-5D-5L.
This included two analyses with a dichotomous indicator variable for compliance: one analysis amalgamated
participants in full and partial groups and the other combined those in none and partial groups.
The CACE estimates were obtained using instrumental variable regression, including the same variables
used in the primary analyses, randomised group as an instrumental variable and the indicator variable
for compliance.
Potential effect modifiers
Potential effect modifiers were selected a priori, informed by previous evidence. Appropriate interaction
terms were added to regression models. Effect modifiers explored included:
l participant age (above or below the median)
l number of long-term conditions (3 or ≥ 4)
l deprivation (quartiles of consenting participants by country)
l probable depression (presence or absence).
Given that subgroup analyses are not usually sufficiently powered to specifically test their effects, these
analyses focused on interpretation of 95% CIs.
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A further subgroup analysis, to explore baseline health status as a potential effect modifier, was added
post hoc to test a hypothesis generated through the process evaluation.
Safety analysis
Serious adverse reactions
As previously mentioned, hospital admissions and deaths were not considered SAEs, unless the research
team was notified (by participants or general practice staff) that the event was considered to be related to
the intervention or the research.
For each treatment arm, we report the number and percentage of participants who experienced a SAE
related to the intervention or research.
Deaths
Given the study population, some deaths were expected during the study period. All deaths were
investigated as described previously.
The numbers and percentages of deaths in each arm were reported. Cox regression with random effects
were considered to calculate the hazard ratio with corresponding 95% CIs and p-values. Models were
adjusted by minimisation variables, age and number of long-term conditions (3 or ≥ 4) and EQ-5D-5L
at baseline.
Unintended consequences
Focusing effort on one group of patients (in this case, those with multimorbidity) could lead to reduced
efforts and reduced quality of care in the other patients.29 In order to compare care in patients with and
without multimorbidity, we collected anonymous data about the performance against QOF targets for
all patients in participating practices with any of the index conditions (individually or in combination)
that were included in our definition of multimorbidity, using electronic download from medical records.
Using tests of interaction, we compared care in each arm of the trial in patients with and without
multimorbidity in the year before and the 15 months after the intervention, and also compared patients
with multimorbidity who did or did not participate in the 3D trial.
Process evaluation methods
Aim and design of process evaluation
Process evaluation aids interpretation of trial results. For example, if a trial shows that an intervention
works, process evaluation can explore how the intervention works, what components are particularly
helpful, for whom, why and in what contexts. If a trial shows that an intervention does not work, is this
attributable to intervention failure (flawed intervention concept) or implementation failure (poor intervention
implementation)?97
The design of the process evaluation underwent some evolution during the trial as it became clearer how
the aims could best be met. The final protocol was published in BMJ Open in 2016.71 The design was
informed by process evaluations of public health interventions98 and drew particularly on a process
evaluation framework for cluster RCTs of complex interventions99 and on MRC guidance.100
The evaluation was structured around four trial stages: (1) initial response of the practices to the training,
(2) delivery of the intervention to patients, (3) patients’ and health professionals’ perceptions of the
intervention and (4) maintenance of the intervention over time. In addition, we evaluated how context
influenced the trial in affecting how practices implemented the intervention and through an evolving
usual-care comparator. As well as achieving all the objectives of the protocol, the completed evaluation
includes extra data collected from usual-care practices, providing greater insight into the comparator.
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Summary of process evaluation methods
Multiple methods were used for the process evaluation, combining quantitative and qualitative methods,
and collecting data from various sources, including patients in the trial (and carers), health professionals
and administrative staff and other key stakeholders (e.g. commissioners).
Quantitative process evaluation methods
Quantitative data were collected from all practices in the trial, describing usual care and the context
within which the intervention was being delivered. A mixed quantitative and qualitative pro forma was
completed by practices, which characterised their systems of care for patients with long-term conditions
at the beginning (see Report Supplementary Material 14) and end of the trial (see Report Supplementary
Material 15 and 16). Clinicians in all practices were also asked to complete a questionnaire regarding
their attitudes to care for patients with multimorbidity at the start of the trial (see Report Supplementary
Material 17). Clinicians who had delivered 3D reviews were asked to complete a similar survey reflecting
their opinions of the intervention at the end of the trial (see Report Supplementary Material 18). After
initial training, evaluation forms were completed by all attending clinicians in intervention practices
(see Report Supplementary Material 19 and 20). The monitoring/feedback searches described previously
contributed to the evaluation of intervention fidelity and maintenance (see Table 2), although a summary
of these data was also generated as part of a monthly monitoring search to feedback to practices to
support maintenance (see Appendices 2 and 3).
Qualitative process evaluation methods
Qualitative methods were used at all trial stages. Initially, at least one commissioner from each recruiting
area was purposively sampled for interview to understand the commissioning context and to identify
the barriers to and facilitators of commissioning a service like 3D. Interviews were conducted face to
face or by telephone. It was important to gauge how the new approach would fit in with current local
commissioning models, for example QOF-type incentive targets or Local Enhanced Services, and to be
aware of policy changes in the short- and long-term future.
Four intervention practices were purposively sampled as case studies from the three geographical areas
to include variation in practice size (number of patients), deprivation and similarity of usual care to the
intervention (as determined from practice proformas at baseline). We assumed that (1) larger practices
may have lower continuity of care and a lower proportion of clinicians taking part in 3D which may
affect implementation and (2) practices organised in a similar way to the 3D approach may adopt it more
readily. Thus, we hoped for a sample that would vary in implementation. Practices were recruited as case
studies while undergoing intervention training to allow evaluation of the whole trial process. ‘Responsive’
investigation of emerging issues (identified from practice champion meetings and from researcher
feedback) led to data collection in five other intervention practices. Some qualitative data were collected
from usual-care practices to enable comparison with usual-care systems. When a practice was recruited as
a case study, verbal consent was obtained from the practice champion.
Within each case study practice, purposeful sampling of staff ensured inclusion of all roles involved in 3D,
namely GPs and nurses who delivered 3D reviews, and practice managers and administrative staff who
organised reviews. All staff agreeing to individual interviews or observation provided written consent
(see Report Supplementary Material 21–23).
During recruitment to the trial, patients were informed that they may be invited to participate in an
optional process evaluation. Within case study practices, patients were sampled for interviews, observation
or focus groups. For interviews and focus groups, patients were purposively sampled for variation in age,
sex, self-rated health and satisfaction with care, recorded at baseline. For observation, patients were
sampled for variation in their named GP or nurse. Patients selected to participate received additional
written and oral information and provided written consent (see Report Supplementary Materials 24–28).
METHODS
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Within case study practices, we recorded observations of 3D reviews being delivered to participants by
nurses and GPs, conducted interviews with practice staff, patients and carers, and arranged focus groups
with patients and carers. For observations, clinicians and patients were given the choice of video-recording
without the process evaluation researcher present, or observation and audio-recording by the researcher
(see Report Supplementary Material 29 and 30). Almost all clinicians opted for the latter. Patients generally
had no preference. Practice staff interviews took place at the practice. Patient interviews took place in
patients’ homes, at the practice or other convenient place. Focus groups were arranged in local halls or,
in one case, in the practice. All interviews and focus groups were audio-recorded except for a few informal
interviews following review observations.
Process evaluation: analysis
The qualitative data were used in two main ways: to inform ‘thick description’6 of implementation of the
intervention in case study practices and for cross-case thematic analysis7 of recurring issues relevant to
intervention implementation. The data were analysed in parallel with ongoing data collection, so that
emerging issues were incorporated into future data collection. For the case study descriptions, detailed
narrative summaries were produced describing the local practice context within which the intervention
was being delivered, how the practice responded to, delivered and maintained the intervention, and how
patients, carers, clinicians and practice staff perceived the intervention (see Report Supplementary Material 31).
For the thematic analysis, NVivo v.11 software (QSR International, Warrington, UK) was used to facilitate both
deductive and inductive coding, allowing the identification of both anticipated themes (e.g. those relating
to the key components of the intervention) and emergent themes across the four case studies. Qualitative
analysis was led by the process evaluation researcher (CM), with input from a qualitative methodologist (AH)
and senior academic GP with experience of process evaluations (BG) to enhance the trustworthiness and
credibility of the findings. Cindy Mann collected and analysed all the process evaluation qualitative data.
Alison Shaw and two members of the PPI group read and provisionally coded a sub-set of qualitative
transcripts. Alison Shaw and Bruce Guthrie commented on the developing coding framework, agreed the final
themes and contributed in detail to writing up the qualitative findings. Analysis of all the process evaluation
data took place prior to knowing trial outcomes.
Owing to the multiplicity of methods used in the process evaluation, for ease of reference we have created
a summary table (Table 3) that details the objectives and data collected to evaluate context and each of
four trial stages (response to training, delivery, participant perspectives and maintenance). The process
evaluation results in Chapter 7 are described using the same structure. (See also Report Supplementary
Material 32 for observation, interview and focus group schedules used in case study practices.)
Changes to trial design
Amendments to the trial after the protocol was written are summarised in Appendix 14. Correspondingly,
the trial registry was changed on three occasions (see Appendix 15).
Patient and public involvement
As a key study objective was to provide patient-centred care, it was particularly important to incorporate
a large PPI component within the study. The initial PPI group comprised 14 members who had two or
more long-term conditions (including mental health conditions) or who cared for a person with multiple
conditions. The group met face to face every 3 months to discuss progress and any issues arising from the
study. The group was led by a PPI facilitator (CM) and meetings were attended by the local Bristol research
team. PPI members were reimbursed for their time (£12 per hour, for an average meeting length of
2–3 hours plus preparation time, paid in vouchers), were paid travel expenses and had lunch provided.
Two members of the PPI group were also members of the TSC and trial advisory groups.
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TABLE 3 Summary of process evaluation objectives and methods/data by trial stage
Trial stage Objectives Methods and data
1. Context (and usual
care)
To characterise usual care in all GP
practices at the beginning and end of
the trial period to identify variation in
usual care and how this might affect
implementation
Quantitative
l Practice profile form for every practice at baseline
and end of trial to characterise practice organisation
and usual care for long-term conditions
l QOF data from each practice at baseline and at
the end of the trial
l Continuity of care measure applied to each
practice as part of the trial
Qualitative
l Interviews with commissioners in each
geographical site participating in the trial
To identify changes in the care of
patients with multimorbidity occurring
in both intervention and usual-care
practices during the trial that might
affect outcomes
To understand the local commissioning
context within which the intervention
was to be implemented
2. Initial response
of practices to the
training (adoption)
To explore initial attitudes to the
intervention among practice staff
Quantitative
l Purpose-designed attitudes and beliefs
questionnaire regarding care for people with
multimorbidity to nominated health professionals
in all practices in the trial
l Training evaluation forms from all health
professionals in intervention practices who
attended 3D training to rate the training and
elicit comments about the intervention
l Survey of administrative implementation
completed for each intervention practice to
describe how they had accommodated 3D within
their administrative systems
Qualitative
l Observation of 3D training in six intervention
practices
l Semistructured interviews in each case study
practice with the GP champion for 3D, lead
nurse and lead administrator for 3D
To explore how and why organisational
aspects of the 3D intervention were
implemented (or not)
3. Delivery (nature
and fidelity of the
intervention delivered)
To examine the extent to which
practices delivered components of the
intervention
Quantitative
l proportion of pharmacy reviews completed
during the trial
l proportion of 3D patients screened for
depression during the trial
l proportion of 3D patients who received a printed
agenda to take to part 2 of the review during
the trial
l proportion of 3D patients receiving a health plan
and provided with a printed copy during the trial
Qualitative
l non-participant observation and recording of
17 3D reviews in case study practices, 11 reviews
in other intervention practices and nine reviews
in usual-care practices to evaluate how
professionals were delivering the intervention to
patients, including their use of the 3D template
and to examine patient-centredness. This included
assessment of fidelity of delivery of the intervention
to what the research team intended
l follow-on interviews with 10 patients and 10
health professionals after review observation
To explore how health professionals
in case study practices delivered the
intervention to patients, and how
and why their implementation of the
intervention varied
To explore to what extent health
professionals changed their practice to
make it more patient-centred
To examine fidelity of intervention
delivery
METHODS
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At the start of the study, the PPI group had input into the study logo and strap line and they reviewed all
the participant documentation, including patient invitation letters, patient and carer information sheets,
consent forms, questionnaire instructions and the 3D card. They particularly emphasised the language used
(e.g. preferring ‘patients with several long-lasting health problems’ over ‘multimorbidity patients’), font size
and colour contrast (for those with visual impairments) and formatting (preferring one block of text over
several columns). Nine members were interviewed as part of the development of a new questionnaire to
measure treatment burden.76 As part of the intervention development, the PPI group suggested words and
scripts for practice reception staff to steer patients to make longer appointments with their named GP.
One member volunteered to be video-recorded having a mock 3D review consultation, with the video
available for use in training.
The PPI group engaged with the research process, suggesting questions to ask during focus groups with
patients and interviews with clinicians and points to look out for when observing 3D consultations.
Two members helped to code interview transcripts and corroborate themes.
To help with dissemination, the PPI group reviewed patient newsletters, advised on the format of the study
website and suggested a range of regional and national charities and organisations to target.
At the end of the study, an average of eight or nine members were still regularly attending the PPI meetings.
Three members collaborated on writing an academic paper on how the group worked with researchers.
TABLE 3 Summary of process evaluation objectives and methods/data by trial stage (continued )
Trial stage Objectives Methods and data
4. Perspectives of
patients and practices
To characterise health professionals’
perspectives on the intervention
Quantitative
l Purpose-designed questionnaire to all health
professionals who had delivered 3D reviews
Qualitative
l Semistructured interview towards the end of the
trial with the 3D GP champion, a nurse and the
lead 3D administrator in each case study practice
l Semistructured interviews with a convenience
sample of other nurses and GPs both in case
study practices and other intervention practices
l Semistructured interviews with up to four
patients from each case study practice
l One focus group with patients and carers from
each case study practice
To explore how patients and carers
perceived the intervention
To explore to what extent patients and
carers experienced care as patient-
centred during the trial
5. Maintenance (the
extent to which the
intervention continued
to be delivered over
time)
To characterise the extent to which
practices maintained the components
of the intervention over time
Quantitative
l proportion of participating patients given a 3D
review every 6 months
l the level of continuity of care
l number of practice champion meetings attended
Qualitative
l semistructured interviews with GPs, nurses and
administrators (as for response)
l informal interview with a member of the trial
team (e.g. Senior Research Associate) for each
geographical site
To explore how and why practices
maintained (or did not maintain) reach
and delivery of the intervention
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Chapter 5 Statistical results
Practice recruitment
Across the three sites, 35 practices signed up to the study. Two practices subsequently withdrew prior to
randomisation. The remaining 33 practices were randomised: 16 into the intervention arm and 17 to usual
care. Descriptive characteristics of the 33 practices are shown in Table 4. Compared with all practices in
their local area, practices that agreed to participate tended to be slightly larger, in less deprived areas and
had slightly higher scores for patient satisfaction (see Table 4).
Patient recruitment
The searches of practice records identified 9772 patients with three or more conditions from the list of
long-term condition groups shown in Box 1. This represents 3.9% (9772/248,488) of the adult population
in the participating practices. From those potentially eligible patients, 5253 were randomly selected. GPs
excluded 575 (11.0%) of these based on medical record data because they were ineligible or the GP felt
that it would be inappropriate to invite them to participate. Potential participants who were excluded by
their GPs were much more likely to have dementia or learning difficulties and less likely to have diabetes
mellitus or respiratory conditions than those not excluded (see Appendix 16, Table 39). Excluded patients
were also more likely to be female, older and have four or more conditions than those invited.
The flow of participants in the trial is shown as a CONSORT flow diagram in Figure 6.
Baseline characteristics of patients invited to participate
Between May 2015 and the end of December 2015, 4678 patients were invited to take part in the study
and 1546 (33%) provided consent. Invited patients were generally elderly (mean age 71 years), and slightly
more than half were female. The most common groups of long-term conditions from the QOF were
cardiovascular conditions (including chronic kidney disease), respiratory disease (COPD or asthma), diabetes
mellitus and depression.
Those patients providing consent had similar age and sex characteristics and had similar chronic conditions
to the 3132 patients who were invited but did not respond (Table 5), except that fewer had severe mental
health problems, dementia, depression or a learning disability.
Baseline characteristics of participating practices and patients
Comparability between treatment arms: practices
Table 6 shows key characteristics of participating practices. It shows that practices in the intervention arm
were slightly larger than those in the usual-care arm, but similar in terms of levels of deprivation.
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TABLE 4 Characteristics of participating and non-participating practices
Characteristics
Participating
practices: Bristol
(n= 12)
Non-participating
practices: BNSSG
CCGs (n= 86)a
Participating
practices:
Manchester
(n= 11)
Non-participating
practices: Manchester
CCGs (n= 181)b
All practices:
England
(n= 7674)
Participating
practices: Ayrshire
and Arran (n= 10)
Non-participating
practices: Ayrshire
and Arran (n= 46)
All practices:
Scotland
(n= 982)
Size101,102
Average list size 11,360 9337 8531 6389 7450 6874 6869 5736
Age profiles (%)102,103
Patients aged
65–74 years
10.3 8.7 12.1 10.9 17.2 12.4 12.1 10.2
Patients aged
75–84 years
5.8 5.3 6.9 6.1 7.8 7.0 6.9 5.8
Patients aged
≥ 85 years
2.6 2.3 2.9 2.2 2.3 2.6 2.2 2.0
cDeprivation103,104
Deprivation,
mean (SD)
17.3 (13.0) 20.0 (11.3) 14.9 (8.3) 26.5 (11.5) 21.5 28.8 (14.9) 32.5 (15.5)
QOF105
QOF
achievement
(2014/2015), %
98.7 96.6 96.2 96.7 95.5 99.8 98.8 97.3
Satisfaction with GP surgery (%)106,107
Very positive 46.4 41.9 50.0 51.3 43 49.1 47 87
Positive 42.4 44.2 39.6 36.8 42 39.2 39
Neutral 8.3 9.4 7.0 8.1 10 9.8 12 10
Negative 2.9 4.5 3.5 3.8 5 1.9 2 3
a BNSSG, Bristol, North Somerset, South Gloucestershire.
b Eastern Cheshire, South Cheshire, St Helens, Wigan and Wirral.
c Deprivation is based on IMD 2010 for England and Scottish Index of Multiple Deprivation 2012 for Scotland.
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General practices included
(n = 33)
Patients
Excluded
• Life expectancy 
   < 12 months, n = 83
• High suicide risk, n = 2
• Moving practice, n = 12
• No English language, n = 3
• Died, n = 6
• Lacked capacity, n = 103
• Other, n = 366
Practices allocated to intervention
(n = 16)
• Participants included, n = 797
• Declined to participate, n = 457
Practices allocated to usual care
(n = 17)
• Participants included, n = 749
• Declined to participate, n = 530A
llo
ca
ti
o
n
9 months
Returned questionnaire: 683 (86%)
• Withdrawn from trial, n = 19
• Withdrawn from questionnaires only,
   n = 19
• Deceased, n = 24
• Missing/no response, n = 52
9 months
Returned questionnaire: 673 (90%)
• Withdrawn from trial, n = 8
• Withdrawn from questionnaires only,
   n = 0
• Deceased, n = 17
• Missing/no response, n = 51
• Withdrawn from trial, n = 28 (total)
• Withdrawn from questionnaires only,
   n = 30 (total)
• Deceased, n = 46 (total)
• Missing/no response, n = 48
15 months
• Withdrawn from trial, n = 26 (total)
• Withdrawn from questionnaires only,
   n = 8 (total)
• Deceased, n = 32 (total)
• Missing/no response, n = 45
15 months
Patients consented
(n = 1546)
Fo
llo
w
-u
p
Completed questionnaire: 645 (81%) Completed questionnaire: 638 (85%)
Primary outcome measure
(n = 645) (81%)
Primary outcome measure
(n = 638) (85%)
Excluded by GP
(n = 575)
Randomly sampled for inclusion
(n = 5253)
Eligible
(n = 9772)
FIGURE 6 Flow of patients in trial.
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Comparability between treatment arms: patients
In total, 1546 participants were recruited: 749 in usual-care practices and 797 in intervention practices.
The characteristics of the recruited participants at baseline are presented in Table 7 and are balanced
between treatment arms; therefore, no additional sensitivity analyses were carried out to adjust for
differences at baseline. There was a small baseline imbalance in the EQ-5D-5L, but this was adjusted
for in all analyses, as prespecified in the analysis plan.
Demography
In line with the eligible population, the participants recruited had a mean age of 71 years. More than
70% of participants had retired from work, and only 1% of participants came from black and minority
ethnic groups.
TABLE 5 Characteristics of screened patients
Characteristics
Screened patients
Invited patients who did not
respond or could not be
contacted (n= 3132)
Invited and randomised
participants (n= 1546)
Female, n (%) 1680 (54) 783 (51)
Age, mean (SD) 71.3 (13.5) 70.8 (11.5)
Total number of long-term conditions, mean (SD) 3.3 (0.5) 3.2 (0.5)
Long-term condition, n (%)
Cardiovascular disease 2875 (92) 1445 (93)
Stroke TIA 1050 (34) 527 (34)
Diabetes mellitus 1613 (52) 812 (53)
COPD or asthma 1456 (46) 770 (50)
Epilepsy 185 (6) 76 (5)
Atrial fibrillation 928 (30) 530 (34)
Mental health 200 (6) 66 (4)
Depression 1250 (40) 559 (36)
Dementia 340 (11) 60 (4)
Learning disability 84 (3) 14 (1)
Rheumatoid arthritis 196 (6) 103 (7)
TIA, transient ischaemic attack.
TABLE 6 Comparison of practice characteristics at baseline
Characteristics
Trial arm
Usual care (n= 749) Intervention (n= 797)
Practice data
Practice list size, mean (SD), n 9027.2 (4315.6), 17 9619.2 (3880.2), 16
IMD score for England, mean (SD), n 15.8 (12.2), 12 15.6 (9.6), 11
Percentage of patients in Scottish practices who
live in the 15% most deprived data zones of the
SIMD, mean (SD), n
26.4 (18.3), 5 24.2 (20.0), 5
SIMD, Scottish Index of Multiple Deprivation.
STATISTICAL RESULTS
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Illness burden and treatment burden
Almost two-thirds of participants (66%) reported having fair or poor health, with only 6% reporting
having very good or excellent health (Table 8).
Although participants had a median of three QOF conditions (in line with the inclusion criteria for the trial),
patients self-reported a median of seven long-term conditions from the more comprehensive list of
conditions included in the Bayliss measure.74 Based on the HADS measure, more than one-third of patients
(38%) reported anxiety or depression of at least mild severity.
TABLE 7 Baseline characteristics of recruited participants: demographics and long-term conditions
Baseline characteristics
Trial arm
Usual care
(N= 749)
Intervention
(N= 797)
Demographic data
Mean age (SD) 70.7 (11.4) 71.0 (11.6)
Number female, n (%) 377 (50) 406 (51)
White ethnicity, n/N (%) 729/739 (99) 775/780 (99)
IMD score (SD) using participant postcode (England 2010), mean (SD), n 15.3 (13.6), 527 15.4 (12.9), 552
SIMD score (SD) using participant postcode (Scotland 2012), mean (SD), n 28.0 (17.8), 222 24.2 (16.8), 245
Number fully retired from work, n/N (%) 512/721 (71) 525/759 (69)
Long-term conditions
Median number of long-term conditions (IQR) 3.0 (3.0–3.0) 3.0 (3.0–3.0)
Number with cardiovascular disease, n (%) 698 (93) 747 (94)
Number with stroke TIA, n (%) 241 (32) 286 (36)
Number with diabetes mellitus, n (%) 401 (54) 411 (52)
Number of diabetes mellitus reviews, median (IQR), na 1.0 (1.0–1.0), 400 1.0 (1.0, 1.0), 410
Number with COPD or asthma, n (%) 382 (51) 388 (49)
Number of COPD or asthma reviews, median (IQR), na 1.0 (1.0–1.0), 378 1.0 (1.0–1.0), 387
Number with epilepsy, n (%) 35 (5) 41 (5)
Number with atrial fibrillation, n (%) 249 (33) 281 (35)
Number with a mental health condition, n (%) 37 (5) 29 (4)
Number of mental health reviews, median (IQR), na 1.0 (0.0–1.0), 37 1.0 (0.0–1.0), 28
Number with depression, n (%) 283 (38) 276 (35)
Number with dementia, n (%) 27 (4) 33 (4)
Number of dementia reviews, median (IQR), na 1.0 (0.0–1.0), 27 1.0 (0.0–1.0), 33
Number with a learning disability, n (%) 7 (1) 7 (1)
Number with rheumatoid arthritis, n (%) 55 (7) 48 (6)
Number of rheumatoid arthritis reviews, median (IQR), na 1.0 (1.0–1.0), 55 1.0 (0.0–1.0), 48
SIMD, Scottish Index of Multiple Deprivation; TIA, transient ischaemic attack.
a Number of reviews over the 12 months before recruitment, out of those patients who have been diagnosed with
specified long-term condition and had review data recorded.
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TABLE 8 Baseline values of outcome measures
Outcome
Trial arm
Usual care
(N= 749)
Intervention
(N= 797)
Health and illness data
EQ-5D-5L score, mean (SD), n 0.542 (0.292), 747 0.574 (0.282), 795
Self-rated health, n (%)
Poor 171 (23) 150 (19)
Fair 339 (45) 342 (43)
Good 193 (26) 236 (30)
Very good 38 (5) 50 (6)
Excellent 0 (0) 5 (1)
Missing 8 (1) 14 (2)
Bayliss score, mean (SD), n 19.5 (12.7), 700 18.2 (12.0), 758
Bayliss count of conditions, median (IQR), n 7.0 (5.0–10.0), 748 7.0 (5.0–9.0), 795
HADS anxiety score, mean (SD), n 6.4 (4.8), 740 6.1 (4.6), 785
Normal (0–7), n (%) 473 (64) 505 (64)
Mild (8–10), n (%) 120 (16) 130 (17)
Moderate (11–14), n (%) 97 (13) 107 (14)
Severe (15–21), n (%) 50 (7) 43 (5)
HADS depression score, mean (SD), n 7.0 (4.5), 743 6.3 (4.2), 791
Normal (0–7), n (%) 430 (58) 516 (65)
Mild (8–10), n (%) 148 (20) 142 (18)
Moderate (11–14), n (%) 118 (16) 96 (12)
Severe (15–21), n (%) 47 (6) 37 (5)
Treatment burden
MTBQ score, median (IQR), n 10.0 (2.5–25.0), 736 10.0 (2.5–20.0), 789
MTBQ score, mean (SD), n 15.7 (15.9), 736 13.3 (14.7), 789
MTBQ categorised, n/N (%)
No burden (a MTBQ score of 0) 130/736 (18) 176/789 (22)
Low burden (a MTBQ score of < 10) 179/736 (24) 208/789 (26)
Medium burden (a MTBQ score of < 22) 208/736 (28) 217/789 (28)
High burden (a MTBQ score of ≥ 22) 219/736 (30) 188/789 (24)
MMAS-8a, mean (SD), n 6.7 (1.4), 749 6.8 (1.4), 797
Number of drugs prescribed in the three months before baseline,
mean (SD), n
11.3 (5.4), 738 11.1 (5.2), 778
Number of drugs prescribed in the three months before baseline,
median (IQR), n
10.0 (7.0–14.0), 738 10.0 (7.0–14.0)
Patient-centred care, mean (SD), n
CARE GP score 38.8 (9.8), 714 40.8 (9.1), 781
CARE nurse score 39.0 (9.1), 565 40.7 (9.2), 610
PACIC score 2.4 (1.0), 608 2.6 (0.9), 624
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TABLE 8 Baseline values of outcome measures (continued )
Outcome
Trial arm
Usual care
(N= 749)
Intervention
(N= 797)
Care: patients’ priorities, n (%)
Not at all 145 (19) 114 (14)
Rarely 128 (17) 123 (15)
Some of the time 249 (33) 271 (34)
Almost always 194 (26) 255 (32)
Missing 33 (4) 34 (4)
Care: joined up, n (%)
Not at all 111 (15) 63 (8)
Rarely 96 (13) 69 (9)
Some of the time 280 (37) 310 (39)
Almost always 229 (31) 321 (40)
Missing 33 (4) 34 (4)
Care: overall satisfaction, n (%)
Very dissatisfied 20 (3) 16 (2)
Fairly dissatisfied 37 (5) 24 (3)
Neither satisfied nor dissatisfied 94 (13) 55 (7)
Fairly satisfied 251 (34) 238 (30)
Very satisfied 320 (43) 439 (55)
Missing 27 (4) 25 (3)
Number of patients self-report having a written care, health or treatment
plan, n/N (%)
74/739 (10) 77/787 (10)
Process measures
COC index (continuity of care), mean (SD), na,b 0.3 (0.3), 712 0.4 (0.3), 767
Visit Entropy (continuity of care), mean (SD), na,c 101.1 (66.1), 712 103.9 (67.1), 767
Mean QOF performance, mean (SD), nd 84.5 (18.6), 526 77.2 (23.2), 552
Number of primary care consultations with GP, mean (SD), na 8.8 (7.2), 739 9.5 (7.2), 778
Number of primary care consultations with GP, median (IQR), ne 7.0 (4.0–11.0), 739 8.0 (5.0–12.0), 778
Duration (minutes) of face-to-face consultations in surgery with GP,
mean (SD), na
13.4 (4.7), 437 13.3 (5.1), 346
Number of primary care consultations with nurse, mean (SD), na 5.5 (5.6), 739 6.2 (6.5), 778
Number of primary care consultations with nurse, median (IQR), na 4.0 (2.0–7.0), 739 4.0 (2.0–8.0), 778
Duration (minutes) of face-to-face consultations in surgery with nurse,
mean (SD), nf
14.2 (6.8), 419 14.0 (6.7), 313
a Face-to-face (home or surgery or nursing home) or telephone consultations over the 12 months before recruitment.
b Range from 0 to 1, with 0 indicating no continuity of care (patient saw a different provider at each consultation) and
1 indicating perfect continuity of care (patient saw the same provider at each consultation).
c Range from 0 to -log2(1/k), where k is the total number of care providers visited, with the minimum of 0 indicating
perfect continuity of care (patient saw the same provider at each consultation) and the maximum of -log2(1/k) indicating
no continuity of care (patient saw a different provider at each consultation).
d The percentage of indicators that were relevant to each patient that were met, averaged across all patients. This is the
‘patient average’ approach of Reeves et al.86
e Use of the © MMAS is protected by US Copyright laws. Permission for use is required. A licence agreement is available
from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue, WA 98007, USA or from dmorisky@gmail.com.
f Face-to-face consultations over the 12 months before recruitment only, as duration of telephone consultations and
home visits are not reliably recorded. Available only for English GP practices.
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On average, patients had been prescribed 10 different medications in the 3 months before recruitment.
Although we could not distinguish new from repeat prescriptions, it is likely that these were mainly
repeat prescriptions of long-term medication, indicating that the participants experienced considerable
polypharmacy. The median score on the MTBQ was 10, indicating at least a moderate level of treatment
burden. This score would be achieved, for instance, by having some difficulty in at least two areas of
health care, or severe difficulty in at least one area.
The extent to which current care for people with multimorbidity is patient-centred
from the perspective of patients
Table 8 shows that most patients reported relatively high levels of overall satisfaction with their care,
although reported levels of care co-ordination were somewhat lower. Only 37% of patients reported that
their care was almost always ‘joined up’. The data also show that many patients do not perceive care as
patient centred in terms of focusing on an individual’s experience. A relatively high proportion of patients
(35%) reported ‘rarely’ or ‘not at all’ in discussing what was most important to them in terms of their
health. Only 10% of participants reported having a care plan.
The process of care
Patients reported relatively low levels of continuity of care. The baseline COC score of 0.3 is low by comparison
with other studies of UK primary care108 but similar to a previous study of patients with multimorbidity.2
The data confirm that patients with multimorbidity are very frequent users of primary care, with a median
of 8.0 GP consultations (IQR 4.0–12.0 GP consultations) and 4.0 nurse consultations (IQR 2.0–79.0 nurse
consultations) in the 12 months before recruitment. Their GP face-to-face consultations are also relatively
long, with a mean duration of 13.4 minutes.
Carers
We recruited 145 carers to the substudy. Carers reported higher levels of quality of life but similar levels of
treatment burden as the patients with multimorbidity for whom they care (Table 9).
Characteristics of participants with missing primary outcome data
Of the 1546 participants, 1361 (88%) completed the primary outcome measure, the EQ-5D-5L, at
15 months (including 78 patients who had died, for whom the EQ-5D-5L was treated as zero). There was
a slightly higher follow-up rate for questionnaire data at 15 months in the usual-care arm (85%) than in
the intervention arm (81%).
Baseline characteristics of participants who did or did not complete the primary EQ-5D-5L outcome
measure at 15 months are reported in Appendix 17 (see Table 40). Those who died are recorded as
completing the primary outcome in this table (as they did contribute to the primary outcome analysis with
an EQ-5D-5L value of zero). Those who did not complete EQ-5D-5L at 15 months tended to have slightly
worse health, as indicated by lower EQ-5D-5L scores, worse self-rated health and a greater number of
self-reported chronic conditions (Bayliss count) at baseline.
TABLE 9 Baseline characteristics of recruited carers
Carer data
Trial arm
Usual care Intervention
Carer EQ-5D-5L score, mean (SD), n 0.767 (0.185), 68 0.781 (0.161), 70
Carer experience scale score, mean (SD), n 48.2 (17.4), 67 43.6 (18.8), 66
Carer MTBQ score, mean (SD), n 18.6 (15.8), 74 16.0 (15.7), 71
Carer MTBQ score, median (IQR), n 14.3 (7.1–27.5), 74 12.5 (3.6–23.2), 71
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Primary analysis results
As pre-specified in the protocol and SAP, the primary outcome was health-related quality of life measured
using the EQ-5D-5L at 15 months. Participants who did not complete the EQ-5D-5L because they had
died were recorded as having a value of zero. Missing data, for primary outcome data only, were imputed
using multiple imputation modelling. The primary analysis, as pre-specified in the SAP, was a mixed-effects
multivariable linear regression model adjusted by recruiting centre (Bristol, Manchester and Glasgow),
baseline EQ-5D-5L score, GP practice list size, GP practice deprivation score and GP practice as a random
effect. Including a random effect at the practice level in the model accounts for practice-level differences
in response to a treatment effect. All EQ-5D-5L scores were calculated using the Interim Scoring for the
EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets109 as recommended by NICE’s position
statement on analysing the EQ-5D-5L.110
The primary analysis in Table 10 shows no evidence that there is a beneficial effect of the intervention on
the mean EQ-5D-5L score after 15 months (adjusted difference in means 0.00, 95% CI –0.02 to 0.02;
p-value = 0.93).
Sensitivity analyses were conducted as described below, and all results are consistent with this primary analysis.
Sensitivity analysis 1 was carried out without imputation of missing data, to examine the strong assumption
of missing at random (MAR) required for multiple imputation, given that there were differences between
the characteristics of participants with or without missing data (see Appendix 17, Table 40). These data
include those who have died with an EQ-5D-5L value of 0.
Sensitivity analysis 2 uses these raw data without multiple imputation and without replacing the missing
EQ-5D-5L due to death as 0.
Sensitivity analysis 3 is simple imputation, using the last observation carried forward including for those
missing as a result of death.
Sensitivity analysis 4 uses the raw data without multiple imputation, and the model is additionally adjusted
by days between recruitment and return of the 15-month questionnaire. These data include those who
have died as an EQ-5D-5L value of 0. The mean number of days since recruitment to return of 15-month
TABLE 10 Primary outcome analysis
Primary outcome
and sensitivity
analyses
Usual care
unadjusted
Usual
care (n)
Intervention
unadjusted Intervention (n)
Adjusted
difference
in means 95% CI p-value
Primary analysis, mean (SE)
EQ-5D-5L 0.504 (0.012) 749 0.533 (0.012) 797 0.00 –0.02 to 0.02 0.93
Sensitivity analysis, mean (SD)
1: EQ-5D-5L 0.517 (0.311) 670 0.546 (0.303) 691 0.00 –0.02 to 0.02 0.817
2: EQ-5D-5L 0.542 (0.296) 638 0.585 (0.275) 645 0.01 –0.01 to 0.02 0.525
3: EQ-5D-5L 0.512 (0.310) 749 0.548 (0.300) 797 0.01 –0.01 to 0.03 0.365
4: EQ-5D-5L 0.517 (0.311) 670 0.546 (0.303) 691 0.01 –0.02 to 0.03 0.518
All analyses are adjusted by centre, baseline EQ-5D-5L score, GP practice list size and GP practice deprivation score. GP
practice is included as a random effect.
Sensitivity analysis:
1 – missing EQ-5D-5L at 15 months not multiply imputed, but missing owing to death set as zero.
2 – missing EQ-5D-5L at 15 months not multiply imputed and missing owing to death left as missing.
3 – missing EQ-5D-5L at 15 months imputed using last observation carried forward including for those who died.
4 – missing EQ-5D-5L at 15 months not multiply imputed, but missing owing to death set as zero and additionally adjusted
by days since recruitment to return of 15-month questionnaire.
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questionnaire was 470.9 days (SD 28.1 days) for usual care and 470.9 days (SD 18.7 days) for
the intervention.
The ICC for the primary outcome of EQ-5D-5L was 0.00 (95% CI 0.00 to 0.00) in both the imputed and
non-imputed data sets.
Complier-average causal effect analysis
Compliance (at the patient level) was defined as ‘full’ if two GP 3D appointments and two nurse 3D
appointments were attended over 15 months, as ‘partial’ if at least one GP or nurse 3D appointment was
attended, but there was not full attendance, and as ‘none’ if no GP 3D appointment and no nurse 3D
appointment was attended. ‘Full’ compliance in the intervention group was 49% and, therefore, as
specified in the SAP, a CACE analysis was carried out.
The results can be seen in Table 11. Using an instrumental variable regression model with randomised
group as the instrument and an indicator variable for compliance, the CACE analysis was conducted in two
ways, first, by combining the ‘partial’ and ‘none’ compliers into the non-compliance group and, second, by
combining those in the partial and full compliance group into the compliance group. Both analyses show
that there is no evidence of a difference in effect in the intervention group compared with the usual-care
group. Although there appears to be a trend of greater effect of the intervention in those who had full
attendance, there was no difference between trial arms after adjustment because greater attendance was
associated with higher EQ-5D-5L at baseline.
Subgroup analyses of primary outcome
There was no strong evidence that the intervention was differentially effective for any subgroups defined
by baseline characteristics (Table 12). There was weak evidence that the intervention was less effective than
the usual-care arm in those with four or more long-term conditions. We explored this further in a post hoc
sensitivity analysis, treating death as missing rather than having an EQ-5D-5L of zero (as patients with four
or more conditions were more likely to have died). After this adjustment there was no longer any evidence
of a significant interaction between the number of conditions at baseline and effectiveness (p = 0.672).
TABLE 11 Complier-average causal effect analysis
Participants by amount
of intervention received
EQ-5D-5L at 15-month follow-up
Trial arm, mean (SD), n Adjusted
difference
in means 95% CI p-valueUsual care Intervention
None (no GP and no nurse
3D appointments)
0.517 (0.311), 670 0.418 (0.336), 107
Partial (at least one GP or
nurse 3D appointment)
0.498 (0.336), 207 0.00a –0.04 to 0.03 0.796
Full (two GP and two nurse
3D appointments)
0.609 (0.256), 377 0.00b –0.03 to 0.02 0.798
a Combining those in the none and partial compliance groups into the non-compliance group.
b Combining those in the partial and full compliance group into the compliance group.
Note
All analyses are adjusted by centre, baseline EQ-5D-5L score, GP practice list size and GP practice deprivation score. GP
practice is included as a cluster effect in the estimation of the variance-covariance matrix.
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Secondary outcomes
The secondary outcome analyses are based on multivariate linear or ordered-logistic regression models
(as appropriate) adjusted, as in the primary analysis, by centre, GP practice list size and GP practice deprivation
score and the baseline for the outcome being analysed. GP practice is included as a random effect.
The ICCs for secondary outcomes were all low or very low – these are reported in Appendix 18.
Burden of illness measures
It can be seen in Table 13 that there is no evidence of a difference in mean EQ-5D-5L between the
intervention and usual-care arms at 9 months. A sensitivity analysis was carried out in which those who
died before 9 months did not have their EQ-5D-5L score replaced with 0; this analysis also shows no
evidence of a treatment effect.
TABLE 12 Subgroup analyses of primary outcome
Characteristic
Trial arm
Adjusted
difference
in means by
subgroup 95% CI
Interaction
term
p-value
Usual care Intervention
Unadjusted
EQ-5D-5L score
at 15 months,
mean (SD) n
Unadjusted
EQ-5D-5L score
at 15-months,
mean (SD) n
Participants by median age
< 72 years 0.532 (0.321) 334 0.566 (0.312) 324 0.00 –0.03 to 0.03
≥ 72 years 0.501 (0.301) 336 0.529 (0.295) 367 0.00 –0.03 to 0.03 0.865
Number of long-term conditions
Three 0.539 (0.305) 534 0.581 (0.285) 558 0.01 –0.02 to 0.03
≥ 4 0.428 (0.320) 136 0.402 (0.334) 133 –0.05 –0.09 to 0.00 0.052
Deprivation
England: quartiles of IMD scorea
1st 0.569 (0.290) 119 0.633 (0.277) 124 0.04 –0.01 to 0.10
2nd 0.537 (0.345) 140 0.568 (0.298) 115 –0.04 –0.09 to 0.01
3rd 0.563 (0.285) 105 0.536 (0.305) 127 –0.03 –0.08 to 0.03
4th 0.465 (0.310) 118 0.497 (0.296) 122 0.01 –0.05 to 0.06 0.112
Scotland: quartiles of SIMD scoreb
1st 0.506 (0.306) 47 0.583 (0.316) 55 0.06 –0.02 to 0.14
2nd 0.499 (0.312) 34 0.502 (0.324) 56 –0.08 –0.16 to 0.01
3rd 0.456 (0.321) 48 0.494 (0.311) 52 –0.01 –0.09 to 0.07
4th 0.450 (0.291) 59 0.476 (0.311) 40 0.02 –0.07 to 0.10 0.158
Depression
No 0.536 (0.318) 424 0.571 (0.289) 458 0.00 –0.02 to 0.03
Yes 0.483 (0.297) 246 0.498 (0.326) 233 –0.02 –0.05 to 0.02 0.399
All analyses are adjusted by centre, baseline EQ-5D-5L score, GP practice list size and GP practice deprivation score. GP
practice is included as a random effect.
a Using participant postcode matched to England IMD data 2010.
b Using participant postcode matched to Scotland Scottish Index of Multiple Deprivation data from 2012.
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No other continuous measures of burden of illness measures that were prespecified as secondary
outcomes show evidence of a differential effect (see Table 13).
Self-rated health was a categorical measure of illness burden, and there was no evidence of a differential
effect between the intervention and usual-care arms at either 9 or 15 months (Table 14).
TABLE 13 Burden of illness measures secondary outcomes (continuous)
Burden of illness
measures
Trial arm
Adjusted
difference
in means 95% CI p-value
Usual care Intervention
Unadjusted
mean (SD) n
Unadjusted
mean (SD) n
EQ-5D-5L
9 months 0.526 (0.306) 684 0.566 (0.294) 699 0.01 –0.01 to 0.03 0.533
9 months (deaths
left as missing)
0.540 (0.298) 667 0.586 (0.279) 675 0.01 –0.01 to 0.03 0.234
Bayliss measure of illness burden
9 months 18.1 (12.8) 611 17.6 (13.0) 636 0.30 –0.65 to 1.26 0.536
15 months 18.4 (12.9) 590 16.7 (11.6) 598 –0.64 –1.54 to 0.27 0.167
HADS Anxiety score
9 months 6.1 (4.7) 638 5.7 (4.6) 652 –0.18 –0.50 to 0.14 0.263
15 months 6.3 (4.8) 624 5.8 (4.7) 629 –0.24 –0.57 to 0.08 0.145
HADS Depression score
9 months 6.6 (4.5) 641 6.1 (4.4) 654 0.07 –0.22 to 0.36 0.651
15 months 6.8 (4.6) 625 6.1 (4.6) 630 –0.01 –0.33 to 0.30 0.938
All analyses are adjusted by centre, baseline outcome score, GP practice list size and GP practice deprivation score.
GP practice is included as a random effect.
TABLE 14 Burden of illness measures secondary outcomes (categorical)
Outcome
Trial arm, n (%)
Adjusted odds ratio 95% CI p-valueUsual care (n= 749) Intervention (n= 797)
Self-rated health
9 months N= 666 N= 672
Poor 142 (21) 120 (18)
Fair 287 (43) 284 (42)
Good 186 (28) 205 (31)
Very good 45 (7) 58 (9)
Excellent 6 (1) 5 (1) 0.95 0.76 to 1.19 0.661
15 months N= 631 N= 642
Poor 137 (22) 116 (18)
Fair 264 (42) 284 (44)
Good 169 (27) 177 (28)
Very good 51 (8) 58 (9)
Excellent 10 (2) 7 (1) 0.84 0.67 to 1.05 0.132
All analyses are adjusted by centre, baseline outcome score, GP practice list size and GP practice deprivation score.
GP practice is included as a random effect.
STATISTICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Burden of treatment
There was no evidence of a differential effect between the intervention and usual-care arms in terms of
either the MTBQ or the Morisky Medication Adherence Scale77–79 at either 9 or 15 months (Table 15).
Analysis using MTBQ categorised into different levels of treatment burden shows no evidence of a trend
towards reduced treatment burden at either 9- or 15-month follow-up in the invention arm compared
with the usual-care arm (Table 16).
We also assessed treatment burden in terms of the number of distinct drugs prescribed over the previous
3 months, and the number of indicators of potentially inappropriate prescribing. In calculating the number
TABLE 15 Burden of treatment secondary outcomes (continuous)
Burden of treatment
secondary outcomes
Trial arm
Adjusted
difference
in means 95% CI p-value
Usual care Intervention
Unadjusted
mean (SD) n
Unadjusted
mean (SD) n
MTBQ (patient version)
9 months 14.4 (16.0) 640 12.1 (14.8) 658 –1.09 –2.29 to 0.12 0.077
15 months 15.0 (17.1) 626 12.9 (15.0) 625 –0.46 –1.78 to 0.86 0.494
MMAS-8a
9 months 6.6 (1.4) 749 6.7 (1.3) 797 –0.03 –0.14 to 0.08 0.548
15 months 6.6 (1.3) 749 6.7 (1.2) 797 0.06 –0.05 to 0.17 0.265
All analyses are adjusted by centre, baseline outcome score, GP practice list size and GP practice deprivation score.
GP practice is included as a random effect.
a Use of the © MMAS is protected by US Copyright laws. Permission for use is required. A licence agreement is available
from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue, WA 98007, USA or from dmorisky@gmail.com.
TABLE 16 Burden of treatment secondary outcomes (categorical)
Outcome
Trial arm, n (%)
Adjusted
odds ratio 95% CI p-value
Usual care
(n= 749)
Intervention
(n= 797)
MTBQ
9-months N= 640 N= 658
No burden (MTBQ score of 0) 138 (22) 161 (24)
Low burden (MTBQ score of < 10) 167 (26) 204 (31)
Medium burden (MTBQ score of < 22) 173 (27) 169 (26)
High burden (MTBQ score of ≥ 22) 162 (25) 124 (19) 0.85 0.66 to 1.08 0.190
15 months N= 626 N= 625
No burden (MTBQ score of 0) 130 (21) 150 (24)
Low burden (MTBQ score of < 10) 171 (27) 181 (29)
Medium burden (MTBQ score of < 22) 167 (27) 156 (25)
High burden (MTBQ score of ≥ 22) 158 (25) 138 (22) 0.98 0.79 to 1.21 0.838
All analyses are adjusted by centre, baseline categorical outcome, GP practice list size and GP practice deprivation score.
GP practice is included as a random effect.
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of distinct drugs prescribed, different prescriptions of the same drug or different dosages/formulations
of the same drug were not counted as additional prescriptions. We collected these data in relation to
the 3 months before each participant’s recruitment (baseline) and the 3 months before their 15-month
follow-up data. There was no evidence of a differential effect between the intervention and usual-care
arms in terms of the number of drugs prescribed or the number of potentially inappropriate prescribing
indicators triggered (Table 17).
The assessment of potentially inappropriate prescribing indicators was based on searches of practice
computer records that were only run at the end of the trial and, therefore, baseline data are not available.
These searches were run after the last patient in each practice had finished in the trial, which was a variable
length of time after each patient was recruited. Therefore, this multilevel Poisson model was adjusted using
the number of days between recruitment and practice search date as the exposure covariate. The mean
number of days between recruitment date and practice search date was 601.8 days (SD 44.3 days) for
the usual-care arm and 588.7 days (SD 40.3 days) for the intervention arm. There was no evidence of a
differential effect between the intervention and usual-care arms in the number of indicators of potentially
inappropriate prescribing (see Table 17).
Experience of patient-centred care
We assessed a number of measures of patient-centred care and there is consistent evidence across all of
these measures of more patient-centred care in the intervention arm.
Relational continuity
It can be seen in Table 18 that there is evidence of a small difference in favour of the intervention in mean
CARE GP scores between the intervention and usual-care arms at 9 months and this effect continues,
although slightly weakened, at 15 months. Similarly, there is evidence of a small effect of the intervention
on mean CARE Nurse scores at 15 months (the nurse CARE measure was not assessed at 9 months).
Patient-centred chronic disease management: Patient Assessment of Chronic Illness
Care Scale
The PACIC shows evidence of a positive effect of the intervention compared with the usual-care arm at
both 9 and 15 months.
TABLE 17 Burden of treatment secondary outcomes (count data)
Outcome
Trial arm
Adjusted
difference
in incidence
rate ratiosa 95% CI p-value
Usual care Intervention
Median (IQR) n Median (IQR) n
Number of drugs
prescribed in 3 months
prior to 15 month
follow-up date
11.0 (8.0, 15.0) 736 11.0 (8.0–15.0) 774 1.02b 0.97 to 1.06 0.455
Number of high-risk
prescribing indicators
0.0 (0.0, 1.0) 741 0.0 (0.0–1.0) 780 1.04c 0.87 to 1.25 0.679
a Multi-level Poisson model.
b Analyses are adjusted by centre, number of drugs prescribed in the 3 months before recruitment, GP practice list size
and GP practice deprivation score. GP practice is included as a random effect. End of trial is defined as either date of
death, date of withdrawal or date on which 15-month follow-up was due based on recruitment date.
c Analyses are adjusted by days since recruitment and practice search date as the exposure covariate, centre, GP practice
list size and GP practice deprivation score. GP practice is included as a random effect.
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Other measures of patient-centred care
All of the categorical secondary outcomes relating to patient-centred care at 9 months also show evidence
of a differential effect of the intervention compared with usual care (Table 19). Patients were more likely to
experience care as being related to their priorities, and as being joined up. Patients in the intervention arm
were also more likely to express overall satisfaction with their care than patients in the usual-care arm.
TABLE 18 Experience of patient-centred care secondary outcomes (continuous)
Outcome
Trial arm
Adjusted
difference
in means 95% CI p-value
Usual care Intervention
Unadjusted
mean (SD) n
Unadjusted
mean (SD) n
CARE measure of relational empathy (GP)
9 months 37.5 (10.2) 632 40.6 (9.8) 649 1.44 0.47 to 2.41 0.003
15 months 37.5 (10.0) 601 40.2 (9.7) 617 1.20 0.28 to 2.13 0.011
CARE measure of relational empathy (nurse)
15 months 38.5 (9.5) 462 40.8 (8.9) 535 1.11 0.03 to 2.19 0.043
PACIC measure of chronic disease management
9 months 2.4 (0.9) 554 2.7 (1.0) 556 0.28 0.18 to 0.38 0.000
15 months 2.5 (0.9) 512 2.8 (1.0) 524 0.29 0.16 to 0.41 0.000
All analyses are adjusted by centre, baseline outcome, GP practice list size and GP practice deprivation score. GP practice is
included as a random effect.
TABLE 19 Experience of patient-centred care secondary outcomes at 9 months (categorical)
Outcome
Trial arm, n (%)
Adjusted
odds ratio 95% CI p-value
Usual care
(n= 749)
Intervention
(n= 797)
Care related to patients’ priorities (LTC6) n = 634 n = 639
Not at all 109 (17) 66 (10)
Rarely 115 (18) 86 (13)
Some of the time 243 (38) 238 (37)
Almost always 167 (26) 249 (39) 1.60 1.27 to 2.01 0.000
Care that is joined up (LTC6) n = 629 n = 637
Not at all 91 (14) 46 (7)
Rarely 78 (12) 55 (9)
Some of the time 264 (42) 284 (45)
Almost always 196 (31) 252 (40) 1.34 1.03 to 1.74 0.030
Overall satisfaction n = 634 n = 648
Very dissatisfied 24 (4) 13 (2)
Fairly dissatisfied 40 (6) 29 (4)
Neither satisfied nor dissatisfied 81 (13) 59 (9)
Fairly satisfied 251 (40) 188 (29)
Very satisfied 238 (38) 359 (55) 1.62 1.30 to 2.03 0.000
All analyses are adjusted by centre, baseline outcome, GP practice list size and GP practice deprivation score. GP practice is
included as a random effect.
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The effect of the intervention on the categorical secondary outcomes related to the experience of
patient-centred care also continues at 15 months (Table 20); it is strengthened for care related to patients’
priorities and care that is joined up but is weakened for overall satisfaction.
Patients in the intervention arm of the trial were more likely to report having a written health plan, care
plan or treatment plan. Having a written plan was fundamental to the 3D approach and the relevant
question was included in the baseline and 15-month follow-up questionnaires, but it was not listed as a
secondary outcome in the analysis plan owing to an administrative oversight.
Process measures
We collected data about several process of care measures that were described as secondary outcomes
in the trial registry and SAP because they were important indicators of the impact of the 3D intervention.
The process measures were measured over the follow-up trial period of 15 months from individual patient
recruitment. Each outcome was also measured at baseline using the 12-month period before individual
patient recruitment, unless otherwise specified.
TABLE 20 Experience of patient-centred care secondary outcomes at 15 months (categorical)
Outcome
Trial arm, n (%)
Adjusted
odds ratio 95% CI p-value
Usual care
(n= 749)
Intervention
(n= 797)
Care related to patients’ priorities (LTC6) N = 599 N = 612
Not at all 110 (18) 69 (11)
Rarely 111 (19) 69 (11)
Some of the time 225 (38) 218 (36)
Almost always 153 (26) 256 (42) 1.85 1.44 to 2.38 0.000
Care that is joined up (LTC6) N = 603 N = 614
Not at all 77 (13) 49 (8)
Rarely 85 (14) 49 (8)
Some of the time 268 (44) 259 (42)
Almost always 173 (29) 257 (42) 1.48 1.18 to 1.85 0.001
Overall satisfaction N = 608 N = 614
Very dissatisfied 20 (3) 12 (2)
Fairly dissatisfied 31 (5) 32 (5)
Neither satisfied nor dissatisfied 91 (15) 50 (8)
Fairly satisfied 230 (38) 175 (29)
Very satisfied 236 (39) 345 (56) 1.57 1.19 to 2.08 0.001
Whether patients had a written health
plan, care plan or treatment plan N = 623 N = 623
Yesa 91(15) 141 (2) 1.97 1.32 to 2.95 0.001
a Not pre-specified in the SAP. Those who responded ‘Do not know’ are treated as not having a care plan.
Note
All analyses are adjusted by centre, baseline outcome, GP practice list size and GP practice deprivation score. GP practice is
included as a random effect.
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Continuity of care
As shown in Table 21, there was evidence of improved continuity of care in the intervention arm when
measured using the COC index84 The Visit Entropy measure85 also showed improved continuity in the
intervention arm (lower entropy scores indicate greater continuity) but this did not reach statistical significance.
Quality outcomes framework performance
As shown in Table 21, there was no evidence of any difference between the usual-care or intervention
arms in their QOF performance. In this case, we were testing for the hypothesis that QOF performance
might deteriorate in the intervention arm because of the stronger emphasis on patients’ priorities rather
than the QOF, but there was no evidence of this effect.
Consultations in primary care and secondary care
We assessed the impact of the intervention on consultation rates and lengths in primary and secondary
care (Table 22). There is evidence that the number of consultations in the intervention group increased by a
median of one additional GP consultation and one additional nurse consultation over 15 months compared
with the usual-care arm. There was no difference in the mean duration of GP consultations but the mean
duration of nurse consultations was just over 5 minutes longer in the intervention arm than in the usual-care
arm. These numbers and durations are averaged across all consultations over the trial period, including the
3D review consultations in the intervention arm.
There was no evidence of any impact of the intervention on either hospital admissions or hospital out-patient
attendances. The impact of the intervention on health service utilisation and the associated costs are described
in more detail in Chapter 6.
Process of care measures not defined as secondary outcomes
Several other measures of the process of care were not defined as outcomes but were collected to better
describe differences between the nature of the care provided in the intervention and usual-care arms.
TABLE 21 Process measures: continuity of care and quality of disease management
Outcome
Trial arm
Adjusted
difference
in means 95% CI p-value
Usual care Intervention
Unadjusted
mean (SD) n
Unadjusted
mean (SD) n
COC index
(continuity of care)a
0.3 (0.3) 720 0.4 (0.3) 769 0.08 0.02 to 0.13 0.004
Visit Entropy
(continuity of care)b
107.3 (79.3) 720 99.3 (72.7) 769 –8.76 –18.07 to 0.55 0.065
Quality of disease
managementc
85.6 (17.3) 475 84.3 (17.5) 493 –0.41 –3.05 to 3.87 0.817
a Range from 0 to 1, with 0 indicating no continuity of care (patient saw a different provider at each consultation) and
1 indicating perfect continuity of care (patient saw the same provider at each consultation).
b Range from 0 to -log2(1/k), where k is the total number of care providers visited, with the minimum of 0 indicating
perfect continuity of care (patient saw the same provider at each consultation) and the maximum of -log2(1/k) indicating
no continuity of care (patient saw a different provider at each consultation).
c The percentage of indicators that were relevant to each patient that were met, averaged across all patients. This is the
‘patient average’ approach of Reeves et al.86
Note
All analyses are adjusted by centre, baseline outcome, GP practice list size and GP practice deprivation score. GP practice
is included as a random effect. Both continuity of care outcomes are additionally adjusted by per patient length of time
in trial. Continuity measures include face-to-face or telephone consultations between participants and GP, excluding
consultations with nurses, HCAs, medical students.
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Implementation of 3D reviews (intervention group only)
We collected detailed data about the extent to which the 3D approach was implemented as intended,
based on data extracted either manually or electronically from the medical records of participants in the
intervention arm only. This shows that three-quarters (75%) of the patients received at least one 3D review
(involving both nurse and GP consultation) over 15 months, and about half (49%) had two complete 3D
reviews as intended. About three-quarters (76%) of participants had their medication reviewed by the
pharmacist [but this represents 97% (607/626) of people who had at least one 3D review appointment
with a nurse or GP]. We also extracted information about the extent to which some key questions within
the 3D template were completed. Table 23 shows that these components were completed for at least
90% of the patients who had a review, except for the question about medication adherence, which was
completed for 84% of patients.
The data about completion of the 3D agenda after the nurse review and the 3D health plan were less
reliable and available only at practice level. The relevant code was entered automatically when the template
was printed in England but not in Scotland; therefore, the data in Scottish practices may be less complete.
TABLE 22 Process measures: consultation rates and duration
Outcome
Trial arm
Adjusted
difference
between
groups 95% CI p-value
Usual care Intervention
Usual care n Intervention n
GP consultations
Number of consultations,
mean (SD)a,b
10.7 (9.3) 739 12.2 (9.4) 778
Number of consultations,
median (IQR)a
8.0 (4.0–14.0) 739 10.0 (6.0–16.0) 778 1.13c 1.02 to 1.25 0.021
Duration (minutes),
mean (SD)d
14.4 (5.5) 460 13.6 (4.4) 505 –0.10e –1.58 to 1.38 0.894
Nurse consultations
Number of consultations,
mean (SD)a,b
6.1 (6.2) 739 8.6 (10.2) 778
Number of consultations,
median (IQR)a
4.0 (2.0–8.0) 739 6.0 (4.0–10.0) 778 1.37c 1.17 to 1.61 0.000
Duration, mean (SD)d 15.1 (8.3) 447 19.7 (9.8) 497 5.01e 1.56 to 8.45 0.004
Secondary care
Number of hospital
admissions (including day
cases), median (IQR)
0.0 (0.0–1.0) 743 0.0 (0.0–1.0) 785 1.04c 0.84 to 1.30 0.711
Number of outpatient
attendances, median
(IQR)
2.0 (1.0–5.0) 743 3.0 (1.0–5.0) 785 1.02c 0.92 to 1.14 0.717
a Includes only face-to-face (home or surgery or nursing home) or telephone call consultations. Details of consultations
extracted from medical records – assumes no data means no consultations were attended.
b Statistical comparison between groups was made using medians rather than means.
c Multilevel Poisson model. Reported as incidence rate ratios. Exposure covariate is per patient length of time in trial.
d Face-to-face consultations only because duration of telephone consultations and home visits are not reliably recorded.
Data available only for English GP practices.
e Multilevel linear regression model. Reported as difference in means.
Note
All analyses are adjusted by centre, baseline outcome (not available for hospital admissions or outpatients data), GP practice
list size and GP practice deprivation score. GP practice is included as a random effect.
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However, the findings suggest that the agenda and health plan were printed in about three-quarters of
consultations.
To put these findings in context, we examined the extent to which patients in the usual-care arm attended
QOF reviews (see Completion of long-term condition reviews). If we consider the conditions for which reviews
are required at least annually by the QOF (therefore, their reviews are likely to be coded in the medical
records), patients in the usual-care arm attended at least one disease-specific review on 78% (702/897) of
occasions when a review was required. Therefore, the extent to which patients received 3D reviews is very
similar to the level of implementation of reviews for individual chronic diseases under the QOF.
TABLE 23 Patient-level process of care measures to describe implementation of the intervention
Outcome Intervention (N= 797), n/N (%)
Number of nurse 3D reviews
None 175/797 (22)
One 210/797 (26)
Two 412/797 (52)
Number of GP reviews
None 198/797 (25)
One 182/797 (23)
Two 417/797 (52)
Number of participants receivinga
No 3D reviews with either GP or nurse 171/797 (21)
One 3D review with both GP and nurse 205/797 (26)
Two 3D reviews with both GP and nurse 390/797 (49)
Other (e.g. nurse reviews but no GP review) 31/797 (4)
Medication reviewed by pharmacist 607/797 (76)
Number of time hospital physician was contacted 0/797 (0)
Out of those who had at least one GP or nurse review
Most important problem notedb 616/622 (99)
EQ-5D pain question notedb 611/622 (98)
PHQ-9 enteredb 599/622 (96)
Patient agenda printedb,c 579/622 (93)
Medication adherence notedd 506/599 (84)
First patient goal notedd 590/599 (98)
First plan noted (‘what patient can do’)d 559/599 (93)
First plan noted (‘what GP can do’)d 554/599 (92)
3D plan printedc,d 461/598 (77)
a Numerators in this table are different from those in Table 11 because those in the latter also require a completed
EQ-5D-5L. Denominators relate to the number of people eligible (e.g. 622 patients had at least one nurse review and
599 had at least one GP review).
b In at least one nurse review.
c Data available only at a practice level; missing data possible.
d In at least one GP review.
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Completion of long-term condition reviews
We had hoped to test the hypothesis that the 3D approach would both ensure that more patients had
reviews of each of their conditions while at the same time reducing the number of times that patients had
to attend review appointments (because the 3D intervention was based on doing several reviews at one
appointment). However, it was not possible to do this analysis in a direct way for several reasons. First, the
analysis is limited to the long-term conditions that are included in the QOF, because these are the only
conditions in which there is an agreed set of Read Codes to define the condition and which are likely to
have been entered reasonably consistently. Second, Read Codes for disease reviews are likely to have been
consistently entered only when required by QOF, and not all long-term conditions require reviews to be
recorded. Finally, in some cases, patients with, for example, hypertension will have attended specifically for
review of their blood pressure but in other cases their blood pressure will have been taken opportunistically
when they attended for another consultation. In the absence of a code for ‘hypertension review’, we cannot
distinguish between these events.
However, we have descriptive data that provide some insight. Table 24 shows the number of reviews for
different long-term conditions for which data are available because reviews are required by the QOF.
Because these data are exploratory, we have not undertaken statistical comparisons between treatment
arms. Patients in the intervention arm were more likely to have received at least one review for COPD and
asthma, less likely to have had a review for dementia or severe mental health problems, and similarly likely
to have had a review for other conditions. However, in every condition, more patients in the intervention
arm appeared to have had more than two reviews a year. This could suggest that patients were being
invited for their 3D reviews as well as their disease-specific reviews, whereas the intention was that 3D
would replace disease-specific reviews. This issue of 3D reviews being conducted as well as rather than
instead of disease-specific reviews is discussed further in Chapter 8.
TABLE 24 Number of long-term condition reviews out of those diagnosed with each long-term condition
at baseline
Number of long-term condition reviews
Trial arm, n (%)
Usual care (N= 749) Intervention (N= 797)
Diabetes mellitus (based on diabetic foot risk assessment) n = 400 n = 410
Zero 75 (19) 91 (22)
One 216 (54) 193 (47)
Two 103 (26) 103 (25)
Three 5 (1) 17 (4)
Four 1 (< 1) 6 (1)
COPD or asthma n = 378 n = 387
Zero 94 (25) 71 (18)
One 170 (45) 125 (32)
Two 82 (22) 120 (31)
Three 22 (6) 43 (11)
Four 5 (1) 17 (4)
Five 3 (1) 4 (1)
Six 2 (1) 5 (1)
Seven 0 (0) 1 (< 1)
Ten 0 (0) 1 (< 1)
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Unintended consequences
There is a theoretical concern that focusing effort on one group of patients (in this case, those with
multimorbidity) could lead to reduced efforts and reduced quality of care in the other patients.29 In order
to compare performance in terms of the QOF in patients with and without multimorbidity, we collected
anonymous data about the performance against QOF targets for all patients in intervention practices with
any of the index conditions (individually or in combination) that are included in our definition of multimorbidity,
using electronic download from medical records. We compared QOF performance in patients with and
without multimorbidity in the year before and the 15 months after the intervention, to check whether or not
concentrating effort on patients with multimorbidity has any positive or negative impact on the care of other
patients. We also compared QOF performance in patients in intervention practices who were recruited to the
trial versus those not recruited, to explore whether or not giving extra attention to trial participants was to the
detriment of those not recruited who would have continued to be offered usual care. These analyses were
adjusted for factors that might be associated with having multimorbidity, participating in the trial or with QOF
performance and, therefore, could potentially act as confounders.
It can be seen from Table 25 that patients with multimorbidity were more likely to have all of the QOF targets
met than those with single conditions. QOF performance improved over time in patients with or without
multimorbidity in both arms of the trial, but those with multimorbidity improved less than those with single
conditions. There was no evidence of any interaction with trial arm in this pattern of change (interaction
p-value of 0.608; Table 26). Patients with multimorbidity in the intervention arm of the trial had an improved
QOF performance compared with those in the intervention arm not participating in the trial, and there was
no evidence of any effect of participation in the trial in the usual-care arm (see Table 26). This interaction was
significant (p = 0.049). These analyses are exploratory and should be treated with caution.
TABLE 24 Number of long-term condition reviews out of those diagnosed with each long-term condition
at baseline (continued )
Number of long-term condition reviews
Trial arm, n (%)
Usual care (N= 749) Intervention (N= 797)
Dementia n = 27 n = 33
Zero 5 (19) 9 (27)
One 19 (70) 13 (39)
Two 1 (4) 9 (27)
Three 1 (4) 2 (6)
Seven 1 (4) 0 (0)
Mental health n = 37 n = 28
Zero 12 (32) 11 (39)
One 17 (46) 7 (25)
Two 8 (22) 7 (25)
Three 0 (0) 2 (7)
Five 0 (0) 1 (4)
Rheumatoid arthritis n = 55 n = 48
Zero 9 (16) 8 (17)
One 31 (56) 19 (40)
Two 14 (25) 13 (27)
Three 1 (2) 6 (13)
Four 0 (0) 2 (4)
DOI: 10.3310/hsdr07050 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 5
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Salisbury et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
TABLE 25 Consequences of the intervention on QOF performance in patients with or without multimorbidity
Outcome
Practices, mean QOF score, mean % (SD), n
Practices, adjacent difference in means (95% CI); p-value
a
Usual care Intervention
Usual care Intervention
Comparison of all
patients with
multimorbidity
b
and those with
only a single
condition
Multimorbidity
patients: comparison
of trial participants
and non-participants
Comparison of all
patients with
multimorbidity
b
and those with
only a single
condition
Multimorbidity
patients: comparison
of trial participants
and non-participants
Patients with
any single
condition, not
multimorbid
Patients with
multimorbidity
not participating
in the trial
Patients with
multimorbidity
participating in
the trial
Patients with
any single
condition, not
multimorbid
Patients with
multimorbidity
not participating
in the trial
Patients with
multimorbidity
participating in
the trial
N= 23,810 N= 2450 N= 21,253 N= 2462
Mean QOF
performance
baseline
c
63.4 (35.1),
26,433
76.7 (26.3),
2868
84.5 (18.6),
526
63.6 (35.6),
23,122
75.9 (24.3),
2601
77.2 (23.2),
552
Mean QOF
performance
follow-up
c
68.9 (32.5),
21,876
83.9 (19.1),
1976
85.6 (17.3),
475
67.4 (33.4),
19,262
80.7 (20.9),
1971
84.3 (17.5),
493
–3.28
(–5.11 to –1.45),
0.000
0.10
(–1.63 to 1.83),
0.910
–5.46
(–7.46 to –3.47),
0.000
3.20
(1.29 to 5.11),
0.001
a Adjusted by centre, GP practice list size, GP practice deprivation score, patient age, sex, baseline QOF performance, number of chronic diseases, presence/absence of each chronic disease. GP practice is included as a random effect.
b Including multimorbid patients who were trial participants and non-participants combined.
c The percentage of indicators that were relevant to each patient that were met, averaged across all patients. This is the ‘patient average’ approach of Reeves et al.86
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Carer secondary outcomes
Carers were also asked to complete questionnaires at all time points; these included the carer experience
scale, EQ-5D-5L and the MTBQ (carer version).
As shown in Table 27, there is no evidence of a difference in mean EQ-5D-5L scores for carers between
the intervention and usual-care arms at either 9 or 15 months. There is also no evidence of a difference in
mean carer experience scale scores at 9 months but there is evidence of improved carer experience in the
intervention arm at 15 months (adjusted difference in means 6.51, 95% CI 0.25 to 12.77; p-value = 0.041).
TABLE 26 Analysis of potential unintended consequences on QOF performance
Patient group
Trial arm
Adjusted
difference
in means by
subgroupa 95% CI
Interaction
term
p-value
Usual care Intervention
Unadjusted
mean (SD)
QOF score at
15 months n
Unadjusted
mean (SD)
QOF score at
15 months n
Patients with any single
condition, not multimorbid
68.9 (32.5) 21,876 67.4 (33.4) 19,262 –0.65 –2.92 to 1.61
All patients with
multimorbidity
84.2 (18.8) 2451 81.4 (20.3) 2464 –0.23 –2.89 to 2.44 0.608
Patients with multimorbidity
not participating in the trial
83.9 (19.1) 1976 80.7 (20.9) 1971 –2.54 –5.43 to 0.36
Patients with multimorbidity
participating in the trial
85.6 (17.3) 475 84.3 (17.5) 493 0.03 –3.42 to 3.47 0.049
a Adjusted by centre, GP practice list size, GP practice deprivation score, patient age, gender, baseline QOF performance,
number of chronic diseases and presence/absence of each chronic disease. GP practice is included as a random effect.
TABLE 27 Carer secondary outcomes (continuous)
Outcome
Trial arm
Adjusted
difference
in means 95% CI p-value
Usual care Intervention
Unadjusted
mean (SD) n
Unadjusted
mean (SD) n
EQ-5D-5L
9 months 0.750 (0.197) 63 0.704 (0.259) 50 –0.03 –0.08 to 0.02 0.284
15 months 0.754 (0.178) 56 0.762 (0.166) 43 0.01 –0.04 to 0.06 0.635
Carer experience scale
9 months 43.0 (20.2) 62 44.5 (20.1) 47 2.91 –3.06 to 8.87 0.339
15 months 42.8 (19.2) 55 45.2 (20.3) 39 6.51 0.25 to 12.77 0.041
MTBQ carer version
9 months 17.1 (16.3) 63 18.2 (15.0) 50 2.03 –1.57 to 5.63 0.270
15 months 15.9 (13.5) 56 16.6 (14.7) 43 0.70 –3.20 to 4.61 0.724
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There is no evidence of a difference in mean carer MTBQ at either 9 or 15 months.
It is important to note that the sample size for these analyses is small and the study did not have sufficient
power to detect changes in outcomes for carers unless such changes were large.
Safety
No suspected adverse events were reported during the trial.
During the trial 5.04% (78/1546) of patients died, including 5.77% (46/797) of those in the intervention
arm and 4.27% (32/749) of those in the usual-care arm. The chi-squared test comparing the proportion of
deaths between the two arms did not show any evidence to reject the null hypothesis of no difference in
proportions of deaths between the two arms (p-value = 0.178). The Kaplan–Meier plot for the number of
deaths in each arm is presented in Figure 7 and it can be seen that the confidence bands around the
death rate for the two arms overlap.
Table 28 shows the Cox proportional hazards regression model for the number of deaths within the
trial treatment period, defined as up until the final follow-up questionnaire was due to be completed
(15 months after recruitment) or until a patient withdrew from the trial. There is no evidence of a difference
in deaths between the two treatment groups (p-value = 0.114).
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FIGURE 7 Kaplan–Meier survival estimate showing deaths during the 3D trial.
TABLE 28 Analysis of deaths within trial period
Parameter
Trial arm
Adjusted hazard
ratio (95% CI)a n p-value
Usual care (n= 749) Intervention (n= 797)
Mean (SD) n Mean (SD) n
Time in trial (days) 443.3 (61.4) 749 437.9 (71.0) 797
Deaths 32 (4%) 46 (6%) 1.39 (0.92 to 2.08) 1542 0.114
a Adjusted by site, baseline EQ-5D-5L, age, number of long term conditions (categorised as 3, 4+), GP practice deprivation
score and list size. GP practice is included as a cluster effect.
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For each patient who died during the trial we obtained further details from patients’ GPs of cause of
death, expectedness, relation to the intervention or research process, whether or not and when the patient
last had a review of their long-term conditions (including 3D reviews) and any changes to medication or
other treatment made at the last review.
Figure 8 shows details of the number of deaths, their expectedness and whether or not the patient had
had a long-term condition review. In no case did a patient’s GP indicate that they thought that there was
any relationship to the intervention or research process. A full log of the causes of death for each patient is
shown in Appendix 27.
Consented participants
(n = 1546)
Intervention group
(n = 797)
Usual-care group
(n = 749)
Died
(n = 46)
Expected
(n = 20)
Unexpected
(n = 26)
Reviews
• 3D, n = 12
• LTC, n = 2
• None, n = 6
Reviews
• 3D, n = 14
• 3D nurse, n = 1
• LTC, n = 3
• None, n = 8
Dieda
(n = 32)
Expected
(n = 15)
Unexpected
(n = 16)
Reviews
• LTC, n = 12
• None, n = 3
Reviews
• LTC, n = 13
• None, n = 3
FIGURE 8 Number of deceased participants by arm, expectedness and 3D or long-term condition review. a, The
expectedness of one death in the intervention arm was unknown.
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Chapter 6 Health economic evaluation
Methods
Aim of economic analysis
The aim was to determine the cost-effectiveness of delivering a complex primary-care-based intervention,
3D, designed to improve the management of care for multimorbid patients, compared with usual care.
Full details of the intervention and the trial population are given in Chapters 3 and 5.
Perspective
The primary economic analysis was from the NHS and PSS perspective. A secondary analysis was
conducted from the perspective of patients and carers (including personal travel costs, expenditure on
private health care, therapies and over-the-counter medication). The societal cost of time off work to
attend health-care appointments was also considered in a separate analysis.
Time horizon
The economic analysis compared the costs and outcomes of each arm over 15 months of follow-up.
Identification of economic outcomes
The primary economic outcome measure was QALYs derived from utility scores, obtained using the
EQ-5D-5L health-related quality-of-life instrument.111
Measurement of outcomes
Measurements were recorded at baseline and at 9 and 15 months post recruitment using questionnaires
as described in Chapter 4. In the case of non-response, EQ-5D-5L data were also collected by telephone.
Valuation of outcomes
Utility scores were derived from responses to the EQ–5D-5L cross-mapped to valuations obtained for the
EQ-5D-3L instrument from a UK population using the methods of van Hout et al.109 This was a change to
the planned analysis (approved by the DMC), as NICE issued a position statement110 recommending this
approach over the planned use of the English EQ-5D-5L value set prior to the commencement of the
analysis. These values were used to form QALYs over the 15-month period by means of linear interpolation
and an area under the curve calculation, adjusting for imbalance in baseline utility scores.112 Patients
who died were treated as if their last-measured utility score was relevant until the date of death, and
immediately set to zero at death.
Identification of relevant resource use
As the trial population had multiple conditions by definition, the scope of the economic evaluation was
defined as resource use related to any health condition experienced by the participant. For the NHS and
PSS perspective, data were collected on use of health services in primary care (consultations, investigations
and prescribed medications) and community care, hospital admissions, outpatient attendances, emergency
care, ambulance use, and social care. For the analysis from the patient/carer perspective, data were
collected on travel costs to GP appointments, and expenditure on over-the-counter medication and private
therapies and treatments. The value of productivity losses was estimated using data on time off work by
both patients and carers to attend primary and secondary care appointments.
Practices in the trial were paid £30 for each complete 3D review (including both a GP and nurse
consultation) to compensate them for the additional time spent on 3D reviews. This cost was not included
within the cost of the intervention because of potential double counting, given that we were including the
cost of the extra GP and nurse time for the longer consultations.
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Measurement of resource use
Where possible, resource use was measured by programmatic downloads of medical records from GP systems,
which was facilitated by the fact that all practices were using the same system (EMIS). These routine downloads
were supplemented with data collected via patient-reported questionnaires administered on paper by post
at 9 and 15 months’ follow-up and at baseline, and with data extracted from participants’ medical records by
trained researchers. Individual data collection methods for each type of resource use are described in more
detail below.
Set-up costs
Study records of the number/role of staff attending each training session were used to track resources
used in the delivery of the training programmes for GPs, nurses and receptionists, including trainee and
trainer time (and preparation time), travel costs and course materials to calculate the fixed cost of training.
Delivery of intervention
Delivery of the 3D GP and nurse appointments was recorded through manual data capture by researchers
reviewing participants’ medical records at the end of the trial. Pharmacist reviews were captured through
electronic practice downloads.
Health and social care utilisation
Details of the number and duration of primary care consultations were extracted from electronic
downloads of routine GP records. These included face-to-face, telephone and home consultations with
doctors, nurses or HCAs based in general practice. Duration details were not available for all consultations.
Therefore, an average duration for each type of consultation by each staff type in each arm was derived
using available data (practices in England only) and applied to all relevant consultations.
Data on medications prescribed and tests/investigations conducted in primary care were also extracted
electronically from GP records. NHS secondary care data were collected from participants’ GP records by
the research team. NHS community care, care from social services and patient personal resource use during
the 15-month follow-up period were captured in the patient-reported questionnaires.
Transport
The patient’s normal transport method for GP appointments and the cost (for public transport) or mileage
(for private transport) to use as a multiplier for calculating costs associated with each consultation, were
collected in the patient-reported questionnaire at baseline.
Productivity
Time off work by patients and carers to attend hospital appointments was captured in the patient-reported
questionnaires at 9 and 15 months. Participants were asked at baseline whether or not they usually took
time off work for GP appointments.
Personal expenditure on health care
Expenditure on over-the-counter medication, and private use of treatments and therapies, was captured in
the patient-reported questionnaires at 9 and 15 months. Details of whether or not the participant paid
prescription charges were requested in the questionnaire at baseline.
Valuation of resource use
Unit costs for NHS staff time for training and delivery of the intervention were based on the most recently
available national estimates.113 Actual expenses incurred for training materials, refreshments and staff
travel were recorded. Based on the proportion of GPs trained in a practice, the training costs were inflated
to estimate the cost of training a full practice, shared among the number of patients eligible for the
intervention in that practice and annualised over an estimated 5-year period of relevance. The costs of
medications were based on the cost recorded within the EMIS system at the time the medication was
prescribed, supplemented by estimates from the British National Formulary where such costs were
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missing.114 When patients were responsible for paying prescription charges, these amounts were applied to
each of the medications recorded in the practice download data and subtracted from the NHS perspective
medication costs (leading to negative NHS medication costs for a small number of participants). Community
and primary care costs were based on national estimates.113
Codes for Healthcare Resource Groups (HRGs), groups of events that have been judged to consume similar
levels of resources, were assigned to secondary care contacts and costed based on the most recently
published national reference costs available.115 Productivity costs were estimated based on average weekly
earnings stratified by age group.116 Mileage costs were estimated using UK government allowances.117
Over-the-counter medication costs and costs arising from private therapies and treatments were all
reported directly by patients. Unit costs used in the analyses are detailed in Appendix 19 (see Table 42).
All costs were reported in 2015/16 GB pounds, adjusted for inflation where necessary. Costs and
outcomes occurring during the final 3 months of follow-up were discounted in line with NICE guidance
(currently 3.5%).118 Dates were not available for all types of resource use measured in the trial; in these
cases, 50% of the costs incurred in the final 6 months of follow-up were subjected to discounting.
The cost of each resource item was calculated by multiplying the number of resource units used by
the unit cost. The total cost for each individual patient was then estimated as the sum of the cost of
resource-use items consumed. These resource use data combined with unit costs were used to estimate
the incremental cost or savings of the 3D approach. The results are reported in accordance with the
specifications of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.119
Changes from the health economic analysis plan drawn up in advance of the analysis are described in
Appendix 20.
Economic analyses
All analyses were conducted by treatment allocated, comparing the two groups as randomised and
including all patients in the primary analysis. A cost–utility analysis was conducted from the NHS and PSS
perspective corresponding to the NICE reference case.118 The costs of each component of the intervention
were estimated separately from each perspective and related to changes in a range of secondary outcomes
in a cost–consequences analysis.120 Statistical analyses were conducted using Stata 14.2.96
Data cleaning and missing costs and outcomes
Data cleaning was undertaken prior to unblinding by the economic researcher. Data cleaning included
the correction of obvious ‘free text’ response errors (e.g. misspelt health professional titles), group coding
of similar resource items (e.g. ‘orthopaedics’ and ‘trauma & orthopaedics’ clinics) to enable unit costing,
and simple imputation of data missing minor details (e.g. bus fares) based on reasonable assumptions
(e.g. mean bus fare). Any areas of uncertainty were discussed between two health economists and,
when necessary, referred for adjudication by a clinical expert. Questionnaires were not classed as ‘missing
data’ for the cost analysis unless the questionnaire was not returned or the majority of responses were
uninterpretable. Medication costs downloaded from GP practice notes were manually amended if they
were clearly wrong (e.g. a prescription for a salbutamol inhaler with a recorded cost of > £1000).
The primary analysis included all participants using imputation to predict missing costs and outcomes.121
Data imputed using chained equation multiple imputation methods for the main statistical analysis were
used (see Chapter 4 Methods, General considerations, Missing data).122,123 To facilitate convergence of the
imputation model, costs were imputed using aggregated cost categories (medications, pharmacy reviews,
secondary care, primary care, social care and other types of care) rather than at the level of individual
resource-use items.
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Analysis of costs and outcomes
The incremental mean difference in QALYs between the two arms of the trial and 95% CIs were derived.
Overall mean NHS and PSS costs and standard errors for both arms of the trial were calculated. The
incremental mean difference in total costs between the two arms of the trial and 95% CIs were estimated.
Relative costs and outcomes
Cost and QALY data were combined to calculate an incremental cost-effectiveness ratio (ICER) and net
monetary benefit (NMB) statistic124 from the NHS and PSS perspective.
In the primary analysis it was estimated whether or not the 3D approach was cost-effective at the
established NICE thresholds of £20,000 and £30,000 per QALY gained. The probability that the 3D
approach was cost-effective at various societal ‘willingness to pay for a QALY’ thresholds was depicted
using a cost-effectiveness acceptability curve (CEAC). All measures of cost-effectiveness (ICER, CEAC and
NMB) and CIs were derived parametrically using the output of seemingly unrelated regression analysis to
account for the correlation between costs and outcomes, and controlling for baseline imbalance in utility
for the QALY equation. Clustering within GP practices was accounted for by including the randomisation
variables in the regression.
Both costs and consequences were collated into a cost–consequences matrix presented from the NHS
and PSS perspective, the patient/carer perspective and the societal productivity perspective for each arm.
Consequences included QALYs accrued by both participants and carers, and deaths. The cost–consequences
analysis was based on available cases, which differed in number for each type of health-care resource or
outcome; an available case was defined as an individual having complete data for each relevant time point.
Linear regression output was used to derive CIs parametrically, accounting for clustering within practices.
Sensitivity analyses
One-way sensitivity analyses were used to judge the potential impact of sources of uncertainty, including
a complete case analysis to assess the impact of the imputation process, an analysis excluding participants
who died to assess the impact of the imbalance in deaths between arms and an analysis without
discounting either costs or outcomes to assess the impact of the discount rate. A complete case was
defined as a participant for whom full resource-use data and full outcome data were available.
Results
Missing data
Of all participants, 797 were randomised to be offered the 3D approach, and 749 were randomised to receive
usual care. Missing data occurred for a number of reasons, including withdrawal from the trial or leaving the
participating practice. Twelve participants (1.5%) in the 3D arm and six (0.8%) in the usual-care arm had
no information on secondary care use because it was not possible to locate their medical records (p = 0.2).
Practice downloads of medication and investigation data failed for 18 participants (2.3%) in the intervention
arm and eight (1.1%) in the usual-care arm (p = 0.07), and 19 (2.4%) and 10 (1.3%) participants were
missing consultation data from practice downloads in the 3D and usual-care arms, respectively (p = 0.13).
Inevitably, not all participants returned all questionnaires at all time points; 165 participants (20.7%) in the
intervention arm and 125 (16.7%) in the usual-care arm did not return a questionnaire at one or more of
the follow-up points (p = 0.04). Not all those who did return questionnaires completed the resource-use
questions; in total, 181 (22.7%) in the intervention arm and 146 (19.5%) in the usual-care arm were missing
resource-use data from questionnaires at one or more follow-up points (p = 0.12). Complete data sets were
available for 1191 participants (599 (75.2%) in the 3D arm and 592 (79%) in the usual-care arm, p = 0.07).
Participants with missing data were in a significantly poorer health state at baseline [mean EQ-5D-5L score:
0.453 (95% CI 0.422 to 0.485)] than participants with full data sets [mean EQ-5D-5L score: 0.589 (95% CI
0.574 to 0.605)].
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Primary analysis
Outcomes and resource use
The primary analysis using imputed data showed that participants in the intervention arm gained a mean
of 0.007 additional QALYs over the 15 months of the trial compared with participants in the usual-care
arm (95% CI –0.009 to 0.023). Total costs from the NHS and PSS perspective were £126 (95% CI –£739
to £991) higher in the intervention arm than in the usual-care arm. Disaggregated resource-use data are
presented in Appendix 21, Table 43.
Cost-effectiveness of 3D
Cost-effectiveness statistics from the NHS and PSS perspective are given in Table 29. The ICER was
£18,499, and the NMB at a societal willingness-to-pay value of £20,000 was £10 (95% CI –£956 to
£977). At this willingness-to-pay value, the probability that the 3D approach is cost-effective was 0.508,
and at £30,000, the probability of cost-effectiveness was 0.558. A CEAC depicting the probability of
cost-effectiveness at a range of willingness-to-pay values is shown in Figure 9.
The CEAC is relatively flat, because of the similarity between the trial arms in estimates of both costs and
effects, with considerable uncertainty around both parameters. Therefore, the probability that the intervention
is more cost-effective than usual care is between 40% and 60% at any cost-effectiveness threshold between
£10,000 and £40,000. We further consider the interpretation of the economic analysis below.
Sensitivity analyses
Results from an analysis restricted to complete cases only are given in Table 30. In contrast to the primary
analysis, the complete-case analysis suggested that the 3D approach was dominant (i.e. the intervention
was associated with both lower costs and better outcomes), with a probability of cost-effectiveness of
0.705 at a willingness-to-pay threshold of £20,000. A sensitivity analysis excluding participants who died
suggested that the probability of cost-effectiveness of the 3D approach at £20,000 was 0.561. A further
sensitivity analysis using undiscounted costs and outcomes did not suggest that the discount rate affected
the conclusions.
TABLE 29 Cost-effectiveness of the 3D approach from a NHS and PSS perspective
Costs, outcomes, cost-effectiveness
Trial arm
Incremental
difference (95% CI)Usual care Intervention
Number of cases included in analysis 749 797
Costs (£)a
Mean (SE) unadjusted costs from the NHS and PSS
perspective
6032 362 6124 317
Mean (SE) adjusted costs from the NHS and PSS
perspective
6014 343 6140 333 126 (–739 to 991)
Outcomesa
Mean (SE) unadjusted QALYs over 15 months of follow-up 0.651 0.013 0.691 0.012
Mean (SE) adjusted QALYs over 15 months of follow-up 0.668 0.006 0.675 0.006 0.007 (–0.009 to 0.023)
Cost-effectiveness statistics
ICER: £18,499
NMB at £20,000 (95% CI): £10 (–£956 to £977)
NMB at £30,000 (95% CI): £78 (–£974 to £1130)
SE, standard error.
a Costs were adjusted for randomisation variables; QALYs were adjusted for randomisation variables and baseline utility.
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Cost–consequences analysis
Costs and selected outcomes (on an available case basis) are presented in Table 31 from the primary
perspective of the NHS and PSS and the secondary perspective of the patient/carer themselves alongside
an estimate of the societal loss of productivity.
Costs from all perspectives were very similar between arms and no cost group differed significantly (other
than those associated with the intervention itself). Other than for day-case/outpatient care, emergency care
and medications, costs to the NHS were higher in the intervention arm than in the usual-care arm, and
social services usage was higher in the usual-care arm. Overall costs from the NHS and PSS perspective
were slightly higher in the usual-care arm although, again, the difference was consistent with chance.
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FIGURE 9 Cost-effectiveness acceptability curve from the NHS and PSS perspective.
TABLE 30 Sensitivity analysis: cost-effectiveness of the 3D approach from a NHS and PSS perspective based on
complete cases only
Costs, outcomes, cost-effectiveness
Trial arm
Incremental
difference (95% CI)Usual care Intervention
Number of complete cases included in analysis 592 599
Mean (SE) unadjusted costs from the NHS and PSS
perspective
4916 290 4757 222
Mean (SE) adjusted costs from the NHS and PSS
perspectivea
4905 258 4768 256 –137 (–852 to 577)
Mean (SE) unadjusted QALYs over 15 months of follow-up 0.698 0.014 0.750 0.013
Mean (SE) adjusted QALYs over 15 months of follow-upa 0.722 0.005 0.726 0.005 0.004 (–0.010 to 0.019)
ICER: intervention dominates
NMB (95% CI) at £20,000: £222 (–£584 to £1028)
SE, standard error.
a Costs were adjusted for randomisation variables; QALYs were adjusted for randomisation variables and baseline utility.
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Costs borne by patients and carers were higher overall in the intervention arm, although the medication
costs (both prescription charges and over-the-counter remedies) were slightly lower; no patient cost group
exhibited a statistically significant difference. The societal cost of productivity losses was similar in the two
arms (and statistically consistent with chance), although slightly higher in the 3D approach arm.
Quality-adjusted life-years (adjusted for baseline utility scores) were slightly higher for patients and lower
for carers in the intervention arm than in the usual-care arm; however, the difference was consistent with
chance. Although there was a higher number of deaths in the intervention arm, the difference was not
statistically significant.
All costs and consequences are based on available data; the totals from each perspective are not, therefore,
equal to the sum of the components. CI were calculated using standard errors from standard linear regressions
adjusted for cluster at the level of the practice. QALYs were adjusted for baseline utility scores.
TABLE 31 Costs and consequences of the 3D approach and usual care
Costs and outcomes
Trial arm
Difference (95% CI)
Usual care Intervention
Usual care n Intervention n
Mean costs from the NHS perspective (£)
Practice-based consultations 627 715 726 715 99 (–7 to 205)
Practice-based investigations 45 717 61 755 15 (–6 to 37)
Community-based health care 160 601 167 615 7 (–35 to 49)
Inpatient stays 1867 722 1920 766 52 (–470 to 574)
Outpatient visits and day cases 614 722 613 766 –1 (–168 to 167)
Accident and emergency visits 102 722 99 766 –3 (–24 to 19)
Ambulance trips to hospital 131 601 141 615 10 (–56 to 77)
Prescribed medications 1230 717 1221 755 –8 (–220 to 203)
Pharmacy reviews 0 722 8 766 8 (7 to 9)
Intervention set-up 0 749 4 797 4 (3 to 5)
Social services 559 601 403 615 –156 (–476 to 164)
All NHS and PSS 4929 598 4746 609 –183 (–923 to 556)
Mean costs from the patient/carer perspective (£)
Prescription charges 5 717 4 755 –2 (–6 to 2)
Travel to GP practice 24 711 34 749 10 (–4 to 24)
Over-the-counter medications 39 601 35 615 –3 (–16 to 9)
Private health care 93 601 122 615 29 (–40 to 97)
All patient/carer 162 597 195 608 33 (–35 to 101)
Mean societal productivity loss (£)
Productivity loss 122 597 161 608 39 (–47 to 125)
Outcomes
QALYs (patient) 0.693 647 0.695 665 0.003 (–0.013 to 0.019)
QALYs (carer) 0.943 50 0.920 41 –0.024 (–0.064 to 0.017)
Deaths 32 749 46 797 p = 0.18 (χ2 test)
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Discussion
No consequential difference was observed between arms for overall costs, resource use of any category
or QALY outcomes. We concluded that the 3D intervention was unlikely to be either more or less
cost-effective than usual care in the primary analysis from the NHS and PSS perspective. The NMB was
very small, but positive, indicating that the costs associated with the intervention are less than society is
willing to pay for the benefits that can be achieved.
From the NHS and PSS perspective, costs were slightly higher in the intervention arm in the primary
analysis based on a full imputed data set, but were slightly lower in the intervention arm when complete
cases were examined. This suggests that the participants with missing data were higher users of health
and social care than responding participants, and this is consistent with the fact that complete cases had
higher utility at baseline than those with missing data. Although the complete-case analysis suggested that
the 3D approach was dominant (i.e. it provided higher gains at lower cost than usual care), the results
should be treated with caution given the substantial uncertainty, and the likelihood that this represents a
biased sample of healthier participants.
The 3D participants had a mean utility of 0.558 (SD 0.287) at entry to the study, which compares poorly
to a UK population norm of 0.779 for ages 65–74 years.125 As a result of this, the participants were
substantial users of health care, with inpatient hospital care and medications both high contributors to
overall costs. Participants had a small positive increase in QALYs in the intervention arm, and carers for
these participants had a small decrease in QALYs compared with those in the usual-care arm; it is possible
that an analysis that took into account carer outcomes might reach an alternative conclusion. The small
contribution to overall costs made by productivity losses is consistent with the predominantly retired study
population; at baseline, > 65% of participants described themselves as ‘fully retired from work’.
The set-up costs for training the staff involved in delivering the intervention were small, varying from
£1.70 per patient (in the least costly practice) to £8.71 per patient. It was estimated that the training
received by 3D practitioners would be relevant for 5 years; however, it is possible that skill sharing might
take the place of formal training if the intervention were rolled out. The number of patients to benefit from
the training is also probably an underestimate, as new patients would join the practice and existing patients
would become eligible for the intervention over the years. It is, therefore, likely that the set-up costs are
slightly overestimated. The software template used to manage the 3D approach was developed using trial
funding, and would not incur ongoing costs to the NHS as the supplier would incorporate it into the basic
product. However, development costs would be incurred for the intervention to be implemented in other
software systems. It was not possible to identify 3D appointments reliably through the practice record
downloads; these appointments are, therefore, aggregated with all other practice-based appointments.
A crude estimate of the budget impact of implementing the intervention in England can be made using
the trial results. England had a population of 43.5 million adults in 2016.126 A total of 3.5% of adults
in the trial practices were both eligible for the 3D approach, and were considered suitable by their GP,
suggesting an eligible population of 1.5 million people. At an incremental cost of £126 over 15 months,
the intervention could be estimated to cost approximately £154M per year. However, given the uncertainty
around the cost estimate, it is possible that the intervention could be associated with a saving of £900M
per year, or a cost of as much as £1.2B per year.
Strengths
This economic evaluation was conducted alongside the largest RCT of its kind. Meticulous data collection
practices allowed individual patient data to be measured for all the key cost drivers. The study contributes
to the growing body of evidence supporting the care of patients with multiple long-term health conditions.
Patterns of missing resource-use data were similar between arms, and high questionnaire return rates were
achieved.127 Although imputed and complete-case analyses suggested different conclusions, the results
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were consistent with the minimal differences in costs and outcomes observed between arms, and the
substantial uncertainty surrounding the results.
Limitations
Medication costs were based on scripts issued by the GP, and it is not certain that all scripts were filled by
the participant; the medication costs may, therefore, be overestimated. In addition, a number of errors were
identified in the medication costs downloaded from GP practice notes; although both high and low outliers
were checked carefully and manually corrected as necessary, the volume of medications prescribed to the
3D population rendered it infeasible to check every entry, and it is possible that some errors persisted.
Use of care homes was not included in the economic evaluation. This can be a significant contributor to
costs of social care; however, the funding of care homes within the UK is complex, with patients often
paying considerable amounts themselves. The follow-up period of the 3D trial was only 15 months and
longer-term outcomes are unknown. However, given the lack of any difference between arms in the
utility values measured at 15 months post recruitment, it is unlikely that the conclusions would change
substantially. Use of simple mean imputation methods for estimating missing information (such as the
cost of a bus fare) in the questionnaire data will have reduced standard errors and underestimated the
uncertainty around these costs.
Quality-adjusted life-year outcomes for participants who died were based on an immediate reduction from
the previous known EQ-5D-5L value to zero at death. Although this will be accurate for some participants
who died suddenly after living previously in a consistent health state, it is likely that some patients would
have undergone a decline in health-related quality of life while approaching death. The QALYs may,
therefore, be slightly overstated. Dates of completion of the EQ-5D-5L instrument were based on the
recruitment date and expected follow-up dates and were not always the same as the date on which the
patient actually filled in the questionnaire.
We used the NICE threshold of £20,000 to assess cost-effectiveness, as is conventional with most
economic analyses of health-care interventions conducted in the UK. However, this threshold is largely
arbitrary and has been controversial for many years.128 Some economists have argued that the threshold
should be lower because implementing new interventions at a cost of £20,000 per QALY could displace
other existing interventions that are more cost-effective.129 Conversely, other economists have argued
that the threshold should be higher,130 or that there is insufficient consensus to justify a change from
the £20,000 threshold.131 Studies of the social value of a QALY suggest a range between £18,000 and
£40,000 (but with wide variations depending on the methods used and the population studied).128 These
discussions about thresholds are less relevant to this particular case, because the costs and effects were so
similar in both arms of the trial that it is unlikely that the intervention is either more or less cost-effective
than usual care within a cost-effectiveness threshold in the range between £10,000 and £40,000.
Conclusions
The evidence for the cost-effectiveness of the 3D intervention is equivocal; the results suggest that there
is no strong probability that the intervention is either more or less cost-effective than usual care at any
reasonable threshold of willingness-to-pay from the NHS and PSS perspective. The very small differences in
costs and outcomes are consistent with chance, and the uncertainty is substantial; therefore, the results
should be interpreted with caution. The implementation costs of the intervention are likely to be relatively
small, although individual practices may feel that the disruption of setting up a new system needs to be
considered alongside the potential benefits. Given the equivocal nature of the cost-effectiveness results,
they should be considered in conjunction with evidence from the participants themselves about satisfaction
with the intervention, and with other process outcome measures.
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Chapter 7 Process evaluation: results
Introduction
In this chapter, we present the findings of the 3D process evaluation. Although this chapter appears in the
report after the trial results, the analysis and summary of findings were completed and conclusions were
drawn before knowing the trial results.
We begin with a brief description of the case study practices followed by the findings organised into
sections corresponding to the objectives as described in Chapter 4. These are:
l context
l initial response of the practices to the training (adoption)
l delivery of the intervention to patients
l patients’ and health professionals’ perceptions of the intervention
l maintenance of the intervention over time.
Intervention practices that were part of the case study element of the process evaluation are referred to
by pseudonyms (e.g. Beddoes), whereas other intervention practices are named Int1–5 and usual-care
practices as UC1–5. Doctors, nurses, administrators and patients are referred to as GP, NU, Admin and
Patient, respectively, along with a practice identifier and a number (because there are multiple people in
each group in many practices). Table 32 shows the process evaluation data collected. The total number
of interviews with staff, including informal debriefs after 3D reviews, was 32 (18 GPs, 20 nurses and
9 administrator interviews). Some individuals were interviewed twice so the actual number of those
interviewed was 11 GPs, 14 nurses and 7 administrators. No-one refused an interview invitation.
Case study practices
Four case study practices were recruited initially following purposive sampling. One of these practices
ceased delivering 3D reviews after completing 18 reviews, just before the process evaluation researcher
was due to make the second visit. A fifth practice was therefore recruited at that time. Our aim was to
achieve a sample that varied in implementation, fidelity and reach and this was achieved. The sample
included the practices with the highest reach and with the lowest reach (measured by the proportion of
patients with a full 3D review delivered in each round), both small and large, in deprived and moderately
affluent areas and with varying systems of organising reviews. A brief description of each follows in
Table 33. A full description can be found in Report Supplementary Material 31.
Context
It was important for the process evaluation to understand context for two main reasons. First, the trial took
place between August 2015 and March 2017 at a time of increased workload and resource constraint in
the NHS in all UK jurisdictions. This was evident during the study in the loss of GPs and nurses at several
practices, which at one practice caused withdrawal from delivering 3D reviews soon after they had started.
Another practice, as a result of staff sickness and resignations, delivered only 20 complete first reviews out
of 54 and no second reviews. The level of disruption to practices caused by staff changes is evident in our
case study practices (see Table 33) but there were similar examples in many practices participating in
the trial.
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TABLE 32 Type and amount of qualitative data collected during the trial
Time point during trial
Training
observations Health professional interviews
Patient interviews and
focus groups Review observations
Clinician
debrief after
reviews
Training
evaluation forms
Practice profile
(all practices)
Clinician
questionnaire
Commissioners
Practices
including
two group
interviews Intervention
Usual
Care
Early trial, August 2015–
January 2016
7 clinical 7 3 GPs 88 session 1 33 154 (all practices)
2 admin 3 nurses 81 session 2
4 admin
Mid trial, February 2016–
September 2016
4 GPs 12 interviews 18 4 5 GPs
6 nurses 4 nurses
2 admin
Late trial, October 2016–
April 2017
6 GPs 4 focus groups 10 5 1 nurse 32 64 (intervention
practices)
6 nurses (22 patients)
3 admin 4 interviews
Total by data type 9 7 37 4 focus groups 37 10 169 65 218
16 interviews
Admin, administrator.
PRO
CESS
EVA
LU
A
TIO
N
:RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
74
TABLE 33 Brief description of case study practices
Practices Characteristics Usual care Arrangements for 3D 3D reacha
Beddoes Approximately 5500 patients.
Moderately affluent area.
Four GPs, three nurses
Patients felt that they received very good care.
Continuity of care quite high, depended on patient
preference. Good communication across whole
practice. Had just started combined reviews in
patient’s birthday month. Patients responsible for
making the appointment but reminded if they
did not
Late start to 3D owing to staff sickness. Three GPs and
three nurses took part. All practice staff involved in
making plans. Patients received a letter asking them to
contact the practice to make an appointment for first
part of the review. After the nurse review the patient
made an appointment for the GP part. Nurse reviews
30 minutes, GP reviews 20 minutes
First round 82%
Second round 82%
Davy Approximately 13,500 patients.
Moderately affluent area.
Approximately 13 GPs, six nurses
Patients found it difficult to access appointments.
Low continuity of care. Communication with and
within the practice seemed difficult. Staff groups
seemed separate. Single-disease reviews arranged
by letter to patient
Extremely delayed start owing to sickness and loss of
staff. Four GPs and three nurses trained but two GPs
and one nurse left. One administrator sent a letter
with a 3D appointment for both nurse and GP.
Appointments first identified by a senior administrator.
The rest of reception staff unaware. Review length
variable for nurses, 20 minutes for GP
First round 36%
None in second
round
Harvey Approximately 15,000 patients.
Deprived area. Approximately
sixteen GPs and four nurses
Patients felt well-served by the practice but some
disruption during trial due to GPs leaving. Each GP
saw their own list of patients so continuity was very
high. Combined reviews in patient’s birthday month.
Patients invited by letter to make appointment.
Review length depended on patient’s conditions
Delayed start owing to difficulty arranging training
dates and change to recall system. Three GPs and two
nurses trained but one GP left half way through and
was replaced by two or three others. One administrator
sent a letter inviting patient to telephone to arrange 3D
appointment. All receptionists aware and could book
reviews. Length of nurse reviews depended on patient’s
conditions. GP reviews 20 minutes
First round 77%
Second round 44%
Lovell Approximately 4000 patients.
Very deprived area. Three GPs,
two nurses
Patients extremely happy with care. Continuity of
care quite high and communication good as a small,
stable practice. Single-disease recall for review by
letter with specified appointment. Patients opted in
or were contacted again. Other conditions covered
within appointment where possible
All GPs and nurses took part. All administrative staff
aware but only one could arrange reviews. She sent a
letter to patients with specific appointments for nurse
review and GP review. Patients had to opt in and if
they did not respond they were telephoned. Nurse
reviews 40–50 minutes, GP reviews 20 minutes. Some
difficulty in second round reviews owing to taking over
another practice
First round 94%
Second round 93%
Plimsoll Approximately 7500 patients.
Very deprived area. Four GPs, one
nurse practitioner, two nurses and
nurse practice manager
Reviews were arranged by an administrator sending
the patient up to three letters. All reviews done
together. Continuity of care mainly through nurses
Two GPs, the nurse practitioner and the practice
manager trained. One GP and the practice manager
left during the first round of reviews. Length of reviews
40 minutes with nurse, 20 minutes with GP
First round 41%
Withdrew from
case study before
second round
a Percentage of eligible patients receiving full review in each round.
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Second, it was clear from interviews with commissioners in all three areas at the start of the study that 3D
aligned with commissioner priorities, which themselves reflected national policies. These put a strong
emphasis on patient-centred care and self-management in long-term conditions. The 3D study offered one
potential way of achieving this, with the additional possibility of cutting costs, aligning with the best
standards of care and increasing patients’ involvement in disease management. A research study that
offered some practical support and evidence about something they were moving towards anyway was
appealing to commissioners:
It just makes absolute sense. And actually fits really well with the pieces of work that we have got
going on at the moment . . . that the patient should be treated as a whole, there should be shared
decision making, and they should be really setting their own goals and aspirations.
Commissioner 3 South West
The disadvantage of this receptive context was that the usual-care comparator may have been changing
in the same direction as the intervention over the course of the study. The survey of clinicians’ attitudes at
the beginning of the trial (see Appendix 22, Table 44) showed that clinicians were generally in agreement
with the intervention principles. Almost all (96%) agreed that holistic patient-centred care is enhanced by
continuity of care and 93% agreed that patients with three or more long-term conditions should be given
longer appointments to address all their concerns. More than half (57%) agreed that patients’ main
concerns may be overlooked during long-term condition reviews.
Our survey of current care for patients with long-term conditions at the beginning of the trial (Table 34)
confirmed that some components of the 3D intervention, particularly combined reviews of all of a patient’s
long-term conditions at one time, were already being implemented in some practices. Combined reviews
were more common than anticipated across all areas, with 94% of practices using some kind of
combination. This survey also showed that practices claimed to be offering several other aspects of the
intervention at baseline, including care plans (52% using them in three or more conditions), combined
templates (33% using them for some conditions), depression screening (36%) and a policy that patients
should see their named GP (30%) (see Table 34). A repeat of the survey of current care in all practices at
the end of the trial showed little evidence of change over the period of this study, except that the use of
combined templates was slightly more common (39% of practices) and care planning much less common
(only 12% of practices using them in three or more conditions).
Initial response of the practices to the training
This section examines clinicians’ and administrative staff members’ initial perceptions of 3D, how they
evaluated the training and the steps they took to prepare to deliver the intervention, which we call adoption.
General practitioners and nurses delivering 3D participated in two separate training sessions delivered in
each practice. Training sessions for two practices in each of the three areas were observed by the process
evaluation researcher who took field notes. Some variation in content and format of training was observed
across practices. For example, reduced length of training as a result of attendance difficulties meant that
some content was sometimes omitted. Observations indicated that training in some patient-centred skills,
such as collaborative goal-setting, was lacking, which was regretted by some clinical staff:
To get doctors to do goal-setting you probably need to get them to practise it. And so it may have
been better to have done some role plays . . . maybe a demonstration of how to do it for those people
who really never do it, and then having a go.
Interview GP1 Harvey
Observations and feedback also suggested that clinicians wished to see live demonstration of the 3D
computer template with a real patient and practice working through it. ‘Would probably have been easier
PROCESS EVALUATION: RESULTS
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if we had all gone through the template individually’ (comment on training evaluation form). Concerns
about using the template were apparent in some of the training evaluation forms collected from all
intervention practices but 91% agreed that they now felt confident using it (see Appendix 23, Table 45
and Appendix 24, Table 46). The evaluation forms showed that training was generally well received,
with 100% agreeing that it was relevant and thinking that the practice would be able to implement 3D
(see Appendix 23, Table 44 and Appendix 24, Table 45). Clinicians valued the discussion of difficulties
faced by patients with multimorbidity and the 3D concept, but enthusiasm was tempered by concerns
about whether or not sufficient time would be available. Time was mentioned as a concern in
approximately 50% of comments (see Report Supplementary Material 33 and 34).
Administrative staff generally had separate training for setting up 3D reviews and implementing greater
continuity of care. However, practices were left to decide how best to undertake the arrangement of reviews
and how to accommodate them within their existing systems. Consequently, administrative implementation
was varied and several practices experienced difficulties, whereas others managed it smoothly:
You’re trying to tally it up with the doctor and the nurse, trying to find the time with the nurse if they
have got more than one problem.
Interview administrator 2 Davy
TABLE 34 Components of usual care for patients with long-term conditions at baseline and trial completion
Components of usual care
Time point, n (%)
Baseline End of trial
Intervention
(N= 16)
Usual care
(N= 17)
Intervention
(N= 15)
Usual care
(N= 17)
Are all long-term conditions reviewed together in a pre-planned way?
Fully combined reviewsa 7 (44) 4 (24) 7 (47) 7 (41)
Partially combined reviewsb 8 (50) 12 (71) 7 (47) 8 (47)
Not combined 1 (6) 1 (6) 1 (7) 2 (12)
Are written care plans given to all patients for all long-term conditions?
Care plans for most conditions (more than eight) 1 (6) 1 (6) 1 (7) 2 (12)
Care plans for three to seven conditions 6 (38) 9 (53) 1 (7) 0 (0)
Care plans for two conditions or fewer 9 (56) 7 (41) 13 (87) 15 (88)
Does the practice use combined templates for long-term condition reviews?
Fully combined templates 0 (0) 0 (0) 4 (27) 3 (18)
Some conditions combined 6 (38) 5 (29) 2 (13) 4 (23)
None combined 10 (62) 12 (71) 9 (60) 10 (59)
Are all patients with two or more long-term conditions formally screened for depression?c
Screening for depression all patients 6 (38) 6 (35) 8 (53) 5 (29)
Screening for only certain conditions or no screening 10 (62) 11 (65) 7 (47) 12 (71)
Does the practice have a policy that patients see their named GP?
Practice policy that patient sees named GP 3 (19) 7 (41) 7 (47) 8 (47)
No specific practice policy that patients see named GP 13 (81) 10 (59) 8 (53) 9 (53)
a Fully combined reviews: pre-planned, all conditions, clinician and patient aware all conditions for review.
b Partially combined reviews: combine whenever possible or combine some pre-identified conditions.
c Screening for depression: formal method recorded in the patient record (e.g. Patient Health Questionnaire-2 or PHQ-9).
One intervention practice in Scotland dropped out after the start of the trial so no data were available from it for the
end-of-trial survey.
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Findings from the survey of administrative implementation of 3D in all intervention practices (see Appendix 25,
Table 47) indicated variation in set-up across practices. Practices varied in the length of time they allocated
to the nurse part of the review (between 20 and 60 minutes). In some practices, the second nurse review
was shortened, as not all the QOF-required work needed repeating. GPs were almost all allocated double
appointments of 20 minutes for their reviews. Practices also varied in the time interval between the nurse and
GP parts of each review, ranging from the same day to several weeks. Variation in the way practices arranged
reviews with patients was also noticeable. Some sent pre-arranged appointments, which was generally the
model used by practices who had just one administrator arranging reviews. Others asked the patient to
contact them to arrange the appointment, which required all receptionists to be aware of 3D.
Some practices faced significant logistical challenges, which affected reach. For example, loss of nurses
and GPs in Davy caused difficulties with appointment availability and contributed to their very late start,
the completion of fewer than half of the required number of first-round reviews and the delivery of no
second-round reviews:
It’s not been brilliant the situation with the GPs; we have had GPs leave who were taking part in the
study, so that has caused a lot of problems trying to book appointments.
Interview administrator 1 Davy
Other practices faced difficulties with reduced staff availability or were involved in mergers during the trial:
Now that they have taken over the other practice at [local village], we do not have our doctors here.
We have only got them here every second week, all week, so that proved quite difficult . . . on the
second reviews, to try and get that done. But we got there.
Interview Administrator 1 Lovell
All practices had to disrupt their existing recall systems for the 3D participants and it was apparent from
staff interviews at the end of the trial that some patients continued to receive their standard reviews in
addition to the 3D reviews:
It’s been a bit chaotic sometimes . . . I think some patients have been involved in the 3D but they have
not had their other recalls cancelled, so they have been coming in and in and in . . . they have had so
many reviews it’s just been unreal.
Interview NU1 Beddoes
Intervention delivery to patients and perspectives of staff and patients
This section examines the delivery of the intervention by practice staff. Adoption, reach and delivery of
organisational components, such as continuity of care, varied by practice, whereas delivery of 3D reviews
varied considerably between individual clinicians. The process evaluation assessed fidelity to the delivery of
intervention components both quantitatively and qualitatively, and focused on the patient-centredness of
3D reviews. We first consider the organisational components before looking at 3D review components and
patient-centredness.
Continuity
Continuity of care was an important component to patients. It was considered an integral part of patient-
centred care and also more efficient:
Not only would it save time and money . . . it would make you feel better if you’re seeing the same
doctor because you only have to keep going through everything every time you see a different doctor.
Focus group patient 5 Davy
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Some clinicians considered their continuity to be already adequate. In the two small case study practices,
they felt that communication was good and often the patients were well-known so there was good
continuity of care even if not with an individual GP. Second, patients to whom it was important tended
to ensure their own continuity of care by requesting to see a particular GP and practices tried to
accommodate this:
Most people see the doctor they want to see, so I think from a continuity point of view we know our
patients very well and we’ve all been here a long time.
Group interview GP1 Lovell
In one of the two larger case study practices, each patient was already allocated to a specific GP and was
always booked with that GP if possible. Continuity was considered indispensable for most patients:
Our feeling is that we don’t understand why all practices don’t have what we have . . . these patients
who have a lot of ill-health, I think they really benefit from that and I know that I find it easier because
I know them really well.
Interview GP1 Harvey
Because in some practices not all GPs participated in the 3D study, in these practices some patients were
allocated a different GP or nurse for 3D reviews from the one they usually saw, which some found
disappointing and they often continued to see their usual GP between reviews:
The only thing I found was that [GP3] is my doctor and has been for many, many years but I was
asked to go to [GP1] for this particular study and I thought ‘oh well I’ll have to go to her’ . . .
she doesn’t really know me.
Focus group patient 8 Beddoes
In most practices patients were divided between nurses depending on the conditions they had, but in one
practice all reviews were completed by the only nurse qualified to review all conditions:
I was the only one that was doing it so those patients that were used to seeing [NU2], [NU3] or [NU4]
for their diabetes had to see me.
Interview NU1 Int5
Longer appointments
Although practices were asked to facilitate longer appointments for 3D participants with their named GP
between reviews, none of the case study practices in fact did so. Patients who presented their 3D card
found that receptionists either were not aware of what it meant or denied that they were entitled to
priority in that way. Observation of practice champion meetings indicated that some practices did not think
that 3D patients deserved what they perceived as special treatment.
Secondary care geriatrician
Access to a secondary care geriatrician for advice about 3D patients was not taken up by any of the
intervention practices. Observation of the practice champion meetings indicated that this was probably
because practices already had their own networks to get advice.
Reducing number of visits
Interviews with practice staff indicated considerable variation. Reviews sometimes did not cover all
conditions at once, meaning that some patients had to return on another occasion. Respiratory conditions
alongside diabetes mellitus posed problems in many practices either because they lacked nurses with both
skill sets or it made the reviews too lengthy. Therefore, many patients returned for a separate COPD review.
In one practice, the part of the review about quality of life and patient concerns was done separately from
the long-term condition reviews. In another practice, a nurse practitioner with a prescribing qualification
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undertook both parts of the review at the same time unless the patient specifically wished to see the GP or
had issues, such as depression, which the nurse felt unable to address.
3D review components
The trial team used monthly searches to monitor and feed back completion of each intervention
component in the template. This enabled a quantitative assessment of intervention reach (completion rates
of each review) and the fidelity of delivery (the proportion of reviews that were complete or included the
core components, e.g. a pharmacy review or a health plan). These data are shown in Table 23. Reach in
the first round of reviews varied considerably between practices with a mean of 75% (see Appendix 26,
Table 48). In the second round the mean dropped to 49%.
Observations of 3D reviews and interviews with clinicians provided insight into the delivery of the various
components. Most elements of the template were completed consistently, as shown in Table 23. Although
all clinicians completed all the components when they were being observed they varied in how they did so.
This variation in template use provided insight into variation in delivery.
Template use
The adaptive template was intended to facilitate a patient-centred approach and delivery of all intervention
components. The template itself was perceived by clinicians to be the core of the intervention, dictating
conduct of the review. Observed nurses followed the template closely and overtly, working through each
section to complete a comprehensive review. Some went through it quite quickly, but others explored
patients’ situations at length. Most nurses had difficulty using an unfamiliar template and some found it
confusing. In contrast to their usual long-term condition templates, they felt that they had to follow the 3D
one step-by-step because it was unfamiliar and complex, and they were concerned that they might forget
something. They repeatedly referred to it, interrupting and slowing the flow of their consultation and
diverting their attention from the patient:
I found with the 3D I really stick, I follow the template, because otherwise I just, I’m lost, I don’t know
what I am doing.
Interview NU1 Harvey
Some nurses welcomed the inclusion of all of a patient’s conditions in one template and the addition of
patient-centred questions:
It’s very comprehensive, I really did like the fact that it was very patient-centred . . . it was asking
questions I think that we wouldn’t normally ask like, how does this affect your life . . . it was asking
direct questions which I don’t think we do that well, most of the time.
Interview NU1 Int5
General practitioners varied more in their template use. Some followed it strictly, using the agenda created
by the nurse, but others followed their own structure and made independent enquiries about patients’
concerns. They quite often referred to the template at the end and completed it at the end of discussions
rather than as they went along. Most GPs disliked having to use the template as they did not usually
consult in that way and often found it too intrusive and disruptive of communication with patients,
although they could also see some benefits:
I mean obviously there are advantages to it, it reminds you to ask about certain things which you
might not remember. But it is a challenge to try not to use it too much really, because uh . . . because
it can interfere with how you communicate.
Interview GP1 Harvey
Both nurses and GPs struggled to print the patient agenda or the health plan from the 3D template at the
end of their reviews, which sometimes caused frustration or requests for an administrator to help.
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Comprehensive review
The template created the structure for a comprehensive review. Clinicians welcomed the extra time, not
only for the opportunity it gave to consider the patient’s agenda, but also to look back at problems and
get a good sense of the whole of the patient’s health. However, they did not think that it would be
feasible to offer this to all their patients with multimorbidity without extra funding.
Patients especially valued receiving a proactive, comprehensive review. Having all their conditions and
problems considered was felt by patients as more ‘personal’ because they were being considered as a
whole person rather than being fragmented into a series of health conditions:
So the great thing about this is that they’re looking at you as a whole being and taking everything
into account and that is very new.
Interview patient 7 Beddoes
Knowing that they had more time relieved the pressure many patients experienced in routine consultations:
The time is limited when you have an appointment, and [3D] is more relaxed – you can talk to the
doctor without having to say, ‘oh I’m keeping them back’.
Interview patient 2 Lovell
Agreeing patient agenda
Almost all clinicians agreed with the patient-centred approach of asking patients about their main
concerns as an integral part of a review. However, observation indicated that nurses sometimes translated
problems into more medical language when writing them on the agenda. For example, a painful swollen
knee became ‘pain and mobility problems’. Others took a more patient-centred approach and checked
wording with patients or used patients’ own wording:
Nurse: The first question is ‘what is the most important problem that you would like us to work on
over the next few months’?
Review observation NU1 Patient 7 Harvey: The most important problem? . . . My breathing.
Nurse: To help your breathing is it? . . . To help my breathing [saying what she is typing]. So to you
that’s the most important thing.
A wide range of patient concerns were elicited, usually at the start using the question written in the
template, but sometimes emerging later. At the second nurse review, instead of using the wording
from the template, nurses often referred back to the first review:
So, first question is what is the most important health problem that you would like us to work on over
the next few months?
Review observation, NU1 Harvey
Is there anything new from last time you were here that you want me to highlight for [GP1]?
Review observation, NU1 Int2
At the end of the review patients received an agenda for the GP to address, created by the template,
summarising their priorities and any concerns arising from the disease checks.
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Clinicians were generally very positive about focusing on patients’ concerns, as distinct from the clinicians’
agenda, but not all GPs used the agenda that patients presented from the nurse review:
So that’s the very first thing out of the box is, what’s the most important thing to you, it’s not what’s
important to me because of QOF, it’s not . . . what I think is important, it’s what the patient thinks
is important.
Interview NU1 Int5
However, other clinicians were less positive, being aware of the potential tension between the clinician
and patient agenda and the need to complete certain aspects of the review because of QOF:
It’s QOF that gets the income so therefore there are certain questions I have to ask to tick the box to
say that has been done and that doesn’t necessarily always equate with what the patient’s main
issue is.
Interview NU1 Davy
Clinicians felt that the long-term conditions were more medically important than some patients’ concerns,
which were often minor acute problems or social issues. Others mentioned that patients were raising
concerns that they felt were inappropriate because they were intractable problems that had already been
discussed multiple times. Another difficulty clinicians described was that many patients could not think of
any current problems they would like addressed and one nurse commented that she had to ‘find problems
that weren’t there’. Occasionally problems were elicited, of which clinicians had previously been unaware,
for example, heart failure, melanoma or osteoarthritis.
Patients, for their part, welcomed the opportunity to raise all their concerns. Patients felt that they could
raise issues that they would normally consider too trivial to discuss and that these were followed through
by the GP who would go generally through the whole agenda:
There was certainly plenty of opportunity to raise things, you were quite frequently being asked,
‘Is there anything else you want to think about?’ . . . It certainly allowed things to be picked up
that might not have been normally dealt with in a more focused appointment.
Focus group patient 7 Lovell
Observations indicated that some patients gave their agenda to the GP without looking to see what the
nurse had written, and the GP did not always go through the whole of the agreed agenda:
She did give me a printout of what we discussed but some of the things that the nurse had put
through I don’t think she looked at and she just concentrated on what I could do to help myself.
Interview patient 1 Harvey
Depression screening
Depression screening was ticked as having been completed in almost all of the reviews (see Table 23) but
there was wide variation in how it was performed. Clinicians in general were not enthusiastic about it and
several nurses said it was outside their usual remit and they felt unable to address issues that might be
raised. One nurse said she did not always do it as she did not understand it:
It’s the depression ones I find hard because I don’t deal with that a lot.
Interview NU1 Harvey
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Some nurses were uncomfortable with particular questions, for example whether or not the individual felt
a burden to their family and friends, and would apologise for asking:
Feeling bad about yourself or that you or . . . that you are a failure or have let yourself or your family
down? I just hate asking that question.
Review observation, NU2 Harvey
In most of the observed reviews, depression screening was completed by the nurse reading out the questions
to the patient. How this was done ranged from a ‘tick box’ approach that favoured a ‘no problem’ answer
from the patient to an in-depth discussion of psychosocial issues.
General practitioners did not attach great weight to the depression screening results, despite acknowledging
that mood was important. One commented that it might have more of a role in prompting patient reflection
about their health than in identifying depression, as GPs felt they could do that anyway:
Rather than for us as clinicians to pick up, it might have a role for patients to think about it more.
Group interview GP1 Lovell
A few patients mentioned the depression screening as having been beneficial. In one focus group, three
patients stated that it had highlighted a problem and that this had subsequently been addressed which
they felt had been a benefit:
She went through everything obviously and it turned out, well . . . I knew, I was very low and I wasn’t
sleeping very well and so she went through all that and gave me tablets for it and fine today, so
that’s helped.
Focus group patient 4 Lovell
However, one of the three was disappointed that the nurse just collected the information and did not
discuss it:
I don’t think the nurse particularly picked up on it very well . . . I put the questionnaire on the desk but
she never actually picked it up at that point . . . when she did refer to it, it was just to do a tally, so it
was the score more than the content.
Focus group patient 7 Lovell
Pharmacist review
Eight of the nine pharmacists who carried out the medication reviews for the 3D study were interviewed in
a separate substudy: four were employed by the CCG, three by the GP practice and one by a community
pharmacy. Eight GPs were also interviewed. Although the research team intended that the pharmacist
review preceded the GP review to inform the GP–patient discussion, in a small number of practices it
occurred later owing to organisational problems. However, a pharmacist review was conducted in almost
all cases in which the patient had at least one 3D review appointment (see Table 23). One of the
pharmacists carried out face-to-face reviews with patients in their homes but all the other pharmacist
reviews were done remotely. In one case patients who would have been reviewed by the in-house
pharmacist were ‘excepted’ from this system and reviewed remotely.
General practitioners and pharmacists were generally positive about the prescribing aspect of the 3D
intervention, particularly the format of having blood tests, followed by a nurse appointment, remote
pharmacist review and GP appointment. The pharmacists found this especially useful because blood
tests were up to date and the nurses had sometimes noted patient concerns about their medicines.
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The pharmacist who carried out face-to-face reviews argued that elderly patients taking lots of medicines
benefited most from this type of review, particularly from being seen in their own homes and having
the time taken to discuss each medication in turn. GPs most valued pharmacist recommendations that
improved the safety of prescribing, such as picking up medication errors, adjusting medication doses
owing to renal impairment and identifying potential drug interactions, and recommendations that reduced
the number of tablets or simplified treatment regimens:
A patient . . . who had been put on a vitamin D replacement, on a high dose . . . that had never been
dropped down and she had been on it for about 18 months . . . so that was all very useful.
Interview GP1 Harvey
Several of the pharmacists referred to the STOPP/START criteria, which provided them with objective
evidence to recommend stopping certain medicines. GPs perceived that the majority of pharmacist
recommendations related to changes in NICE guidelines and that these recommendations were generally
less valued by GPs. Some GPs argued that the recommendations were technical and irrelevant in the social
and medical context of individual patients. GPs who had a good working relationship with the pharmacist
were more likely to action the recommendations than GPs who had never met the pharmacist:
. . . rarely the GP . . . took up on my suggestion . . . Quite often the ones where it was inhaler related
they were never really changed.
Interview community pharmacist
Medication adherence and reviews
Observation indicated that GPs usually reviewed medication and checked adherence towards the end of
their review after they had been through the presenting issues. However, in 24% of reviews there was
no indication that the pharmacist’s comments had been noted and in approximately 16% medication
adherence was not completed (see Table 23). Despite this, several GPs thought that the medication
adherence questions were a worthwhile addition to a medication review and not something they
usually did:
There have been examples where people have said I really don’t like this tablet or that tablet,
and I don’t think I’ve asked it in quite the same way before.
Interview GP1 Harvey
Patients also seemed to welcome medication reviews and several patients commented that they would like
to discuss their medication more often.
Not frequently enough in my opinion . . . I’m a little bit unhappy about the way they just leave you on
a prescription then that’s it. They seem quite happy to just leave things as they are.
Focus group patient 6 Beddoes
However, some felt that changes had been imposed that they did not welcome:
The thing I ended up with was ‘I think we should take you off statins. I think you’re on too many
tablets’. Well personally, I feel it’s the tablets, having gone through what I have, that’s kept me going
and so I didn’t want to.
Focus group patient 8 Beddoes
Collaborative health plan
The creation of a health plan was included in the GP part of the review and was the element with which
GPs seemed to have most difficulty. However, 77% completed it in the template at least partially (see
Table 23). GPs perceived that often they were expected by patients to ‘give them the answers’ and
creation of the health plan was almost always led by the GP rather than the patient. It was generally
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formulated as a problem list with accompanying actions for the GP and patient rather than as goals for the
patient to achieve:
As far as your . . . very severe aches and pains, I’m going to add paracetamol . . . and let’s review that
in 1 month, OK? As far as things that you could do . . . if you get some CBT [cognitive–behavioural
therapy] psychology that [might] help a bit . . . so let’s put that in.
Review observation GP2 Harvey
However, there were some examples of genuine collaboration, in line with a patient-centred approach and
one GP was surprised by some goal suggestions.
Because I think, you know your body better than me and I think from that respect, you know, if you’re
willing to give that a bash, certainly we can keep in touch and monitor the progress of that.
Review observation GP1 Patient1 Int2
Sometimes patients do come up with a totally different goal that I had never dreamt of.
Interview GP1 Harvey
The same GP felt that the concept of working collaboratively towards the patient’s goals was novel
but welcome:
It’s more what’s important to you at this moment in time, and how can we try to get there together?
And I think that is quite a novel concept.
Interview GP1 Harvey
General practitioners noted that patients had often forgotten at the second review what goals were
agreed at the first. This meant that they could be ‘starting from scratch’ instead of reviewing progress.
There were doubts about the usefulness of the health plan but a perceived obligation to complete it even
when the patient had no particular concerns:
Often they say ‘No, no there’s nothing I want to discuss’ and you eventually tease out one or two
things from them.
Interview GP1 Beddoes
Rather than facilitating a sense of shared responsibility for health, several GPs perceived the idea of a written
plan as controlling rather than as collaborative. Some had difficulty translating the verbal plan into the
format of the 3D health plan and one GP felt that it was overly simplistic and even patronising or accusing:
I felt it was almost that you were actually chiding them in some ways, to say, ‘You should do this,
should do that . . . It’s almost like when we were at primary school, taking home your homework
tasks and goals for the week.
Group interview GP3 Lovell
However, one or two GPs did support the idea of giving patients a written summary of the agreed plan.
For patients, the health plan was not a prominent feature of the intervention, although a few highlighted
perceived benefits. One had used it to check progress at the second review and another had found it
helpful as a record of the plan agreed at the first review:
Coming away with that written piece of paper that they printed off is useful for me, because you can’t
always retain the information, because we changed some of the medication and we talked about
ways forward.
Interview patient 7 Beddoes
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A couple of patients felt that it had not contributed anything and that the GP had completed it unilaterally
rather than as a collaborative action plan:
Well I think it was mainly the doctor’s plan but it was a very airy fairy plan. There was nothing . . . that
you could turn round and say ‘oh, that’s a good idea, we’ll try this’.
Focus group patient 3 carer Davy
Patient-centred approach
Many clinicians referred to the need to change patients’ behaviour and take more responsibility for their
own health. This was mainly in relation to ensuring that they came prepared with an agenda they wished to
address and getting them used to the idea that they would be asked about their most important concerns:
Patients need to be taking ownership themselves so that we can then help them with it, but they
actually own that problem.
Interview GP1 Beddoes
One GP acknowledged the difficulty presented by the power imbalance in the therapeutic relationship:
The other side of it is to try to empower patients to demand their goals are met and for us to listen to
that and do something about it . . . But in the doctor–patient relationship we are incredibly powerful
in consultation.
Interview GP1 Harvey
Some patients did feel empowered by the experience of having their opinion sought and perceived that
the 3D review process helped to create an interaction during which the clinician had to listen to the
patient and the patient could be more assertive about their priorities:
This gives me that kind of overview where you think ‘well I’m the person that’s getting attended here,
it’s not what this GP wants or thinks it’s what . . . my needs are’.
Focus group patient 7 Lovell
One patient also highlighted a difference in the relationships she had with clinicians:
I suppose one of the positive things that you could say came out of this was the different relationship
that you have with your nurse and GP, that perhaps you didn’t have before.
Focus group patient 3 Lovell
Summary
It was apparent that the use of the template and completion of components varied in ways that affected
patient-centredness and fidelity to the intervention. Some reviews adhered very well to the patient-centred
approach of 3D and the template was fully completed. In others, the template was fully completed but
in a way that seemed to prioritise the template rather than the patients’ needs, and conversely some
consultations were very responsive to the patient but the template was not fully completed.
Clinicians were positive about prioritising the patient agenda but had some concerns over the need to
balance it with clinician priorities within the time available. They felt that patients needed to become more
responsible for their own problems. The patient-centredness of the clinicians’ approach was affected by
the template, which had a negative effect on their communication but a positive one on their attention to
patient concerns within long-term condition reviews.
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The majority of patients felt that participating in 3D had been beneficial. There was clear consensus that
the most valued aspect was the extra time and the opportunity to discuss everything that was concerning
them. However, a notable number of patients, particularly in the two smaller case study practices, claimed
that the reviews had made no discernible difference to the quality of care because their usual care was
very good. Some also said that they were generally given as much time with the GP as they required,
although they felt uncomfortable taking it. The main difference seemed to be in feeling they were given
more dedicated time in which to discuss their own concerns. In the fourth case study practice, most
patients had not received the 3D intervention or felt it did not match their expectations.
Maintenance of the intervention over time
This section examines the maintenance of the intervention over the course of the trial and what reach
was achieved. It includes reflections on how the intervention could be improved if it were continued, and
data from interviews and end-of-trial surveys of practices and clinicians about future intentions regarding
continuing aspects of the intervention.
Practice champion meetings
Practice champion meetings to support maintenance were originally planned to take place three times
during the intervention. The first meeting in each area was quite well attended, but subsequent meetings
were difficult to arrange and attendance was variable. However, the meetings provided useful two-way
feedback and provided an opportunity for the researchers to clarify aspects of the intervention, such as
continuity, use of 3D cards, goal-setting and second round reviews.
Reach
The monitoring data collected from the 3D template (see Table 23) showed that 75% of first reviews were
completed but only 49% of second reviews, and the interviews provided some explanation for that.
First, some practices saw less value in another full review only 6 months after the first and faced difficulty
fitting them in within the trial deadline. This meant that sometimes they made fewer attempts to contact
patients who failed to respond to the first appointment letter. Second, many patients had received their
usual reviews in addition to the first 3D review and were confused about the need to come in again for a
review. Third, several clinicians felt that it was unnecessary for the patient to see both nurse and GP for
the second review. One suggested model was for the nurse to conduct the second review and arrange a
follow-up GP appointment only if there were further issues to address. Linked to this was a suggestion
that the template should include a box to tick to say that there was no need to see the GP. In such cases
the second review would be completed at the nurse appointment:
I think the bits I’d tweak would be definitely the 6-month review. I think I’d try and make it less clunky,
probably just with the nurse with the option to see a doctor if there were items that needed to be
discussed.
Interview GP1 Beddoes
Several nurses were unsure what should be covered in the second review and thought that they had to
complete all the boxes in the template, including some disease review items that normally would be done
annually. They were also uncertain about whether or not they should be reviewing progress made on
previous problems or identifying new ones and thought that it would be difficult to do both. It was
suggested that some refresher training would have been helpful.
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Patients came to a similar conclusion about the second round of reviews and recognised that the
unpredictable nature of their conditions might necessitate care at other times:
Patient: I actually think . . . if they continue then perhaps going to see a nurse once every 3 months
and she asks you about everything, that would perhaps save you having to go to the doctors over
something that you could sort out.
Focus group Patient 4 Beddoes
Both clinicians and patients commented on whether or not the patients selected for the 3D study were
those who would benefit most from the extra resource. Clinicians suggested that those who were still very
well and stable despite having several conditions were less likely to benefit, but, at the other extreme, the
health of very unwell patients was unlikely to be improved. Furthermore, it was felt to be too much to
expect very ill patients to attend reviews because of mobility problems. Therefore, from the perspective
of clinicians, those most likely to benefit were perhaps in the mid-range of morbidity, with scope for
improvement because they were still ‘developing their conditions’ or managed sub-optimally:
The ones who are quite happy living with their conditions . . . were a little bit bemused by it all . . . the
other group who have got intractable health and social problems, there’s not really much we can do
about that. People in the middle I think definitely have found it useful.
Interview GP2 Int1
How to select these patients was recognised as a challenge and likely to require a combination of computer
searches based on similar criteria to those used for 3D and individual clinician knowledge of the patients to
select those who were considered most likely to benefit.
Patients views differed slightly in that some thought that the intervention should be targeted at people
who were more unwell, especially in a resource-poor health service:
I suppose really, for somebody that was quite poorly, then yes it would be helpful. But for me I just
get on with things.
Focus group patient 6 Harvey
All clinicians who had delivered the intervention were asked in the end-of-trial questionnaire whether or
not they would continue with any of the components of the intervention. Sixty-four responses were
received (80% of those surveyed). The results are shown in Table 35.
Notably, a majority of clinicians stated that they would continue to offer many aspects of the intervention,
including a focus on patients’ quality of life (90% responded ‘yes’), asking about patients’ most important
concerns and priorities (84%), enquiring about medication adherence (92%) and providing a health plan
(58%). Half (48%) of respondents reported that they would continue to conduct a combined health
review (in contrast to the interview data, in which the idea of a combined review appeared more generally
supported). However, most clinicians (71%) said that they would not continue to use the 3D template,
with only two of the 64 saying that they definitely would. Criticisms expressed in interviews were that it
needed simplifying and was sometimes repetitive (e.g. pain appeared as an identified problem and was
also asked about in the quality of life questions):
There’s quite a lot of . . . tick boxes that you could perhaps streamline those into shorter areas.
Interview GP1 Beddoes
Although the clinicians were in favour of many aspects of the intervention, their answers were often
qualified by this already being their usual practice. Only 29% of clinicians felt that the 3D trial had
changed their practice, with a further 15% being unsure. The large number of clinicians answering
‘maybe’ to questions about continuing various components often qualified their answers by referring
to time or funding constraints.
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In contrast to the questionnaire data, a number of clinicians who were interviewed thought that 3D had
changed their clinical practice, although there were also several who said that it had not. The main change
identified was that they would include an enquiry about patients’ most important concerns and quality of
life in their future consultations, although, as noted above, many claimed to be doing this already:
It’s reminded me a lot about what’s important to me isn’t necessarily what’s important to the patient
. . . having those very focused questions at the beginning of the consultation, has slightly changed
what I do, in the fact I now do it myself.
Interview NU1 Int5
Predictions
Based on our analysis, which was completed before the outcome of the trial was known, the following
predictions were made about intervention effectiveness. These were that there would be:
1. a difference in patient perceptions of care because patients liked the intervention and being asked
about all their conditions and receiving an all-round review
2. no change in EQ-5D-5L or other health outcomes as there was no change apparent in quality of care
received or in clinician behaviour other than use of the template.
TABLE 35 Clinician questionnaire responses at end of trial
The 3D model included the following components. Will you continue to use
any of them?
Response (%)
Total (n)Yes Maybe No
1. Asking patients about their priorities and most important concern 84.4 14.1 1.6 64
2. Focus on quality of life (e.g. pain, mobility, function) 90.5 79.4 1.6 63
3. Using a formal depression screening tool (e.g. PHQ-9, for patients with
multimorbidity)
25.0 35.0 40.0 60
4. Annual pharmacist review 21.8 52.7 25.5 55
5. Enquiring about medication adherence 92 3 5 64
6. Agreeing patient and clinician actions in a health plan 58 24 18 62
7. Allocating extra time to patients with multimorbidity 41 41 18 61
8. Comprehensive review of all health problems at once 48 27 25 63
9. Six-monthly review 22 47 31 62
10. Two part review: nurse appointment to gather information then GP
appointment to make a plan
12 40 48 60
11. Personal continuity – trying to ensure that patients with multimorbidity see same
GP for every appointment
68 25 7 60
Please answer the following questions:
12. Will you continue to use the 3D template? 3 26 71 63
13. Do you think most of your patients understood the purpose of the 3D reviews? 54 16 30 63
14. Were 3D patients continuing to attend other long-term condition reviews during
the study?
48 13 39 62
15. Has taking part in 3D changed your clinical practice in any way? 29 15 56 62
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Given that the qualitative data suggested that some patients might be either too well or too ill to benefit
and that those in between had the most capacity to benefit, a subgroup analysis of patients categorised
by health status was also suggested.
The results of this post hoc analysis are shown in Table 36 and do not show any evidence to support a
relationship between baseline quality of life and effectiveness of the intervention.
Apart from the lack of effect in the above post hoc subgroup analysis, the process evaluation predictions
were confirmed by the results of the trial. This strengthens our belief that the process evaluation findings
from a subset of practices are more widely applicable, and that the process evaluation findings provide an
explanation for the lack of effectiveness found in the main trial evaluation.
Conclusion and implications for future implementation
Clinicians, patients and commissioners all supported the intervention concept in principle. Clinicians
thought that it embodied care that they would like to deliver and patients welcomed it as care that they
would like to receive. However, the process evaluation suggested that there were difficulties delivering the
intervention, which makes it difficult to assess whether or not the intervention would be effective if fully
implemented. The difficulties experienced with implementation are consistent with concerns expressed by
professionals about the feasibility of the intervention in the current health-care context.
TABLE 36 Post hoc subgroup analysis, relationship between baseline EQ-5D-5L and effectiveness
Tertiles of
baseline
EQ-5D-5L
scorea
Trial arm
Adjusted
difference in
means by
subgroup 95% CI
Interaction
term p-value
Usual care Intervention
Unadjusted
mean (SD)
EQ-5D-5L at
15 months n
Unadjusted
mean (SD)
EQ-5D-5L at
15 months n
First 0.231 (0.265) 224 0.266 (0.266) 200 0.01 –0.02 to 0.05
Second 0.558 (0.207) 222 0.562 (0.204) 235 0.00 –0.04 to 0.03
Third 0.766 (0.179) 222 0.753 (0.227) 254 –0.02 –0.05 to 0.02 0.537
a Analyses are adjusted by centre, baseline EQ-5D-5L score, GP practice list size and GP practice deprivation score.
GP practice is included as a random effect.
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Chapter 8 Discussion and conclusions
Summary of main findings
In this study we have developed, implemented and evaluated the 3D approach to improving the
management of patients with multimorbidity in general practice.
The first aim of the 3D approach was to improve participants’ quality of life. The results show no evidence
of effect from the 3D approach in respect of health-related quality of life measured using the EQ-5D-5L,
which was the primary outcome, nor in any other measure of health or illness. The second aim of the
3D intervention was to reduce treatment burden through co-ordinating disease reviews and simplifying
medication, but there was no evidence of benefit in this respect. The third aim was to improve patient-
centred care, and a wide range of measures showed that this aim was achieved. These measures included
PACIC, which assesses key aspects of the chronic care model such as patient activation, goal-setting and
care co-ordination. Participants in the intervention arm reported higher PACIC scores, better relational
empathy, consultations that were more likely to address their main priorities and care that was well
co-ordinated than those in the usual-care arm. Intervention arm practices also provided greater continuity
of care.
The process evaluation demonstrated that the implementation of the intervention was not complete.
It highlighted several difficulties that practices experienced in implementing the new approach to care,
although the main aims and principles underlying the 3D approach were broadly welcomed by both
practice staff and patients.
The economic evaluation showed that the 3D approach was associated with no meaningful differences
in either QALYs or costs compared with usual care. The combined effect was that the 3D approach was
unlikely to be either more or less cost-effective than usual care at the usual thresholds for willingness
to pay.
In summary, the 3D approach was not associated with any measurable benefits in terms of quality of life,
illness burden or treatment burden but did achieve its aim of providing more patient-centred care. Moreover,
these benefits were achieved at little or no additional cost to the NHS and social services, and the intervention
was slightly more cost-effective than usual care. This may justify implementation of the 3D approach, and
further development of the approach may overcome some of the difficulties observed in implementation so
that it becomes more effective over time.
Strengths and limitations of methods
Validity
The 3D study is the largest trial so far conducted of an intervention designed to improve care for
multimorbidity (the WISE trial of care planning included in the Cochrane multimorbidity review was larger
but was not designed as an approach to multimorbidity and included people only with diabetes mellitus,
COPD and/or irritable bowel syndrome).36,92 The 3D approach is based on a patient-centred care model and
attempts to operationalise most of the strategies to address multimorbidity that are currently recommended
in national and international guidance.5,39,40,69,132–134 The intervention was supported by both local health-care
commissioners and doctors and nurses in practices, who felt that it would help them to deliver the kind of
care that was appropriate.
DOI: 10.3310/hsdr07050 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 5
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Salisbury et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
The trial was rigorously conducted in line with recommended standards for cluster randomised trials in
order to maximise internal validity,135 and external validity was maximised by testing the 3D approach in
a range of general practices and settings in a pragmatic cluster randomised trial.
Despite the challenge of conducting this trial in multiple centres in general practices facing high levels of
stress, the trial was largely conducted as planned, with recruitment rates similar to those anticipated and
high rates of patient follow-up over 15 months.
We collected data on a broad range of outcomes in three main domains of illness burden, treatment
burden and patient-centred care in order to assess the full range of effects of this complex intervention.
We also collected data on intermediate outcomes or processes, such as continuity of care and the number
of drugs prescribed, which helped to demonstrate whether or not the 3D approach had the intended
effects on the process of care. This was further explored through a mixed-methods process evaluation,
which helped to interpret findings. Finally, we conducted an economic evaluation, which has been lacking
in most previous studies of interventions for multimorbidity.
The design and conduct of this trial benefited from strong PPI involvement. We recruited a very engaged
and constructive PPI advisory group. Members helped to shape the design of the intervention and the trial,
contributed to the design of patient-facing materials, such as questionnaires, and, through discussion with
the research team, helped to interpret the findings.
Bias
As with most trials of service redesign, it was impossible to mask GPs or patients so that they were unaware
of their allocation in the trial. Most outcome measures were based on self-report, which is appropriate given
that the most important and relevant measures of success of this intervention were the benefits perceived
by patients rather than changes in biological parameters. However, the use of self-report raises the possibility
that participants in intervention practices would be biased towards positive reports in response to the efforts
of their practices to improve care. Given the high levels of patient satisfaction at baseline, however, the
opposite effect is also possible, with participants tending to say positive things about current practice and
being more willing to criticise any changes.
Most of the measures used for the process evaluation and the economic evaluation were obtained by
electronic download from medical records, but details of secondary care use were collected manually from
records that inevitably showed whether or not the patient had received the intervention and, therefore,
were not collected blind.
Owing to chance imbalance, participants in the intervention arm had higher EQ-5D-5L scores at baseline
than those in the usual-care arm. This was adjusted for in all analyses. However, regression to the mean
would tend to reduce the difference between the trial arms over time; therefore, adjusting for baseline
imbalance makes it less likely that any true difference between the intervention and trial arms would be
detected. In other words, adjustment for baseline imbalance is conservative, reducing the risk of a false
positive result but increasing the risk of a false negative result.
Imprecision
The number of eligible patients (3.9% of the adult population) and the level of follow-up (83% providing
primary outcome data) were both higher than anticipated in the sample size estimate. Although the level
of follow-up in the trial was high, especially given that participants were predominantly elderly with
complex health needs, any level of attrition raises the possibility of bias and imprecision in estimates.136
We addressed this possibility by using multiple imputation to ensure that all participants were included in
analyses in the arms to which they were allocated (‘intention to treat’) and because this was stated a priori
as our approach to analysis for the primary outcome. However, imputation depends on the assumption
that missing data are missing at random,121 which was not the case in this study. Nevertheless, the extent
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to which data needed to be imputed was limited (because of high follow-up rates) and we conducted
several sensitivity analyses, all of which supported the primary analysis.
One key consideration was whether or not the outcome measures, particularly the EQ-5D-5L, which was the
primary outcome, were sensitive to change. This problem was discussed at length both within the research
team and with the funding body when the study was first designed. It is well recognised that the EQ-5D
measure has limited sensitivity to change,137,138 although responsiveness has been demonstrated in some
specific chronic conditions.139–141 Our decision to use the EQ-5D-5L was based on several considerations.
First, improving quality of life was the most important aim of our intervention, and it was, therefore,
appropriate to choose it as the primary outcome measure despite the known measurement difficulties.
Second, the EQ-5D is the ‘gold-standard’ quality-of-life measure recommended by NICE for comparing
the benefits of different interventions. Third, we used the EQ-5D 5-level version (EQ-5D-5L), which was
designed to be more responsive than the older 3-level version.142 Finally, early results from the CARE Plus
pilot study of an intervention for multimorbidity in deprived areas suggested that the EQ-5D-5L was
sensitive to intervention effects in a similar population of patients after 6 months’ follow-up.38
The alternative to using a measure of quality of life would have been to use a measure, such as PACIC,73
but this would have been criticised on the grounds that better health care is of limited benefit if it does
not lead to better health outcomes. However, it was possible that the 3D intervention could show little
benefit in quality of life as measured by EQ-5D-5L but be associated with other important benefits, such as
improved patient experience, and be considered successful on that basis. Furthermore, an intervention with
little or no benefit in quality of life could still be cost-effective if it was associated with minimal increases or
reductions in costs.
This trial had a large number of participants, which gives it power to detect small differences. It also
involved the measurement of several secondary outcomes to enable us to fully understand the intervention
from a range of perspectives. However, these benefits also mean that some significant findings could be
due to chance owing to multiple testing, and that some observed differences could be small and not
clinically meaningful. The observed effect sizes for some measures were small (e.g. 0.13 for the CARE
measure for GPs), for others were modest (e.g. 0.3 for PACIC) and for others were large (e.g. adjusted
odds ratio of 1.97 for use of care plans).
Most of the measures used in this study are well established, but some are new. We developed and validated a
new measure of treatment burden (the MTBQ) because the few existing measures had significant limitations.76
The MTBQ shares with all other measures of treatment burden the problem of a skewed distribution of
responses, which makes it harder to detect differences between groups of participants. An advantage of the
MTBQ is that, unlike most other measures of treatment burden, we have shown that it is responsive in relation
to changes over time.76
We used Visit Entropy as a measure of continuity, which is a new measure designed to address some
mathematical problems of older measures, such as the COC index.84,85 In our study, both measures suggested
improved continuity in the intervention arm, but this was statistically significant for the COC but not for the
Visit Entropy measure.
Imprecision was a particular issue in the economic analysis. We have presented means in the presentation
of findings, as is conventional in economic analysis. However, the frequency distributions of almost all
items of resource use were skewed, and in some cases highly so. In particular, a small number of patients
in both arms of the trial had lengthy hospital admissions incurring very high costs. The consequence is
that, despite the large size of this trial, our estimates of the cost of each component of resource use have
very wide CIs. This causes some difficulties of interpretation for policy, given the large number of people
with multimorbidity in the population and the wide variation in possible cost implications at a national
level from the implementation of 3D. Possible interpretations include the possibility of saving expenditure
as well as the possibility of incurring additional cost.
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Generalisability
The study was highly pragmatic, seeking to show the effect of real-life implementation of the 3D approach.143
However, the pragmatic nature of the study also made it difficult to show significant effects on health. The
results show the difficulty of achieving change in health-care delivery, and such changes are even harder to
achieve when they are being conducted for a small number of people in each practice in the context of a
research study. As discussed in more detail in the next section, introducing the intervention as part of a
research study had inevitable consequences for implementation, which were likely to dilute any effects.
Ideally, the 3D approach would be implemented as a whole-system change, with practices reorganising
their systems to offer the 3D approach to all patients with multimorbidity. This was indeed the research
design originally considered, but it was rejected for the reasons described in Chapter 4.
We successfully recruited patients with a wide range of long-term conditions. Of all potentially eligible
patients invited, 33% agreed to participate. This recruitment rate is typical of similar studies based in
primary care144 and is higher than some related studies.145 We found few differences in the characteristics
of participants and non-participants, which supports generalisability, except that fewer participants had
severe mental health problems, dementia, depression or learning disability. This was partly because many
patients with these characteristics were excluded by their GPs, which is unfortunate because some of
these patients could have most to gain from the 3D approach. However, despite these problems of
under-representation we recruited 135 patients with these conditions who would often be excluded
from trials.
The areas included as the setting for this trial were chosen to include populations with a range of characteristics,
including in respect of deprivation and ethnicity. However, patients from black or minority ethnic groups were
under-represented among the patients choosing to participate.
The design of the intervention is in line with recommendations from North American40 and European133
agencies and also the World Health Organization46 (see How the 3D approach reflects and operationalises
current guidance). Therefore, the findings from this trial are likely to be relevant to other countries that
have a main provider organisation providing generalist primary care for people with multimorbidity,
including the Primary Care Medical Home model.146 They are less likely to be generalisable to countries
in which many people directly access specialists for their chronic disease management.
Interpretation of findings
The trial did not show any evidence that the 3D intervention was associated with improvements in the
primary outcome of quality of life. This could be due to the problems of measurement previously discussed,
but it also raises the question of whether the lack of effect could be due to a failure of implementation or
a failure of the concepts underlying the intervention design. If the intervention was not implemented as
intended it is impossible to be sure from this study whether or not the intervention would have worked if it
had been fully implemented. But if the intervention was fully implemented, the lack of effect could suggest
that the conceptual model for the intervention was flawed.
Implementation
This study required intervention practices to introduce a new way of working for a relatively short period of
time in a small minority of their patients with multimorbidity. Meanwhile, they continued to provide usual
care for most other patients in a way which was highly familiar, which they had practised for several years,
had administrative structures to support and were financially incentivised to deliver.
Given the speed of work in general practice and the familiarity that staff had with existing disease-specific
templates that they had used for many years, it is not surprising that some found it difficult to adapt to
the new 3D template, especially since each individual member of staff used it with only a small number of
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patients. Their unfamiliarity with the template also meant that it required more of their attention and
influenced their consultation style in a way which mitigated against the patient-centred approach
intended. This is consistent with earlier work by Swinglehurst et al.,147 which has illustrated how templates
tend to shape and constrain the nature of consultations.
Introducing the intervention in the context of a trial had other adverse effects. In particular, in some
practices, not all GPs agreed to take part in the trial, which meant that some participating patients had to
consult a different doctor from the one they usually saw. Although one of the aims of the 3D approach was
to encourage greater continuity of care, participation in the trial had the opposite effect for some patients.
Despite this, we did find some evidence of improved continuity overall. Another strategy to encourage
patient-centred care was to offer longer consultations to patients with multimorbidity. Although practices
provided long appointments for the 3D reviews, none of the practices observed in the process evaluation
offered patients more time when making routine appointments, although we tried to use strategies to
promote this, including 3D cards for patients and pop-up reminders for receptionists. This appeared to be
because of concerns about adding to the pressures on the limited appointment time available.
Consequently, the intervention was not as fully implemented as intended, which would have diluted any
effects. Although three-quarters of patients received at least one 3D review during the 15-month follow-up
period, only about half received the two reviews that were planned. Even though the quantitative data
show that the intervention appears to have been fairly well implemented (e.g. completion of the template
was relatively good), the process evaluation suggested that some of these changes were superficial. For
example, nurses lacked confidence in screening for mental health problems, and goal-setting and care
planning by doctors appeared to be less patient-centred and less well negotiated with patients than
intended. The finding from the process evaluation that some clinicians felt that patients raised issues that
were not ‘appropriate’ implies that some clinicians’ attitudes reflected a medically driven sense of priorities
rather than a patient-centred approach.
It is important to note that in a pragmatic trial we would not expect all patients to be reviewed, either
because the practice failed to offer a review or because patients declined one or failed to attend. The data
suggest that the 3D intervention was implemented to a similar extent to disease-specific chronic disease
reviews under usual care, suggesting that, although implementation of 3D was not complete, it was
probably what could be expected and the trial provides a fair reflection of likely implementation of 3D in
normal practice.
The intervention relied on several changes to IT, including a programme to identify patients with
multimorbidity, a system to flag up these patients when they made appointments and the introduction of
the 3D template. Some of these new systems had limitations because of constraints of the EMIS system
itself. In particular, the practices in Scotland had to use a less functional version of the template because
their version of EMIS could not support the template used in England. The template incorporated a facility
to print the 3D Health Plan when the consultation finished, but some practices had difficulties achieving
this, which could reflect problems with installation or staff training. Some aspects of the template were
less than ideal because of a lack of suitable Read Codes for topics, such as multimorbidity and goal-setting.
These problems could be resolved in time, but not within the duration of the trial.
An important issue that affected implementation was the wide variation between practices in the roles
and competencies of their practice nurses. Some nurses were trained to work only with specific long-term
conditions and did not feel confident to work with patients with other conditions. Because of this variation
in competencies the 3D approach was designed so that it did not rely on highly skilled nurses, with the
nurses’ main role being to collect data with management decisions being made by doctors. However,
some practices had very experienced nurses who were usually responsible for management decisions in
at least some long-term conditions, and they felt that the 3D approach devalued their specialist expertise
role. To fully implement the 3D approach would require an investment in training so that all practice
nurses were confident to undertake reviews of all common long-term conditions. Greater standardisation
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in nursing competencies would make it possible to revise the 3D template to maximise the contributions of
nurses and doctors.
Although the pharmacist review of medication was popular with both doctors and patients, it was not
effective at achieving the main aim of simplifying medication regimes or reducing the number of drugs
prescribed. Reducing unnecessary prescriptions was one of the main ways in which we hoped the 3D
approach would reduce costs and be cost-effective. The process evaluation suggested that pharmacists
tended to concentrate on technical aspects of prescribing rather than simplification. They often focused on
ensuring that patients were prescribed in accordance with guidelines. This is entirely appropriate in many
people with multimorbidity, but medicines optimisation in the context of multimorbidity should also
include consideration of when recommendations based on guidelines may not be appropriate, including
stopping ‘indicated’ medicines.19 It is possible that pharmacists are not well placed to make decisions to
diverge from guidelines, because this may depend on complex trade-offs relating to patients’ priorities and
goals, competing priorities and acceptance of risk.
Another key aspect of the intervention that was intended to make the 3D approach more efficient than
usual care was replacing multiple separate reviews of each long-term condition with one co-ordinated 3D
review every 6 months. Practices were advised and supported to take participating patients out of their
usual recall systems and to set up a new recall system for 3D patients. However, it became apparent that
some practices offered 3D reviews as well as, rather than instead of, conventional reviews. This would
undermine one of the main ways in which the 3D approach could be cost-efficient.
The process evaluation demonstrated that many usual-care practices were already implementing some of
the strategies advocated by the 3D approach before the trial started, and this became more apparent
during the period of the trial. This issue of interventions building on existing secular trends rather than
being entirely distinct has been discussed by Dixon-Woods et al.148 In particular, practices in this study were
increasingly aiming to combine reviews of different conditions within one appointment. This phenomenon
is an endorsement of the strategies used in the 3D approach, but if there were fewer differences between
the care provided in intervention and usual-care practices this may help to explain the lack of effect on the
primary outcome observed in the trial. However, we think this is unlikely to be a major factor. Although
usual-care practices may have combined some reviews, our data suggest that they were not implementing
other aspects of the 3D intervention designed to promote patient-centred care.
Change in organisational systems is always difficult, particularly in general practices that must provide
very efficient, high-volume care. It is important to recognise that this trial was being conducted at a time
when many practices were under huge strain and struggling to provide essential care, with waiting times
of > 3 weeks for a routine appointment in some cases. Practices were facing other organisational changes,
including the abolition of the QOF in Scotland, which may have affected the attitude of Scottish GPs to the
delivery of the QOF-related aspects of the intervention. Several of the practices in this trial were in turmoil
and facing major problems with recruiting GPs. There were many examples of key medical, nursing and
administrative staff leaving practices during the trial, and this caused major difficulties if these were the
staff who had been trained to deliver the 3D intervention. Two of the 17 practices in the intervention
arm stopped providing the 3D intervention very soon after the trial started (because of staffing problems
rather than problems with the intervention). These patients were still followed up and included in analyses,
following the intention-to-treat principle. The above difficulties of implementation made it harder to detect
any differences between intervention and usual-care arms.
Although implementation of the 3D approach was not complete, this is also true of every other
intervention encouraged by policy-makers. The 3D approach was introduced in the context of a research
trial that may have impeded implementation in some ways (e.g. partial short-term reorganisation of
complex organisational systems). However, we used several strategies to support implementation, such as
training, regular feedback and financial incentives, which are not always widely used when similar NHS-led
initiatives are introduced. The level of implementation achieved using these strategies was higher than has
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been achieved in some trials of related interventions (e.g. the WISE trial of care planning92). It is well
recognised that interventions are frequently adapted and diluted when they are widely implemented in
general practice, so that they no longer reflect their original design.149–151 Therefore, the extent to which
the 3D approach was implemented may not be very dissimilar to other ‘top-down’ initiatives in primary
care, such as policies to encourage care planning,152 a named responsible doctor,153 patient feedback
through the friends and family test,154 or screening for frailty.155
The conceptual model for the intervention
As described above, some of the lack of effect of the intervention could be due to problems with
implementation. Despite these problems, the data suggest that the strategies to encourage implementation
were moderately effective and achieved similar levels of implementation as current well-established chronic
disease management programmes. Most patients received at least one 3D review, longitudinal continuity of
care improved and the 3D template was well completed, meaning that most patients had discussions about
their self-identified main health problems and received depression screening, an assessment of medication
adherence, a pharmacist review of medication and a written care plan. This raises the possibility that the
intervention is misconceived and would not improve the outcome of quality of life even if fully implemented
and even if all outcome measures had been perfectly reliable, valid and responsive to change. The lack
of any signal to suggest any benefit in quality of life would support this interpretation. Furthermore,
the exploratory CACE analysis provided no evidence that full implementation was associated with
greater effectiveness.
The underlying logic for the intervention is shown diagrammatically in Figure 2 and is described in more
detail in Chapter 3. The intention was to encourage practices to provide care in a more patient-centred
way. That would lead to a greater focus on patients’ quality of life, a stronger and more collaborative
partnership between patients and doctors, reductions in treatment burden and more informed and
‘activated’ patients156 through sharing information, setting goals and agreeing treatment plans. Although
the patient-reported outcomes suggest that the 3D was reasonably successful at promoting more patient-
centred care, this did not lead to improvements in quality of life or other measures of illness burden, nor
measures of treatment burden. This implies that the lack of effect on the primary outcome may have partly
been due to implementation failure but also to some extent to failure of the hypothesised causal link
between patient-centred care and health outcomes.
One interpretation could be that 15 months is too short a period to detect any effect. It takes a long time
for new ways of working to bed in and normalise, and it also takes time for patients to adapt to a new
approach. Only half of the participants had two 3D reviews over 15 months and one-quarter had just one
3D review, so it may be unrealistic to expect much change in quality of life resulting from this. Proponents
of the House of Care approach to chronic disease management52 have argued that it takes several
cycles of reviews before benefits are observed.53 Therefore, it may have been necessary to continue the
intervention and to monitor outcomes over several years to detect benefit. An alternative would be a more
intensive intervention. For example, the CARE Plus pilot trial found some improvements in quality of life
but 78% of participants had two or more lengthy review consultations over a 12-month period.38
Direct observation of some 3D and usual-care reviews in the process evaluation suggested some changes
in interactions between patients and doctors to make them more patient-centred, and patients appreciated
this (as shown from their questionnaire responses). However, we observed relatively few changes to
patient treatment, so changes to quality of life or other health outcomes would be likely only through
changes in self-management behaviours.
More fundamentally, it may be a false assumption that improved patient-centred care would lead to
changes in health. Responding to patient’s choices and priorities may not necessarily lead to better health
outcomes.157 This has been observed in previous studies151,158 and is considered in more detail below.
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Patient safety
During the trial, 5% of participants died, which is consistent with the fact that patients were selected
based on them having multiple health problems. We observed a somewhat higher number of deaths in
the intervention arm, which was not statistically significant. However, because of the importance of this
outcome, and because the study was not powered to detect differences in mortality, we investigated each
death by obtaining further details from participants’ GPs and the coroner where applicable. We found that
there were more expected as well as unexpected deaths in the intervention arm, that only 54% (14/26)
of patients dying unexpectedly in the intervention had had a 3D review before their death, and that in
terms of causes of death, the biggest excess was deaths due to cancer. In no case did a participant’s GP
think that there was any connection between the death and the patient’s participation in the trial, and
examination of treatment decisions made at 3D reviews did not suggest any likely relationship with the
patient’s subsequent death. Considering these factors, and after discussion with the independent study
data monitoring and ethics committee, we have concluded that the imbalance in deaths is likely to be
due to chance.
Carers
Some patients with multimorbidity receive substantial support from carers; therefore, we invited carers of
study participants to take part themselves, in order to explore whether the 3D intervention improved the
quality of life, experience and treatment burden of carers. This substudy was exploratory, because we did
not have a priori estimates of the number of patients with carers, or recruitment rates, and, assuming
that only a minority of multimorbidity patients had carers, the study would be underpowered to detect
differences between the intervention and usual care. We did not observe any evidence of an impact of the
intervention on quality of life or treatment burden. However, despite the small sample size, we detected
improvements in the experience of carers in the intervention arm. The carer experience scale includes
topics such as being supported with caring, feeling in control and fulfilment from caring.
How findings compare with previous studies
A Cochrane review of trials of interventions for improving outcomes in patients with multimorbidity in
primary care and community settings was published in 2012, after we started planning this trial. This
review was updated in September 2015 and included 18 relevant trials.36 The review authors distinguished
between 12 trials of organisational interventions and 6 of patient-orientated interventions, although they
recognise the limitations of this distinction and there is much overlap (e.g. a patient-orientated intervention
to promote self-management may rely on an organisational change in how care is delivered). The findings
of the Cochrane review are summarised below:
l little or no improvement in health outcomes (moderate certainty evidence)
l improvements in mental health outcomes in studies that targeted people with depression (high certainty)
l minimal or no improvements in patient-reported outcomes, such as self-efficacy (moderate certainty) –
of relevance to the 3D study, the Cochrane review included quality of life within this category and no
effect was observed, with high heterogeneity between studies
l little difference to health service use (low certainty)
l slight improvements in medication adherence (low certainty)
l slight improvements in patient health behaviours (moderate certainty)
l improvements in provider behaviours in prescribing and quality of care (moderate certainty) –
the PACIC score was included in this category
l few data about costs.
The authors of the Cochrane review suggest that organisational interventions with a specific focus or that
target a particular difficulty (e.g. functional difficulties) may be more effective than those with a broader
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focus such as case management. However, the evidence to support this conclusion is quite limited, and
such focused interventions are not likely to address the wide range of problems experienced by people
with multimorbidity. The main conclusion from the Cochrane review was that there were only a limited
number of studies, with considerable heterogeneity in their findings; therefore, further high-quality
pragmatic trials are needed.
In the 3D trial we collected data about all the outcomes considered in the Cochrane review, except patient
behaviours. Our findings provide further evidence to support the conclusions of the review, in that we found
no evidence of improvements in health-related quality of life, but we did provide evidence of improvements
in measures of patient-centred care such as PACIC. The Cochrane review did not synthesise evidence about
treatment burden, and at the time of the review there were no good measures of treatment burden. Our
findings also support the Cochrane review in finding little evidence of change in health service use. The one
area in which our findings differ from the review was that we found no evidence of improvements in mental
health. The studies in the Cochrane review that did identify such improvements were specifically designed to
focus on improving mental health outcomes. Through the 3D study we have helped to build the evidence
base about the cost-effectiveness of an intervention to improve the management of multimorbidity in
general practice.
The authors of the Cochrane review highlighted the problem of identifying suitable outcome measures
that are appropriate to use to assess the benefits of interventions for multimorbidity and that are sensitive
to change, and our experience supports this conclusion. In subsequent work a consortium of researchers
active in the field of multimorbidity has developed a core outcome set of important domains and suggested
suitable measures (Smith et al.159). Our trial includes all the recommended core outcomes except for
self-efficacy (although we did use the PACIC measure, which includes the related concept of patient
activation).
The last search for the Cochrane review was conducted in September 2015.36 We conducted searches in
MEDLINE and The Cochrane Library in August 2017 using a search strategy adapted from that in the
Cochrane review to identify trials published since September 2015, and we attempted to update the
meta-analyses in respect of quality of life and the PACIC measure in the light of these more recent trials
and the 3D trial. This updated review identified a further 11 studies38,114,160–168 and one previously identified
study with more recent published data.169
We have included the trial by Kennedy et al.92 in the above analyses because it was included in the
Cochrane review, although is not described by the authors as an intervention for multimorbidity, and
patients did not have to have multimorbidity to be included. Similarly, several of the other trials are
interventions for specific comorbid combinations of conditions and are not appropriate as a general
approach to managing multimorbidity.
With respect to quality of life, the Cochrane review identified 10 trials with relevant data.92,145,170–177 These
described studies that varied widely in terms of eligible population, setting and outcome measures. The
Cochrane review authors were able to enter six of these studies into a meta-analysis, but did not report a
pooled effect size due to substantial heterogeneity (I2 = 73%). In our updated review we identified seven
further trials reporting quality of life.38,114,161,163,164,166,168,169 We have combined the results from the trials
from the Cochrane review, the additional trials we identified and the results of the 3D trial and shown
these in a Forest plot (see Figure 10). The data from the individual studies previously included in the
Cochrane review are reported slightly differently in this figure from the data used in the original review
because this figure is based on the generic inverse variance method, which takes account of adjusted
rather than unadjusted analyses of effect where these are available.
In extracting data for this analysis we chose any measure described by the authors as a measure of quality
of life. For studies that used the Short Form Questionnaire – 36 items, we included data for the physical
health summary score. For studies that reported data at multiple time points, we used the time point closest
to 12 months’ follow-up.
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Figure 10 provides further evidence of little or no benefit in terms of quality of life, in that the pooled
effect estimate is very small and the CI overlaps zero. The updated analysis also shows high levels of
heterogeneity so the pooled effect should be treated with considerable caution. There is also the possibility
of publication bias, because a funnel plot shows asymmetry with the largest trials showing no evidence of
effect (Figure 11).
With regard to the PACIC measure, the Cochrane review identified two studies reporting this outcome.145,178
We identified one more recent study.162 The different studies reported data in different ways and were
unsuitable for meta-analysis. However, all of the studies that have reported this outcome, including the 3D
study, have confirmed that interventions to improve management of multimorbidity have a positive effect
on patient-centred chronic care management as measured by PACIC.
A further Cochrane review has explored patient-centredness by synthesising findings from 29 trials of
interventions to train providers to promote a patient-centred approach to consultations (not specifically in
patients with multimorbidity).179 This showed that such interventions were generally effective in ensuring
more patient-centred consultations; however, the impact on patient health status was limited and findings
were mixed. The 3D study is consistent with these findings.
Implications for health care
How the 3D approach reflects and operationalises current guidance
The 3D intervention was designed to implement a range of strategies that are widely advocated to
improve the management of multimorbidity and, indeed, long-term condition management in general.
These strategies include case management, multidisciplinary care, individualisation of care, improved
continuity of care, longer consultations, attention to mental health, pharmacist review of polypharmacy,
shared decision-making, goal-setting and care planning.5,47,52,134,180–182
Since the 3D intervention was designed, several influential guidance documents have formalised
similar recommendations.39,40,46,132,133
In 2016, NICE published guidance on the clinical assessment and management of multimorbidity following
an extensive process of literature review and discussion within a guideline development group, followed
by a process of consultation.39 The main recommendations of relevance to the 3D intervention are
summarised in Box 2. One key finding from the NICE review was the paucity of evidence to inform many
of their recommendations, and it was not possible to formulate clear guidance in relation to several
questions of interest. NICE have published a series of quality standards,183 and the 3D approach meets all
of these standards. As far as we are aware, there is no other service model that has been developed that
would meet these standards, some of which assume components that would currently be difficult to
achieve without the kind of tools developed for the 3D approach (e.g. the identification of patients with
multimorbidity, an individualised management plan for multimorbidity, which includes a record of values,
priorities and goals).
In 2012, a group of 19 experts in the field of multimorbidity took part in a consensus-building workshop
to derive the Ariadne framework of key principles for the management of multimorbidity in primary
care.132 These principles have at their core the sharing of realistic treatment goals by doctors and patients
(Box 3).
The Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS)
was funded by the European Commission to develop a framework for care of multimorbidity patients that
could be applied across Europe. Through a series of consensus-building exercises with experts from 26
European Union member states, the project developed a framework with 16 principles (Box 4).133
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FIGURE 10 Updated meta-analysis for quality of life outcome including 3D study.
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BOX 2 Consensus guidance on managing multimorbidity in primary care: NICE
NICE guidance, recommendations 6 and 7
6. When offering an approach to care that takes account of multimorbidity, focus on:
l how the person’s health conditions and their treatments interact and how this affects quality of life
l the person’s individual needs, preferences for treatments, health priorities, lifestyle and goals
l the benefits and risks of following recommendations from guidance on single health conditions
l improving quality of life by reducing treatment burden, adverse events, and unplanned care
l improving co-ordination of care across services.
7. Follow these steps when delivering an approach to care that takes account of multimorbidity:
l Discuss the purpose of an approach to care that takes account of multimorbidity.
l Establish disease and treatment burden.
l Establish patient goals, values and priorities.
l Review medicines and other treatments taking into account evidence of likely benefits and harms for the
individual patient and outcomes important to the person.
l Agree an individualised management plan with the person, including:
¢ goals and plans for future care (including advance care planning)
¢ who is responsible for co-ordination of care
¢ how the individualised management plan and the responsibility for co-ordination of care is communicated
to all professionals and services involved
¢ timing of follow-up and how to access urgent care.
© NICE 2016 Multimorbidity: clinical assessment and management. URL: www.nice.org.uk/guidance/ng56/resources.
All rights reserved. Subject to Notice of rights. The NICE guidance is prepared for the NHS in England. All NICE
guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of
its content in this product/publication.
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FIGURE 11 Updated meta-analysis including 3D study: funnel plot. SMD, standardised mean difference.
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BOX 3 Consensus guidance on managing multimorbidity in primary care: Ariadne principles
Ariadne framework of key principles
These principles have at their core the sharing of realistic treatment goals by doctors and patients. This should
be achieved through:
l detailed assessment of the patient’s conditions and treatments in the light of their individual circumstances
l taking account of the patient’s priorities and preferences
l individualising management to address these goals and priorities
l paying attention to the patient’s quality of life and functioning
l medication review to address polypharmacy and drug interactions
l assessing mental health alongside physical health
l co-ordination of care to reduce treatment burden.
This box is adapted from Muth et al.;132 licensee BioMed Central Ltd. 2014. This is an Open Access article distributed
under the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/.
BOX 4 Consensus guidance on managing multimorbidity in primary care: JA-CHRODIS framework
Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life
Cycle (JA-CHRODIS)
DELIVERY OF THE CARE MODEL SYSTEM: Regular comprehensive assessment of patients; Multidisciplinary,
coordinated team; Professional appointed as coordinator of the individualized care plan and contact person
for patient and family (“case manager”); Individualized Care Plans.
DECISION SUPPORT: Implementation of evidence based practice; Training members of the multidisciplinary
team; Developing a consultation system to consult professional experts.
SELF MANAGEMENT SUPPORT: Training of care providers to tailor self-management support based on patient
preferences and competencies: Providing options for patients and families to improve their self-management;
Shared decision making (care provider and patients).
INFORMATION SYSTEMS AND TECHNOLOGY: Electronic patient records and computerized clinical charts;
Exchange of patient information (with permission of patient) between care providers and sectors by compatible
clinical information systems; Uniform coding of patients’ health problems where possible; Patient-operated
technology allowing patients to send information to their care providers.
SOCIAL AND COMMUNITY RESOURCES: Supporting access to community- and social-resources; Involvement of
social network (informal), including friends, patient associations, family, neighbours.
As shown from these three sets of guidance, there is considerable consensus about the principles and specific
strategies that are recommended to improve management of multimorbidity. Although these guidance documents
were published after the 3D intervention was designed, it is evident that the 3D approach is entirely consistent
with them and has sought to operationalise most of these recommendations. Despite the broad consensus about
how to improve care, our findings suggest that implementation of these recommendations is not likely to lead to
improved health outcomes, at least at the levels of implementation achieved in this pragmatic trial.
Copyright, reproduced with permission from Society of Academic Primary Care184 and Elsevier [Palmer K, Marengoni A,
Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F, et al. Multimorbidity care model: recommendations from
the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle
(JA-CHRODIS). Health Policy 2018;122:4–11].133 © 2017 Elsevier B.V. All rights reserved.
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The need for and difficulty of improvements in care
Our findings at baseline confirm that patients with multimorbidity are common, have serious health
problems and are frequent users of health care. Only 34% (522/1524) report that their health is good, very
good or excellent. They also report substantial deficiencies in how care is delivered, with 34% (510/1479)
of patients at baseline saying that their main priorities are rarely or never met, 24% (339/1479) saying
that their care is rarely or not at all joined up and only 51% (759/1494) being very satisfied with their care
overall. There is, therefore, clear evidence of room for improvement in care. However, although these
patients have major health-care needs, the evidence from this trial, along with that from earlier studies,
suggests that improving care for them is difficult and improving their health outcomes is extremely
difficult. Unfortunately, this is consistent with other systematic reviews of research on related interventions
to address the most complex challenges facing the health-care system, such as case management,36 care
planning,185 interventions to address medication adherence,186 lay support programmes,187 telehealth
interventions for long-term conditions188,189 and other interventions for the self-management of chronic
disease.92 None of the reviews has demonstrated consistent benefits from interventions, suggesting that
these are ‘wicked problems’190 to which there are no easy solutions.
Is an improvement in patient-centred care a sufficient justification for implementing 3D?
Taken together with most of the previous research, it seems clear that improved patient-centred care
for patients with multimorbidity is unlikely to lead to improved quality of life within a short timescale.
However, it is likely to improve aspects of care that are important to patients.191 The PPI group were strongly
of the view that the importance of improvements in patient-centred care should not be underestimated,
irrespective of health-related outcomes. There is some evidence from other research that patients are willing
to trade off improvements in quality of life to make gains in attributes related to their ability to self-care,
such as increased self-efficacy.192 There is an international consensus that health-care systems should
promote a patient-centred approach on political, ethical and instrumental grounds.46,132,193–195 This is based
on the premise that people requiring health care should be treated with respect and dignity, and that care
should take into account their needs, wants and preferences.193 McGlynn et al.196 have argued in a recent
editorial that ‘the quality measurement enterprise in US health care is troubled’ and should be redesigned
to better reflect individual patients preferences and goals for treatment, given the challenges of managing
patients with multiple coexisting problems. Similarly, in England, Nolte has argued that ‘measurement
and payment remain linked to biomedical outcomes rather than incentivising working with people and
outcomes that matter to users of healthcare, taking full account of their wider social context’.193
Given that our economic analysis demonstrated that the 3D approach was not significantly more costly
than usual care, and is similarly cost-effective to usual care, it is arguable that implementing this or a
similar patient-centred approach has a strong justification.
Feasibility of the 3D approach
Through the 3D trial we have demonstrated that it is possible to implement recommended approaches to
the management of multimorbidity in UK general practice and that patients can experience more patient-
centred care as a result. We have developed a training programme and a sophisticated interactive template
to guide review consultations along with other essential IT infrastructure including a search strategy to
identify patients with multimorbidity, a system for flagging these patients at reception, and searches and
report templates to provide feedback to practices about their progress. All of these resources will be made
freely available. The template and other aspects of IT infrastructure will need ongoing support from an
established software provider, as they will need updating in the light of policy changes. In addition, the
software is currently designed to work only in the EMIS system. However, having demonstrated the
feasibility of providing care in this way it would be possible for other suppliers of GP computer systems to
build similar templates using the same principles.
It is important to note that, although there was little difference in the overall cost of the 3D intervention
compared with usual care, there could be different effects on different parts of the health and social care
system. The intervention appeared to be associated with higher costs for primary care consultations, similar
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costs of medication and for secondary care use, and lower costs for social care. There was considerable
uncertainty around all of these estimates and none of the differences was statistically significant. However,
if 3D were to be implemented on a wide scale, these effects would need to be monitored.
How might the effectiveness of the 3D approach be improved?
Comparing the findings from the 3D study with previous research, it is possible to consider how the 3D
approach might be improved to make it more effective:
l Continue longer – as previously discussed, benefits from the 3D intervention may have become more
evident if it was continued for a longer period.
l Reduce duplication of effort – if practices conducted 3D reviews instead of, rather than as well as,
standard disease reviews this would reduce the cost of the intervention and reduce the burden for
patients of attending multiple appointments.
l More intensive – the ‘dose’ of intervention that participants received in this trial was limited, with most
having only one full 3D review. It is possible that, to be effective, patients needed to be given more
intensive support and follow-up to address problems identified in their 3D review. This might be achieved
through case management from a nurse, through non-clinical support,197 or through web-based or mobile
applications to reinforce self-management and behaviour change.
l Further training of practice staff – the 3D intervention would be strengthened through greater
consistency and more generalist training for practice nurses so that they were confident to manage all
common long-term conditions. The 3D approach provides a structure to facilitate a patient-centred care
approach, but to deliver this more effectively clinicians may benefit from training to help them be more
familiar with concepts, such as goal-setting.
l More attention to mental health – although a focus on depression was one of the key aims of the 3D
intervention (forming the second of the three ‘D’s in the mnemonic), our evidence was that this was not
achieved as well as intended. Nurses felt uncomfortable about depression screening and there is no
evidence that depression outcomes improved. The Cochrane review suggests that it is possible to
improve mental health outcomes in multimorbidity interventions that focus on mental health problems.36
To improve the 3D approach, it is probably necessary to invest in further training of practice nurses in
relation to mental health, and to ensure more intensive treatment for depression through the availability
of psychological therapies as well as drug treatment when required.
l Better patient selection – some of the clinicians interviewed for the process evaluation felt that the
intervention was not necessarily delivered to the patients who needed it most. Although all participants
had three or more long-term conditions, some of these did not require complex management. The 3D
approach may be more effective if it were targeted at people with greater needs. These might be
identified through more sophisticated selection algorithms (e.g. people with ≥ 3 conditions and
prescribed ≥ 10 regular medications, or using an index such as the electronic frailty index)198 or by
allowing GPs to use their clinical judgement to offer it to the patients who they felt would benefit from
it, which was the approach used in the CARE Plus trial.38
l Focus on one aspect of care – the 3D approach was deliberately designed to be comprehensive and
multifaceted in order to address all of a patient’s problems at once. However, the Cochrane review
suggested that interventions that were more focused, for example on functional difficulties or mental
health problems, may be more effective. It is possible that it is too overwhelming for patients and/or
clinicians to try to address too many problems at once, and a simplified approach with a more limited
remit (e.g. aiming just to identify goals and create shared care plans without also trying to undertake
long-term condition reviews) might be more effective.
l Stronger links with social care – many of the problems raised by patients with multimorbidity are complex
and have strong social and psychological components. For these patients, the medical focus of the 3D
review may help to identify but not necessarily to meet their needs. An intervention that placed more
emphasis on meeting social care needs, for example through social prescribing,199 might be more effective.
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Implications for research
This project illustrates an important and common conundrum for research and policy. It may not be
possible to know whether or not this type of intervention is effective until it is normalised and has been
running for several years. This makes trials suboptimal for evaluating final impact because most have a
follow-up of about 1 year. However, policy-makers are criticised if they encourage the widespread
implementation of new systems before evidence of benefit is available.200 In addition, attempting to
evaluate this type of intervention in a rigorous way over a long period of time would be very costly and
face major logistical challenges, because of issues around consent, selection bias, the collection of data
interfering with normal care and changes in the comparator over time.
If implementation of the 3D intervention can be justified on the basis of improvements in patient-centred
care with similar cost-effectiveness to usual care, we would recommend that a longer evaluation should be
undertaken to assess health benefits and costs, based on routine data as far as possible. The 3D approach
should be offered to all patients within some practices as a whole-system change, and evaluated using a
cluster randomised trial (randomising either practices or areas) with long-term follow-up. Alternatively,
it could be evaluated using a controlled before-and-after design or a stepped wedge design, but this
would still require a recognition that these designs have their own limitations and do not resolve all of
the above problems.201
The difficulty of demonstrating improvements in quality of life as a result of interventions in trials is not
confined to 3D. Measures of global health status are useful for describing patient populations in surveys
and other cross-sectional studies and should in theory be the most valid indicators of effective health
care. However, there are very few examples of experimental studies in which improved health care has
been associated with improvements in quality of life202 or self-rated health and numerous examples of a
lack of benefit.203 This could suggest either that quality of life is not directly related to health care, or
measurement failure.204 In order to detect benefit from organisational interventions, we need a stronger
focus on outcomes that matter to patients in primary care, beyond changes in patient experience, and
measures of these outcomes that are valid, reliable and sensitive to change.205,206 In parallel with this
project we have developed a suitable measure, the Primary Care Outcomes Tool (PCOQ), which could be
used in future studies.207 As part of the 3D study we have also developed a new measure of treatment
burden,76 and this new measure is now being used in a number of other studies internationally. Further
experience with this new measure will help us to set our findings from the 3D study in context with the
effect of other interventions.
Research recommendations
l Longer term follow-up (e.g. 5 years) is needed to assess the impact of new systems of care for
multimorbidity on patient health and quality-of-life outcomes.
l Interventions to more effectively simplify drug regimes in patients with polypharmacy need to be
developed and evaluated.
l In order to assess the relationship between improved health care and improved quality of life, an
evidence synthesis is needed using metaregression to identify features of organisational interventions
associated with impact.
l There is a need for new measures of benefit from improved management in primary care that reflect
outcomes that are important to patients and are sensitive to change.
l Further research is needed to understand the extent to which patients value concepts, such as patient-
centred care compared with quality of life, and whether or not they are prepared to make trade-offs
between them.
l Further research is needed to validate the MTBQ in different populations and to test the effectiveness
of interventions to reduce treatment burden.
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Conclusion
In the 3D trial, we evaluated a new approach to care based on a patient-centred care model, incorporating
most of the strategies currently recommended by international consensus guidelines to improve management
of patients with multimorbidity. Although the intervention was associated with improvements in measures of
patient-centred care, there was no evidence that it was associated with improvements in quality of life or
measures of illness burden or treatment burden. However, the intervention was not delivered to its full
extent. Furthermore, the intervention was delivered at little or no additional cost, was similarly cost-effective
to usual care and improved the experience of patients’ carers.
In conjunction with other research this raises questions about whether providing more patient-centred care
leads to better health outcomes and, if not, whether interventions that improve patient-centredness are
justifiable in their own right if they can be delivered at little extra cost.
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Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to anonymised
data may be granted following review via the University of Bristol Research Data Storage Facility.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 3D Trial Steering Committee,
Data Monitoring Committee and advisory group
membership lists
Trial Steering Committee
Professor Carl Heneghan (Chairperson), Director of Centre of Evidence Based Medicine, University of Oxford.
Dr Ann Adams (Academic Nurse), Research Fellow, University of Warwick.
Professor Jose Valderas (Academic GP), Professor of Health Services & Policy, University of Exeter.
Dr Obioha Ukoumunne (Statistician), Associate Professor in Medical Statistics, University of Exeter.
Mr Edmund Brookes (PPI member).
Ms Mandie Lewis (PPI member).
Data Monitoring Committee
Professor Ian Russell (Chairperson), Professor Emeritus, Swansea University.
Professor Michael Moore (Academic GP), Professor of Primary Medical Care, University of Southampton.
Mr Chris Foy (Medical Statistician), NHS Gloucester RDS.
Professor Richard D Neal (Trial Methodologist) Professor of Primary Care, University of Leeds.
Advisory group
Ms Linda Prosser (Chairperson), Director of Commissioning, NHS England, South area.
Professor James Goodwin, Head of Research at Age UK.
Ms Claire Henry, Head of Programme for Long Term Conditions for NHS Improving Quality.
Dr Gill Jenkins, Clinical Lead for Long Term Conditions, Bristol CCG.
Ms Alisa Cameron, Senior Lecturer in School for Policy Studies, University of Bristol.
Edmund Brooks (PPI member).
Mandie Lewis (PPI member).
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Appendix 2 Example of sheet used by research
team to monitor completion of 3D components
(final time point)
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3D component
Practice ID
40 61 20 42 60 65 45 46 27 26 25 48 66 69 30 70 All
3D agenda printed, % 97 92 100 89 97 81 95 98 98 100 100 70 97 58 100 92 96
3D had one GP review, % 91 86 92 102 87 81 93 102 105 92 98 43 78 38 87 77 85
3D had one nurse and GP review, % 86 86 92 102 85 78 93 102 105 92 98 43 78 38 87 77 84
3D had one nurse review, % 88 88 92 102 87 84 93 105 107 94 100 48 78 58 96 79 88
3D had two GP reviews, % 63 50 69 77 44 13 76 93 90 82 75 7 60 0 74 53 59
3D had two nurse and GP reviews, % 47 45 67 50 44 9 76 93 86 82 75 0 50 0 74 53 54
3D had two nurse reviews, % 49 62 69 55 46 31 89 93 90 82 77 2 56 0 80 53 59
3D health plan printed, % 77 81 97 91 62 31 23 100 80 98 85 39 85 80 98 67 83
Adherence medications, % 95 61 94 96 65 92 63 100 39 67 62 44 54 50 93 64 71
EQ-5D pain, % 47 97 100 71 100 96 65 52 100 98 100 5 100 100 100 95 83
GP first goal noted, % 100 97 100 100 76 96 100 100 102 98 102 44 100 95 93 97 94
Most important problem on nurse view, % 100 97 100 100 100 96 100 100 100 100 100 100 100 100 100 97 99
Pharmacist comment, % 84 100 95 82 105 78 83 100 107 106 100 38 78 43 100 102 88
Pharmacist comments noted?, % 56 53 47 77 68 69 92 56 80 95 64 69
PHQ-9 done, % 97 97 100 91 91 96 98 100 98 98 100 100 97 94 100 103 98
What GP can do about main problem noted, % 92 89 100 98 71 73 98 76 100 89 102 33 87 80 90 72 84
What patient can do about main problem noted, % 77 92 86 96 76 73 100 91 100 93 100 39 97 85 90 78 86
3D participants pharmacist comment, % 84 100 95 82 105 78 83 100 107 106 100 38 43 100 102 88
End of study continuity score 50 61 63 41 48 47 54 48 39 37 49 Not possible 38 Not possible 48 35 47
Baseline continuity score 45 39 44 76 64 18 30 32 44 60 30 30 6 16 37 38
Difference 5 22 19 41 –28 –17 36 18 7 –7 –11 8 32 –2 9
Green, good performance; amber, suboptimal performance; red , low performance.
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Appendix 3 Example of monthly feedback report
sent to 3D intervention practices
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Appendix 4 Learning and amendment from
external pilot phase
T able 37 shows the procedures first trialled in the pilot study, the problems revealed by the processevaluation from feedback interviews with GPs and nurses, focus groups of patients, observation of
training and review appointments and discussion with the PPI group and, finally, the changes that these
suggestions led to, which then established the processes to be followed in the main 3D study.
TABLE 37 Changes to main study as a result of pilot phase
Pilot procedure Difficulties raised Changes in main study
Patient consent was specifically for
questionnaires and notes review.
All invited patients were to be
offered the intervention
Patients unclear to what they were
consenting. Non-consented patients
called for review and refusing the 3D
reviews
Patient information improved and patients
now consenting to all trial procedures, not
just questionnaire and notes review
Practices should deliver the
intervention to all invited
participants (approximately
140 patients). Requiring whole-
practice change, training of most
practice staff
Practice concerns of workloads.
Difficulty of arranging training for
majority of practice staff. Disruption
of existing timetabling of clinics and
appointments
Practices delivering only to consented
patients (approx. 40–50 patients – seen as
more achievable). Fewer staff required for
training. Less disruption
Mixed practice training sessions
offered off-site to allow sharing of
experiences
Difficult to arrange training dates
even between two fairly local
practices
Practice staff wished to see a live
demonstration of the template,
which was impossible away from the
practice
In-house training per practice. Could give a
live demonstration of the template and
discuss procedures specific to practice
organisation and requirements
Eligible patients based on all
chronic conditions included in the
QOF
GPs expressed concern that not all
patients warranted extra time as they
did not all have significant morbidity.
Some patients concurred
Review of eligibility criteria: amalgamated
chronic kidney disease with the
cardiovascular group as this requires similar
management. Removed osteoporosis
Replacement of single condition
clinics by 3D review clinics
Some practices did not always cancel
existing clinic reviews, leading to
duplication. Some patients continued
to book appointments (e.g. for
regular blood tests that they
expected)
Created a checklist of changes that are
required by the practice. Discussed at
a post-training meeting (with lead
administrator and/or practice manager)
Obtained extra funding to reimburse time
for rearranging appointment recall systems
Longer appointments offered with
usual GP between reviews
Practices concerned about
committing to longer appointments
between reviews. 3D card creating
an expectation among patients who
may not need longer appointments
Wording changed on 3D card. Practices
commit only to allow possibility of longer
appointments when appropriate
Specific training of receptionists to suggest
scripts for arranging longer appointments
with usual GP
Expect nurse to do first 3D
review appointment followed
approximately 1 week later
by a GP 3D review
Different levels of experience and
training among nurses. Some chronic
conditions nurses (e.g. diabetes
mellitus nurses) already do
medication reviews and care
planning. Worried about de-skilling
Allow a certain level of flexibility depending
on local skills and experience. Suggest some
cases could use a HCA for tests and blood
tests, then some nurses can do some of the
GP aspects of the template. Patients with
diabetes mellitus should see a diabetes-trained
nurse for their 3D reviews
continued
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TABLE 37 Changes to main study as a result of pilot phase (continued )
Pilot procedure Difficulties raised Changes in main study
Use of template to guide only
relevant tests and questions
Some GPs did not use the template.
Requires time to get used to it to
using effectively. Nurses unhappy
about asking some of the questions
on the template
Created an aide memoire to remind
clinicians of the key elements to include in
each of the reviews. Revised training to
include a live demonstration of the
template. Some questions streamlined or
moved from nurse template into GP
template
Patients should be given a
print-out of their agenda and
personalised health plan
Patients not sure how to answer
questions about what is most
important to them. Nurses and GPs
unsure what to put in care planning
sections
Technical problems with printing
agenda and health plan
Practices provided with a template
appointment letter asking patients to
think about what affects their health and
well-being, so that they are prepared for the
review. Care planning reviewed in training
Technical issues resolved
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Appendix 5 The 3D card for participants in
intervention arm
Front view: 
 
 
Back view: 
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Appendix 6 Example screenshots of 3D template
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission.
Introduction screen
Patient priorities (agenda) 
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Depression screening and dementia screening 
General health 
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
Disease specific questions. Different sections of questions appear depending on the patients 
combination of conditions and only appear when relevant
This patient has CKD, diabetes, COPD and asthma. 
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Patient advice 
This varies according to the situation. This patient needed flu and pneumococcal
immunisations and advice about weight loss. 
This completes the nurse consultation
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Pharmacist recommendations 
GP medication warnings and references to NICE guidelines
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Medication adherence questions
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Health plan
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Blood tests  - the tests only appear when they are appropriate, depending on the patient’s 
conditions
Exception reporting
EMIS Web © EMIS Health. All rights reserved. Screenshots used with permission
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Appendix 7 Example 3D patient agenda
document, given to patient after nurse consultation
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Appendix 8 Example 3D health plan, given to
patient after GP consultation
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Appendix 9 Patient baseline questionnaire
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The EQ-5D-5L instrument was used with permission.
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Bayliss Measure of Illness Burden in Multimorbidity questionnaire measures reproduced with permission of
Elizabeth Bayliss.74
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The HADS instrument was used with permission.
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The CARE measure was developed by Professor Stewart Mercer and is freely available for use.72
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Patient Assessment of Chronic Illness Care (PACIC) measure reproduced with permission of the MacColl
Centre for Health Innovation.73
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Questions 4.4.1 and 4.4.2 were taken from the LTC6 measure, which is freely available to use;
see http://personcentredcare.health.org.uk/sites/default/files/resources/ltc6_questionnaire.pdf.
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Use of the ©MMAS is protected by US Copyright laws. Permission for use is required. A licence agreement
is available from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue, WA 98007, USA or
from dmorisky@gmail.com.
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The Multimorbidity Treatment Burden Questionnaire for carers was developed by members of the 3D
study team.76
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Appendix 10 Carer baseline survey
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The EQ-5D-5L instrument was used with permission.
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Carer Experience Scale reproduced with permission of Hareth Al-Janabi.87,88
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The Multimorbidity Treatment Burden Questionnaire for carers was developed by members of the 3D study
team. It is adapted from the Multimorbidity Treatment Burden Questionnaire in Duncan P, Murphy M,
Man MS, Chaplin K, Gaunt D, Salisbury C. Development and validation of the Multimorbidity Treatment
Burden Questionnaire (MTBQ). BMJ Open 2018;8:e019413. This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Appendix 11 Randomisation procedure and
minimisation algorithm
To minimise post-randomisation selection bias, practices will not be randomised until after patients havebeen identified and after the initial patient invitations have been mailed.
Practices will be randomised using an algorithm written in advance by the BRTC (UK Clinical Research
Collaboration registration ID: 2) on a 1 : 1 ratio to receive either the intervention or continue care as usual
(control group). Randomisation will be stratified by recruiting centre (Bristol, Manchester and Glasgow)
and minimised by practice deprivation level and practice size. Practices within each area will be randomised
using a block size of two (one randomised to the 3D intervention and the other to usual care) to ensure
balance across the treatment arms given the relatively small number of practices. Within each centre, each
block of two practices will be randomised at the same time in the following way.
Within each centre, the initial block of two will be randomised using simple randomisation, such that one
is allocated to the intervention and the other to usual care. For each subsequent block of practices, an
algorithm (written within Stata specifically for this study) will determine the allocation of the two practices
that creates the best balance in terms of size and deprivation and then weights the randomisation in
favour of this allocation (rather than being deterministic); the weights are determined by the degree of
imbalance in terms of size and deprivation (Table 38 and example below).
Example use of Table 38: suppose the first practice in the next block of two is allocated to usual care and the
second to 3D (denoted allocation 01 in Table 38) and that this would lead to an absolute difference in median
practice size between the two treatment groups of 327, whereas if the first practice is allocated to 3D and the
second to usual care (allocation 10), the absolute difference in median practice size is 116. Then the difference
in imbalance (allocation 01 minus allocation 10) in terms of practice size is + 211, a greater imbalance when
the allocation is 01. Suppose also that allocation 01 would lead to an absolute difference in median deprivation
score between the two treatment groups of 3, whereas allocation 10 would lead to an imbalance of 9. Then
the difference in potential imbalance (allocation 01 minus allocation 10) would be –6, a greater imbalance
than when the allocation is 10. From Table 38, considering potential imbalance in both size and deprivation,
this would result in a weighting of 0.65 in favour of allocation 01.
TABLE 38 Randomisation weightings (in favour of allocation 01) for each block of two practices
Practice size Deprivation score
Difference in imbalance (allocation 01 minus allocation 10)a
Difference in imbalance
(allocation 01 minus allocation 10)a ≤ –12 –11 to –8 –7 to –4 –3 to 3 4 to 7 8 to 11 ≥ 12
≤ –900 0.80 0.80 0.80 0.8 0.75 0.65 0.50
–899 to –600 0.80 0.80 0.80 0.75 0.65 0.50 0.35
–599 to –300 0.80 0.80 0.75 0.65 0.50 0.35 0.25
–299 to 299 0.80 0.75 0.65 0.50 0.35 0.25 0.20
300 to 599 0.75 0.65 0.50 0.35 0.25 0.20 0.20
600 to 899 0.65 0.50 0.35 0.25 0.20 0.20 0.20
≥ 900 0.50 0.35 0.25 0.20 0.20 0.20 0.20
a Allocation 01: first practice in the block of two is allocated to usual care and second practice is allocated to 3D;
allocation 10: first practice allocated to 3D and second practice to usual care.
Note
Light green shading, randomisation of two practices weighted in favour of allocation 01; dark green shading,
randomisation of two practices weighted against allocation 01 (hence, in favour of allocation 10).
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Appendix 12 Final participant follow-up
questionnaire
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The EQ-5D-5L instrument was used with permission.
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Bayliss Measure of Illness Burden in Multimorbidity questionnaire measures reproduced with permission of
Elizabeth Bayliss.74
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The HADS instrument was used with permission.
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The CARE measure was developed by Professor Stewart Mercer and is freely available for use.72
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Patient Assessment of Chronic Illness Care (PACIC) measure reproduced with permission of the MacColl
Centre for Health Innovation.73
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Questions 4.4.1 and 4.4.2 were taken from the LTC6 measure, which is freely available to use;
see http://personcentredcare.health.org.uk/sites/default/files/resources/ltc6_questionnaire.pdf.
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Use of the ©MMAS is protected by US Copyright laws. Permission for use is required. A licence agreement
is available from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue, WA 98007, USA or
from dmorisky@gmail.com.
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The Multimorbidity Treatment Burden Questionnaire for carers was developed by members of the 3D
study team.76
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Appendix 13 Final carer follow-up questionnaire
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The EQ-5D-5L instrument was used with permission.
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Carer Experience Scale reproduced with permission of Hareth Al-Janabi.87,88
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The Multimorbidity Treatment Burden Questionnaire for carers was developed by members of the 3D study
team. It is adapted from the Multimorbidity Treatment Burden Questionnaire in Duncan P, Murphy M,
Man MS, Chaplin K, Gaunt D, Salisbury C. Development and validation of the Multimorbidity Treatment
Burden Questionnaire (MTBQ). BMJ Open 2018;8:e019413. This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Appendix 14 Research Ethics Committee
approved amendments to the study protocol
Research Ethics Committee
Amendment/Protocol Number Trial design Description of change
Protocol v2.0 Exclusion criteria Include patients lacking capacity to consent in Scotland only as
ethics approval not given
Protocol v3.0 Pilot practice
recruitment
Intended to recruit two pilot practices each in Bristol and
Glasgow, but recruited two in Bristol and one in Manchester,
owing to delays in developing IT template for Scottish systems
Amendment 5, Protocol v4.0 Inclusion criteria Chronic kidney disease included within cardiovascular disease
cluster condition and osteoporosis removed from inclusion list
Amendment 6.0, Protocol v5.0 Patient consent Given the cluster design of the trial, pilot practices intended
to deliver the intervention to all invited patients and consent
was for questionnaire data collection only. Pilot practices found
this unfeasible, therefore, consent in the main study included
consent for the intervention if practice randomised to that arm
Amendment 6.0, Protocol v5.0 Decline form Removal of decline form from invitation pack and instructions
changed for active decline
Amendment 2, Protocol v3.0
Amendment 4, Protocol v4.0
Secondary outcome
measures
Intended to use Tran208 measure of treatment burden but used
Boyd Health-Care Task Difficulty209 in pilot study
Boyd Health-Care Task Difficulty removed from main trial and
replaced with in-house designed Brief/MTBQ
Some questions from LTC6-QIPP removed (although two
questions retained) owing to repetition
Amendment 10, Protocol v6.0 Follow-up time
points
Originally 6 and 12 months post recruitment in pilot practices,
but changed to 9 and 15 months in main study
Amendment 2, 7, 11,
Protocol v3.0, 6.1
Process evaluation Increase number and clarify optional observation/audio or video
recording of review consultations with patients and health-care
professionals in intervention and usual-care practices to
enhance assessment of variation in reviews
Amendment 12, Protocol v7.1 Pharmacy review
substudy
Inclusion of qualitative substudy exploring GPs and
pharmacists’ views of the 3D pharmacy reviews
LTC6-QIPP, Six-item Long-Term Conditions questionnaire-Quality, Innovation, Productivity and Prevention.
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Appendix 15 Changes to trial registry:
ISRCTN06180958
Date Stage of trial Changes
28 April 2015 Following pilot study Adults lacking capacity to consent in Scotland were added as an
exclusion criterion, owing to ethics committee advice
Inclusion criterion were modified following the pilot study to remove
osteoporosis and to combine chronic kidney disease within the
cardiovascular disease group
Change in measure of treatment burden from Tran208 to MTBQ
Omission of LTC6 questions (administrative error in updating registry)
19 January 2016 During trial recruitment
and follow-up, before analysis
Follow-up time points changed from 6 and 12 months to 9 and
15 months, in light of experience of lag time before practices started
delivering intervention
EQ-5D at 9 months specified as a secondary outcome
2 February 2017 On completing SAP,
before any analysis
More detailed specification of measures used for each outcome
LTC6 questions reinstated (omitted from registry during changes of
28 April 2015 by mistake)
Continuity of care (specified in protocol but not previously included
in registry owing to administrative oversight)
Number of high-risk prescribing indicators added (always intended
and specified in protocol but reliable measures only became possible
during the trial)
Cost-effectiveness: included in the protocol and analysis plan, but
now specified as an outcome rather than as an approach to analysis
in the light of recent experience of publishing other trials
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Appendix 16 Characteristics of excluded patients
compared with invited non-participants and
consented participants
TABLE 39 Characteristics of excluded patients compared with invited non-participants and consented participants
Characteristic
Excluded
(N= 575)a
Non-participants
(N= 3132)b
Participants
(N= 1546)
Dementia, n (%) 225 (39) 340 (11) 60 (4)
Depression, n (%) 246 (43) 1250 (40) 559 (36)
Severe mental health group, n (%) 47 (8) 200 (6) 66 (4)
Learning difficulties, n (%) 48 (8) 84 (3) 14 (1)
Epilepsy, n (%) 46 (8) 185 (6) 76 (5)
Diabetes mellitus, n (%) 198 (34) 1613 (52) 812 (53)
Cardiovascular Disease Group, n (%)c 521 (91) 2875 (92) 1445 (93)
Stroke or TIA, n (%) 215 (37) 1050 (34) 527 (34)
Rheumatoid arthritis, n (%) 37 (6) 196 (6) 103 (7)
Respiratory (asthma or COPD), n (%) 191 (33) 1456 (46) 770 (50)
Atrial fibrillation, n (%) 164 (29) 928 (30) 530 (34)
Male, n (%) 242 (42) 1452 (46) 763 (49)
Female, n (%) 333 (58) 1680 (54) 783 (51)
Age (years), mean (SD), range 77.14 (14.2), 18–106 71.35 (13.4), 20–101 70.79 (11.5), 25–96
Morbidity count, mean (SD), range 3.39 (0.64), 3–6 3.26 (0.53), 3–7 3.23 (0.48), 3–6
Three comorbidities, n (%) 395 (69) 2444 (78) 1234 (80)
Four comorbidities, n (%) 140 (24) 577 (18) 277 (18)
Five comorbidities, n (%) 35 (6) 99 (3) 31 (2)
Six comorbidities, n (%) 5 (1) 11 (0.4) 4 (0.3)
Seven comorbidities, n (%) 0 (0) 1 (0.03) 0 (0)
TIA, transient ischaemic attack.
a Eligible on record search but excluded by GP before invitation.
b Non-participants combines patients who declined and those who did not respond.
c Includes hypertension, peripheral artery disease, chronic kidney disease, coronary heart disease and/or heart failure.
Note
Because an inclusion criterion was having three or more conditions, the percentages in each column exceed 100%.
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Appendix 17 Baseline characteristics of those
participants with missing or completed primary
outcome data
TABLE 40 Baseline characteristics of those participants with missing or completed primary outcome data
Baseline characteristics
Trial arm
Usual care (n= 749) Intervention (n= 797)
Non-missing
primary outcomea
(n= 670)
Missing primary
outcome (n= 79)
Non-missing
primary outcomea
(n= 691)
Missing primary
outcome (n= 106)
Demographic data
Age (years), mean (SD) 70.8 (11.3) 69.3 (11.9) 71.0 (11.1) 70.9 (14.6)
Number female (%) 328 (49) 49 (62) 356 (52) 50 (447)
Number white, n/N (%) 653/661 (99) 76/78 (97) 673/678 (99) 102/102 (100)
Number fully retired from
work, n/N (%)
465/647 (72) 47/74 (64) 462/660 (70) 63/99 (64)
Long-term conditions
Participants with
cardiovascular disease, n (%)
624 (93) 74 (94) 652 (94) 95 (90)
Participants with stroke TIA,
n (%)
215 (32) 26 (33) 247 (36) 39 (37)
Participants with diabetes
mellitus, n (%)
363 (54) 38 (48) 359 (52) 52 (49)
Participants with COPD or
asthma, n (%)
346 (52) 36 (46) 336 (49) 52 (49)
Participants with epilepsy,
n (%)
31 (5) 4 (5) 33 (5) 8 (8)
Participants with atrial
fibrillation, n (%)
226 (34) 3 (29) 250 (36) 31 (29)
Participants with a mental
health condition, n (%)
30 (4) 7 (9) 23 (3) 6 (6)
Participants with depression,
n (%)
246 (37) 37 (47) 233 (34) 43 (41)
Participants with dementia,
n (%)
21 (3) 6 (8) 23 (3) 10 (9)
Participants with a learning
disability, n (%)
6 (1) 1 (1) 4 (1) 3 (3)
Participants with rheumatoid
arthritis, n (%)
52 (8) 3 (4) 44 (6) 4 (4)
Number of chronic conditions,
median (IQR)
3.0 (3.0–3.0) 3.0 (3.0–3.0) 3.0 (3.0–3.0) 3.0 (3.0–3.0)
continued
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TABLE 40 Baseline characteristics of those participants with missing or completed primary outcome data (continued )
Baseline characteristics
Trial arm
Usual care (n= 749) Intervention (n= 797)
Non-missing
primary outcomea
(n= 670)
Missing primary
outcome (n= 79)
Non-missing
primary outcomea
(n= 691)
Missing primary
outcome (n= 106)
Clinical data
EQ-5D-5L score, mean (SD), n 0.556 (0.288), 668 0.304 (0.536), 79 0.593 (0.269), 689 0.446 (0.327), 106
Self-rated health, n (%)
Poor 141 (21) 30 (38) 118 (17) 32 (30)
Fair 304 (45) 35 (44) 302 (44) 41 (39)
Good 181 (27) 12 (15) 208 (30) 28 (26)
Very good 38 (6) 0 (0) 49 (7) 1 (1)
Excellent 0 (0) 0 (0) 5 (1) 0 (0)
Missing 6 (1) 2 (3) 10 (1) 4 (4)
Bayliss score, mean (SD), n 18.7 (12.5), 624 26.3 (12.7), 76 17.8 (11.8), 660 21.3 (13.0), 98
Bayliss count of conditions,
median (IQR), n
7.0 (5.0–9.0), 669 9.0 (7.0–11.0), 79 7.0 (5.0–9.0), 689 7.0 (5.0–10.0), 106
CARE GP score, mean (SD), n 38.7 (9.8), 638 39.3 (9.6), 76 40.9 (9.2), 683 40.4 (8.7), 98
CARE nurse score,
mean (SD), n
39.1 (9.1), 512 38.3 (8.9), 53 41.0 (8.9), 532 38.3 (11.0), 78
PACIC score, mean (SD), n 2.4 (1.0), 552 2.6 (0.9), 56 2.6 (0.9), 544 2.6 (1.0), 80
Care: patients’ priorities, n (%)
Not at all 134 (20) 11 (14) 94 (14) 20 (19)
Rarely 116 (17) 12 (15) 107 (15) 16 (15)
Some of the time 221 (33) 28 (35) 239 (35) 32 (30)
Almost always 171 (26) 23 (29) 225 (33) 30 (28)
Missing 25 (4) 5 (6) 26 (4) 8 (8)
Care: joined up, n (%)
Not at all 99 (15) 12 (15) 48 (7) 15 (14)
Rarely 86 (13) 10 (13) 60 (9) 9 (8)
Some of the time 2541 (37) 29 (37) 277 (40) 33 (31)
Almost always 207 (31) 22 (28) 279 (40) 42 (40)
Missing 27 (4) 6 (8) 27 (4) 7 (7)
Care: overall satisfaction, n (%)
Very dissatisfied 19 (3) 1 (1) 13 (2) 3 (3)
Fairly dissatisfied 32 (5) 5 (6) 21 (3) 3 (3)
Neither satisfied nor
dissatisfied
86 (13) 8 (10) 44 (6) 11 (10)
Fairly satisfied 228 (34) 23 (29) 210 (30) 28 (26)
Very satisfied 281 (42) 39 (49) 383 (55) 56 (53)
Missing 24 (4) 3 (4) 20 (3) 5 (5)
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TABLE 40 Baseline characteristics of those participants with missing or completed primary outcome data (continued )
Baseline characteristics
Trial arm
Usual care (n= 749) Intervention (n= 797)
Non-missing
primary outcomea
(n= 670)
Missing primary
outcome (n= 79)
Non-missing
primary outcomea
(n= 691)
Missing primary
outcome (n= 106)
HADS anxiety score, mean
(SD), n
6.2 (4.7), 663 8.3 (4.8), 77 5.9 (4.5), 684 7.6 (5.4), 101
HADS depression score, mean
(SD), n
6.7 (4.5), 665 9.0 (4.4), 78 6.0 (4.1), 687 8.2 (4.6), 104
MTBQ score, mean (SD), n 15.5 (15.7), 659 17.7 (17.2), 77 13.1 (14.6), 684 14.3 (15.3), 105
MTBQ score, median (IQR), n 10.0 (2.0–22.0), 659 12.0 (5.0–27.0), 77 10.0 (2.0–20.0), 684 10.0 (0.0–22.0), 105
MMAS-8, mean (SD), nb 6.7 (1.4), 670 6.5 (1.7), 79 6.8 (1.3), 691 6.6 (1.5), 106
TIA, transient ischaemic attack.
a All those who have died (n= 78) are counted as not missing primary outcome.
b Use of the © MMAS is protected by US Copyright laws. Permission for use is required. A licence agreement is available
from Donald E Morisky, MMAS Research LLC, 14725 NE 20th, St Bellevue, WA 98007, USA or from dmorisky@gmail.com.
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Appendix 18 Intracluster correlation coefficients
TABLE 41 Intracluster correlation coefficients
Outcome measure ICC 95% CI
EQ-5D-5L 0.00 0.00 to 0.00
Bayliss 0.00 0.00 to 0.00
CARE GP 0.00 0.00 to 0.00
CARE nurse 0.00 0.00 to 0.00
PACIC 0.02 0.00 to 0.07
HADS Anxiety 0.00 0.00 to 0.00
HADS Depression 0.00 0.00 to 0.00
Global MTBQ (multi-level linear regression) 0.00 0.00 to 0.00
MMAS-8 0.00 0.00 to 0.00
Carer EQ-5D-5L 0.00 0.00 to 0.00
Carer experience 0.00 0.00 to 0.00
Carer MTBQ 0.01 0.00 to 0.00
QOF performance 0.04 0.01 to 0.10
COCI 0.08 0.04 to 0.13
Visit Entropy 0.02 0.01 to 0.05
Duration of face-to-face consultations in surgery with GP 0.09 0.04 to 0.19
Duration of face-to-face consultations in surgery with nurse 0.19 0.10 to 0.32
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Appendix 19 Health economic analyses unit costs
TABLE 42 Health economic analyses unit costs
Service
Unit
cost (£) Notes Source
Social services
Social home care provided for social services 12.00 Independent sector home care provided
for social services, face to face, based on
30-minute visit
Curtis and Burns113
Daycare 61.00 Per client attendance
Social worker 55.00 Based on 1-hour appointment
Meals on wheels 7.03 Curtis210
Prescription charges
Prescription charge per item 8.40 Department of
Health and Social
Care211Prescription charge 3-month prepayment
certificate
29.10
Prescription charge 12-month prepayment
certificate
104.00
GP practice services
GP appointment Curtis and Burns;113
and Matheson212
Usual-care arm 51.84 Per surgery consultation lasting
14.4 minutes (3D data)
Intervention arm 48.60 Per surgery consultation lasting
13.5 minutes (3D data)
GP home visit 100.00 Based on consultation lasting 15 minutes
and 12 minutes’ travel time,213 plus 5 miles’
travel cost (NHS travel reimbursed at 56 p
per mile)
GP telephone call
Usual-care arm 41.40 Based on consultation lasting
11.5 minutes (3D data)
Intervention arm 32.40 Based on consultation lasting 9 minutes
(3D data)
GP e-mail consultation 21.60 Based on 6-minute consultation
Nurse appointment
Usual-care arm 10.85 Based on 15.1-minute appointment
(3D data), inflated from 2014/15 costs
Intervention arm 14.16 Based on 19.7-minute appointment
(3D data), inflated from 2014/15 costs
Nurse telephone call
Usual-care arm 4.24 Based on 5.9-minute call, inflated from
2014/15 costs
Intervention arm 5.03 Based on 7-minute call, inflated from
2014/15 costs
Nurse home visit 22.21 Based on 15-minute visit, 12 minutes’
travelling, 5 miles’ travel costs (NHS travel
reimbursed at 56 p per mile)
continued
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TABLE 42 Health economic analyses unit costs (continued )
Service
Unit
cost (£) Notes Source
HCA face-to-face appointment
Usual-care arm 3.45 Based on 9.4-minute appointment
(3D data), band 2 nurse
Intervention arm 3.59 Based on 9.8-minute appointment
(3D data), band 2 nurse
HCA telephone call
Usual-care arm 5.87 Based on 16-minute call (3D data),
band 2 nurse
HCA home visit 12.70 Based on 15-minute appointment,
12 minutes’ travelling, 5 miles’
travel costs, band 2 nurse (NHS travel
reimbursed at 56 p per mile)
Community services
Occupational therapy visit 16.00 Based on band 5 occupational therapist,
30-minute appointment
Curtis and Burns113
Occupational therapy home visit 25.20 Based on band 5 occupational therapist,
30-minute appointment, 12 minutes’
travelling, 5 miles’ travel costs (NHS
travel reimbursed at 56 p per mile)
Occupational therapy telephone call 5.33 Based on band 5 occupational therapist,
10-minute call
SALT visit 16.00 Based on band 5 SALT, 30-minute
appointment
SALT home visit 25.20 Based on band 5 SALT, 30-minute
appointment, 12 minutes’ travelling,
5 miles’ travel costs (NHS travel
reimbursed at 56 p per mile)
SALT telephone call 5.33 Based on band 5 SALT, 10-minute call
Physiotherapy visit 16.00 Based on band 5 physiotherapist,
30-minute appointment
Physiotherapy home visit 25.20 Based on band 5 physiotherapist,
30-minute appointment, 12 minutes’
travelling, 5 miles’ travel costs
(NHS travel reimbursed at 56 p per mile)
Physiotherapy telephone call 5.33 Based on band 5 physiotherapist,
10-minute call
Chiropody/podiatry visit 16.00 Based on band 5 podiatrist, 30-minute
appointment
Chiropody/podiatry home visit 25.20 Based on band 5 podiatrist, 30-minute
appointment, 12 minutes’ travelling,
5 miles’ travel costs (NHS travel
reimbursed at 56 p per mile)
Chiropody/podiatry telephone call 5.33 Based on band 5 podiatrist,
10-minute call
Community/district nurse/mental
health nurse visit
22.00 Based on band 6 district nurse,
30-minute appointment
Community/district nurse/mental
health nurse home visit
46.80 Based on band 6 district nurse, 1-hour
appointment including travel time,
5 miles’ travel costs (NHS travel
reimbursed at 56 p per mile)
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TABLE 42 Health economic analyses unit costs (continued )
Service
Unit
cost (£) Notes Source
Community/district nurse/mental
health nurse telephone call
7.33 Based on band 6 district nurse,
10-minute telephone call
NHS counselling/cognitive
behavioural therapy visit
21.00 Based on band 6 counsellor, 30-minute
appointment
NHS counselling/cognitive behavioural
therapy home visit
32.20 Based on band 6 counsellor, 30-minute
appointment, 12 minutes’ travelling,
5 miles’ travel costs (NHS travel
reimbursed at 56 p per mile)
NHS counselling/cognitive behavioural
therapy telephone call
7.00 Based on band 6 counsellor, 10-minute
call
NHS 111 telephone call 8.06 Maximum call cost of £7.80 in May 2013 Health
Committee214
NHS walk-in centre visit 41.74 Weighted mean of type 4 non-admitted,
emergency medicine per attendance
Department of
Health and Social
Care115
OOH service visit 82.32 Average OOH hourly evening rate was
£58.36 in 2005 compared with £36.75
for normal hours. Same differential
applied to current GP in-hours costs
O’Dowd;215 and
Curtis and Netten216
OOH service home visit 158.80
OOH service telephone call 65.74
Ambulance services
Paramedic at home not involving a hospital
visit
184.00 Ambulance services, see, treat and refer Curtis and Burns113
Ambulance to hospital 238.00 See and treat and convey (including
carbon 39 kgCO2e)
Curtis and Burns113
Investigations (in outpatients)
MRI 155.64 Department of
Health and Social
Care115DEXA 71.00
CT scan 104.88
ECG 72.00
Ultrasound 58.47
Fluoroscopy 147.68
Investigations (directly accessed)
Cytology 16.88 Directly accessed pathology services Department of
Health and Social
Care115Histopathology and histology 30.77 Directly accessed pathology services
Clinical biochemistry 1.18 Directly accessed pathology services
Haematology 3.10 Directly accessed pathology services
Immunology 6.42 Directly accessed pathology services
Microbiology 7.63 Directly accessed pathology services
Other 3.13 Directly accessed pathology services
MRI scan 147.25 Diagnostic imaging, directly accessed,
weighted mean
CT scan 107.52 Diagnostic imaging, directly accessed,
weighted mean
Ultrasound scan 52.82 Diagnostic imaging, directly accessed,
weighted mean
continued
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TABLE 42 Health economic analyses unit costs (continued )
Service
Unit
cost (£) Notes Source
Bone scan 210.11 Nuclear medicine, directly accessed,
weighted mean
X-ray 30.26 Directly accessed diagnostic services,
plain film
DEXA 68.29 Diagnostic imaging, direct access
ECG 67.06 Diagnostic imaging, direct access,
≥ 19 years
Secondary care
Outpatient attendance 135.27 Weighted mean, consultant led Department of
Health and Social
Care115Day case 733.31 Weighted mean of all day cases
Elective inpatient 3749.81 Weighted mean
Non-elective inpatient, long stay 3058.14 Weighted mean
Non-elective inpatient, short stay 615.83 Weighted mean
Elective excess bed-day 361.67 Weighted mean
Non-elective excess bed-day 298.41 Weighted mean
Individual HRGs Mapped directly from reference costs file
Productivity losses
Median hourly wage, age 22–29 10.52 Excluding overtime, for employees on
adult wages not affected by absence
Office for National
Statistics116
Median hourly wage, age 30–39 13.57
Median hourly wage, age 40–49 13.92
Median hourly wage, age 50–59 13.18
Median hourly wage, age 60+ 11.26
CT, computerised tomography; DEXA, dual-energy X-ray absorptiometry; ECG, electrocardiogram; MRI, magnetic resonance
imaging; OOH, out-of-hours; SALT, speech and language therapist.
Note
Inflated figures, where applicable, were calculated using Bank of England calculator.217
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Appendix 20 Changes to the 3D health
economics analysis plan
U tility scores were derived from responses to the EQ-5D-5L cross-mapped to valuations obtained for theEQ-5D-3L instrument from a UK population using the methods of van Hout et al.109 Prior to starting
the analysis, NICE issued a position statement recommending this approach over the planned use of the
English EQ-5D-5L value set. In consultation with the 3D DMC, a decision was taken to follow NICE advice.
1. Bootstrapping techniques were ultimately not used to derive CIs as resource intensity was an issue
given the scale of missing data. The seemingly unrelated regression method used to estimate mean
incremental costs and outcomes was used to generate CIs.
2. Manual data capture of 3D appointment durations was undertaken only for a random sample of
appointments to allow an estimate of the difference compared with normal GP appointments. It was
not possible to accurately identify the 3D appointments in the GP practice downloads, which could
have led to double counting had they been costed separately.
3. The economic researcher was unblinded prior to the multiple imputation process being undertaken.
This was necessitated by the decision to apply arm-specific costs for practice-based consultations.
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Appendix 21 Mean number of health and social
care resource-use contacts over 15 months of
follow-up
TABLE 43 Mean number of health and social care resource-use contacts over 15 months of follow-up
Services
Trial arm, mean (SD), n
Usual care Intervention
Inpatient stays 0.50 (1.05), 722 0.55 (1.09), 766
Inpatient nights 4.51 (16.6), 722 3.84 (11.94), 766
Outpatient visits 3.60 (4.00), 722 3.64 (3.73), 766
Day cases 0.15 (0.54), 722 0.14 (0.51), 766
Accident and emergency visits 0.63 (1.41), 722 0.61 (1.14), 766
Ambulance journeys 0.55 (1.83), 601 0.60 (3.50), 615
GP face-to-face consultations 7.27 (5.93), 715 8.70 (6.26), 754
GP home visits 0.64 (1.89), 715 0.79 (2.16), 754
GP telephone calls 2.88 (5.00), 715 2.99 (4.53), 754
Nurse face-to-face consultations 5.40 (5.70), 715 7.93 (10.09), 754
Nurse home visits 0.06 (0.40), 715 0.09 (0.54), 754
Nurse telephone calls 0.60 (1.56), 715 0.76 (1.63), 754
HCA face-to-face consultations 2.42 (4.30), 715 3.55 (7.75), 754
HCA GP home visits 0.00 (0.05), 715 0.08 (0.28), 754
HCA GP telephone calls 0.03 (0.17), 715 0.03 (0.17), 754
Prescribed medications 143.44 (130.57), 717 132.23 (117.36), 755
GP investigations 19.60 (16.52), 717 22.61 (16.99), 755
Pharmacist reviews 722 0.78 (0.42), 766
Occupational therapist clinic visits 0.18 (1.10), 601 0.2 (1.28), 615
Occupational therapist home visits 0.24 (1.29), 601 0.08 (0.5), 615
Occupational therapist telephone calls 0.06 (0.53), 601 0.01 (0.14), 615
SALT clinic visits 0.02 (0.33), 601 0.1 (1.03), 615
SALT home visits 0.04 (0.69), 601 0 (0.00), 615
SALT telephone calls 0.00 (0.08), 601 0 (0.00), 615
Physiotherapist clinic visits 0.80 (2.74), 601 1.03 (2.67), 615
Physiotherapist home visits 0.16 (1.34), 601 0.15 (0.92), 615
Physiotherapist telephone calls 0.00 (0.06), 601 0.01 (0.11), 615
Podiatrist clinic visits 1.26 (2.83), 601 1.19 (2.53), 615
Podiatrist home visits 0.13 (0.84), 601 0.21 (1.46), 615
Podiatrist telephone calls 0.01 (0.13), 601 0.02 (0.49), 615
continued
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TABLE 43 Mean number of health and social care resource-use contacts over 15 months of follow-up (continued )
Services
Trial arm, mean (SD), n
Usual care Intervention
Community mental health nurse clinic contacts 0.27 (2.59), 601 0.08 (0.42), 615
Community mental health nurse home visits 0.21 (2.45), 601 0.35 (5.16), 615
Community mental health nurse telephone calls 0.02 (0.23), 601 0.01 (0.13), 615
District nurse home visits 1.21 (4.08), 601 1.48 (6.54), 615
District nurse telephone calls 0.03 (0.30), 601 0.05 (0.84), 615
Counsellor clinic visits 0.24 (2.34), 601 0.14 (0.99), 615
Counsellor home visits 0.01 (0.10), 601 0.01 (0.18), 615
Counsellor telephone calls 0.00 (0.08), 601 0.00 (0.06), 615
NHS 111 telephone calls 0.21 (0.85), 601 0.18 (0.57), 615
NHS walk-in centre visits 0.08 (0.41), 601 0.09 (0.50), 615
GP out-of-hours clinic visits 0.08 (0.34), 601 0.07 (0.28), 615
GP out-of-hours home visits 0.04 (0.33), 601 0.06 (0.56), 615
GP out-of-hours telephone calls 0.02 (0.20), 601 0.03 (0.28), 615
Paramedic attendances at home 0.09 (0.43), 601 0.05 (0.29), 615
Other health-care clinic visits 0.11 (0.88), 601 0.25 (3.24), 615
Other health-care home visits 0.06 (0.65), 601 0.04 (0.41), 615
Other health-care telephone calls 0.01 (0.19), 601 0.01 (0.10), 615
Carer contacts 30.93 (148.26), 601 25.27 (135.78), 615
Daycare contacts 2.14 (17.53), 601 1.17 (10.50), 615
Meals on wheels 2.66 (28.32), 601 0.93 (18.98), 615
Social worker contacts 0.77 (11.35), 601 0.45 (3.98), 615
SALT, speech and language therapist.
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Appendix 22 Clinicians’ attitudes at baseline
TABLE 44 Clinicians’ attitudes at baseline
Attitudes
Number (%) of clinicians who
agree or strongly agree
Total
Doctors
(77 doctors from
31 practices)
Nurses
(57 nurses from
29 practices)
Patients’ main concerns may be overlooked during review
of LTCs, n (%)
56 (73) 25 (44) 81 (60)
Depression is difficult to identify reliably without using a measure
(such as PHQ-9), n (%)
8 (10) 21 (37) 29 (22)
Polypharmacy is difficult for patients to manage, n (%) 72 (94) 44 (77) 116 (87)
Multimorbidity is difficult for clinicians to manage, n (%) 67 (87) 39 (68) 106 (79)
Patients with multimorbidity have a special need for holistic,
patient-centred care, n (%)
69 (90) 52 (91) 121 (90)
Holistic, patient-centred care is enhanced by continuity of care, n (%) 76 (99) 56 (98) 132 (99)
Patients with ≥ 3 conditions need longer appointments
to address all their concerns, n (%)
71 (92) 55 (96) 126 (94)
Patients being reviewed for a LTC should be given a written
care plan, n (%)
42 (55) 39 (68) 81 (60)
Patients prefer it if I make a plan, instead of asking them what they
would like to do, n (%)
11 (14) 17 (30) 28 (21)
Patients are more likely to keep to goals and plans that they suggest
themselves, n (%)
57 (74) 47 (82) 104 (78)
In this practice, the care patients receive for their LTCs is well
co-ordinated, n (%)
49 (64) 44 (77) 93 (69)
In this practice, review of LTCs is too disease-orientated and not
holistic enough, n (%)
30 (39) 18 (32) 48 (36)
LTC, long-term condition.
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Appendix 23 Session A numerical training
evaluation results
TABLE 45 Session A training evaluation results
Questionsa
Strongly disagree,
n (%) Disagree, n (%) Agree, n (%)
Strongly agree,
n (%) Total, n
Ayrshire (N = 27)
1. Reflect on problems 20 (74) 7 (26) 27
2. Identify strategies 21 (78) 6 (22) 27
3. Understand in broad terms 20 (74) 7 (26) 27
The training was relevant 15 (56) 12 (44) 27
The materials were helpful 18 (67) 9 (33) 27
Practice able to implement 12 (44) 15 (56) 27
Feel positive 13 (48) 14 (52) 27
3D will benefit patients 16 (59) 11 (41) 27
Bristol (N = 35)
1. Reflect on problems 1 (3) 26 (74) 8 (23) 35
2. Identify strategies 3 (9) 24 (71) 7 (20) 34
3. Understand in broad terms 2 (6) 22 (63) 11 (31) 35
The training was relevant 25 (71) 10 (29) 35
The materials were helpful 28 (80) 7 (20) 35
Practice able to implement 26 (74) 9 (26) 35
Feel positive 23 (66) 12 (34) 35
3D will benefit patients 1 (3) 19 (56) 14 (41) 34
Manchester (N = 26)
1. Reflect on problems 19 (73) 7 (27) 26
2. Identify strategies 18 (69) 8 (31) 26
3. Understand in broad terms 15 (58) 11 (42) 26
The training was relevant 14 (54) 12 (46) 26
The materials were helpful 17 (65) 9 (35) 26
Practice able to implement 12 (46) 14 (54) 26
Feel positive 1 (4) 6 (23) 19 (73) 26
3D will benefit patients 8 (31) 18 (69) 26
a Refer to training evaluation form part A for full wording of questions.
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Appendix 24 Session B numerical training
evaluation results
TABLE 46 Session B training evaluation results
Questionsa
Strongly disagree,
n (%)
Disagree,
n (%)
Agree,
n (%)
Strongly agree,
n (%) Total, n
Ayrshire (N = 27)
1. Be familiar with use of template 4 (15) 15 (56) 8 (30) 27
2. Consider issues around med
adherence
3 (11) 17 (63) 7 (26) 27
3. Using case study, how best to create
care plan
3 (11) 16 (59) 8 (30) 27
4. Appreciate next steps 2 (8) 16 (62) 8 (31) 26
Training will benefit personal practice 1 (4) 21 (81) 4 (15) 26
Programme materials helpful 22 (81) 5 (19) 27
Practice able to implement 3D 19 (70) 8 (30) 27
People with multimorbidity will benefit 1 (4) 17 (63) 9 (33) 27
I think I have the skills 19 (73) 7 (27) 26
Feel confident about using template 3 (12) 17 (65) 6 (23) 26
Bristol (N = 33)
1. Be familiar with use of template 2 (6) 20 (61) 11 (33) 33
2. Consider issues around medication
adherence
2 (6) 15 (48) 14 (45) 31
3. Using case study, how best to create
care plan
1 (3) 3 (9) 17 (52) 12 (36) 33
4. Appreciate next steps 4 (12) 22 (67) 7 (21) 33
Training will benefit personal practice 3 (9) 26 (79) 4 (12) 33
Programme materials helpful 26 (79) 7 (21) 33
Practice able to implement 3D 1 (3) 23 (72) 8 (25) 32
People with multimorbidity will benefit 3 (10) 15 (48) 13 (42) 31
I think I have the skills 26 (79) 7 (21) 33
Feel confident about using template 3 (9) 23 (70) 7 (21) 33
Manchester (N = 21)
1. Be familiar with use of template 9 (43) 12 (57) 21
2. Consider issues around med
adherence
12 (60) 8 (40) 20
3. Using case study, how best to create
care plan
12 (57) 9 (43) 21
4. Appreciate next steps 11 (52) 10 (48) 21
Training will benefit personal practice 11 (52) 10 (48) 21
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TABLE 46 Session B training evaluation results (continued )
Questionsa
Strongly disagree,
n (%)
Disagree,
n (%)
Agree,
n (%)
Strongly agree,
n (%) Total, n
Programme materials helpful 13 (62) 8 (38) 21
Practice able to implement 3D 9 (43) 12 (57) 21
People with multimorbidity will benefit 10 (48) 11 (52) 21
I think I have the skills 14 (67) 7 (33) 21
Feel confident about using template 13 (62) 8 (38) 21
a Refer to training evaluation form B for full wording of questions.
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Appendix 25 3D intervention practices: baseline
characteristics, administrative implementation and
intervention reach
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TABLE 47 3D intervention practices: baseline characteristics, administrative implementation and intervention reach
Practice
List size to
nearest
500 IMD
b
Number of
GPs and
nurses
Number
involved in
3D delivery
Combined reviews at
baseline
Continuity
(Visit
Entropy)
c
Number
of 3D
patients
Administration
staff involved
Method of
inviting
patients
Paired
appointments
Number of
attempts to
arrange
review Length of 3D reviews
Reach, n (%)
of patients
reviewed
GPs Nurses GPs Nurses Combined
Partially
combined Start End First Second Nurse GP First Second
20 4500 7.9 4 2 2 2 Not combined 114.5 42 39 All receptionists,
IT staff member
and LTC recall
administrator
Letter inviting
call
No 3 3 40 minutes 20 minutes 36 (71) 26 (67)
25 15,000 15.1 16 5 3 2 Yes 81 58 53 All receptionists,
practice manager,
two administrators
Letter inviting
call
Yes 3 3 40 minutes 20 minutes 52 (90) 40 (75)
26
b
5500 14.5 4 3 3 3 Yes (BM) 90.2 57 49 All Letter inviting
call
No 3 2 First 30 minutes
Second 20 minutes
First 20 minutes
Second 10 minutes
44 (80) 40 (82)
27 10,000 11.2 10 4 2 2 Yes 80.3 48 42 All receptionists,
assistant practice
manager, secretary
Appointment
letter
No 2 2 40 minutes 20 minutes 44 (92) 36 (86)
30 10,000 35.9 12 5 3 3 Yes 61.9 48 46 Research nurse led.
Not all aware
Telephone
call
No 3 3 40–60 minutes ? 40 (83) 34 (74)
40 10,500 7.9 9 3 3 1 Yes 87.8 46 43 Administration
manager. All
aware
Appointment
letter
Yes 2 2 First 40 minutes
Second 20 minutes
20 minutes 37 (80) 20 (47)
42 6000 4.8 6 2 2 1 Yes 54.5 49 44 Lead administrator.
All aware
Appointment
letter
Yes 2 2 First 40 minutes
Second 20 minutes
20 minutes 45 (92) 22 (50)
45 8000 30.1 6 3 5 2 Yes 84.6 54 46 Admin manager.
All aware
Appointment
letter
Yes 2 2 First 40 minutes
Second 20 minutes
20 minutes 43 (80) 35 (76)
46
b
4000 25.8 4 2 3 2 Yes 75.2 48 44 One specific
person. All aware
Appointment
letter
Yes 4 4 40–50 minutes 20 minutes 45 (94) 41 (93)
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Practice
List size to
nearest
500 IMD
b
Number of
GPs and
nurses
Number
involved in
3D delivery
Combined reviews at
baseline
Continuity
(Visit
Entropy)
c
Number
of 3D
patients
Administration
staff involved
Method of
inviting
patients
Paired
appointments
Number of
attempts to
arrange
review Length of 3D reviews
Reach, n (%)
of patients
reviewed
GPs Nurses GPs Nurses Combined
Partially
combined Start End First Second Nurse GP First Second
48
a
7500 57.3 2 1 75.9 44 42 14 (32) 0
60
b
15,000 29.6 13 4 5 2 Yes (BM) 99.1 43 39 All receptionists
and IT lead. All
aware
Letter inviting
call
Some not
paired
3 2 Depending
conditions
20 minutes 33 (77) 17 (44)
61 13,500 9.4 10 3 9 4 Yes 90.3 48 42 All receptionists
and LTC recall
administrator
Letter inviting
call
Yes 2 2 40–50 minutes 20 minutes 36 (75) 19 (45)
65 13,500 25.3 9 7 0 1 Yes 65.2 38 32 Nurse practitioner
led. Not all aware
Letter inviting
call
Saw nurse only 2 2 Decided per
patient
NA 25 (66) 3 (9)
66 14,500 10.4 12 4 3 2 Yes (BM) 69.3 58 50 Administration
manager. Unsure if
all aware
Appointment
letter
Yes 2 2 40–50 minutes 20 minutes 39 (67) 25 (50)
69
b
14,500 10.9 3 2 Yes (BM) 76.5 55 53 Three
administrators. Not
all aware
Appointment
letter
Some not
paired
? ? Variable 20 minutes 20 (38) 0 (0)
70 5000 8 4 2 4 3 Yes 111.7 52 47 Receptionist and
admin manager.
Not all aware
Telephone
call
Yes 2 2 Decided per patient 36 (69) 25 (53)
BM, birthday month; LTC, long-term condition.
a Practice withdrew from case study.
b Case study practices.
c Greater continuity of care indicated by lower Visit Entropy score.
Note
Dark green, practice withdrew; light green, case study practices.
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Appendix 26 Variation in implementation
between intervention practices
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TABLE 48 Variation in implementation between intervention practices
Intervention
practice ID
Participants, n (%)
Continuity of care at
follow-up, mean (SD),
number of participants
Visit Entropy at follow-up,
mean (SD), number of
participants
Total
participants
No 3D
reviews
One full 3D review
(GP and nurse)
Two full 3D reviews
(GP and nurse) Incomplete reviews
20 41 5 (12.2) 10 (24.4) 26 (63.4) 0 (0.0) 0.4 (0.3), 41 130.5 (75.1), 41
25 62 11 (17.7) 12 (19.4) 39 (62.9) 0 (0.0) 0.5 (0.3), 56 114.7 (80.2), 56
26 57 11 (19.3) 5 (8.8) 40 (70.2) 1 (1.8) 0.4 (0.3), 55 104.2 (71.8), 55
27 51 6 (11.8) 5 (9.8) 40 (78.4) 0 (0.0) 0.4 (0.3), 48 100.9 (79.3), 48
30 48 3 (6.3) 3 (6.3) 37 (77.1) 5 (10.4) 0.3 (0.2), 47 86.7 (56.3), 47
40 46 6 (13.0) 17 (37.0) 20 (43.5) 3 (6.5) 0.5 (0.3), 46 98.5 (75.9), 46
42 50 4 (8.0) 23 (46.0) 23 (46.0) 0 (0.0) 0.3 (0.1), 46 56.2 (30.4), 46
45 54 11 (20.4) 7 (13.0) 36 (66.7) 0 (0.0) 0.5 (0.3), 54 130.2 (79.9), 54
46 49 3 (6.1) 5 (10.2) 40 (81.6) 1 (2.0) 0.5 (0.3), 48 111.1 (72.7), 48
48 46 26 (56.5) 18 (39.1) 0 (0.0) 2 (4.4) 0.3 (0.3), 41 88.7 (68.6), 41
60 43 9 (20.9) 15 (34.9) 17 (39.5) 2 (4.7) 0.6 (0.3), 43 110.5 (82.3), 43
61 49 10 (20.4) 16 (32.7) 21 (42.9) 2 (4.1) 0.4 (0.3), 46 97.7 (70.1), 46
65 38 10 (26.3) 23 (60.5) 2 (5.3) 3 (7.89) 0.4 (0.3), 38 106.3 (76.3), 38
66 57 18 (31.6) 14 (24.6) 25 (43.9) 0 (0.0) 0.3 (0.3), 56 95.9 (79.0), 56
69 54 23 (42.6) 19 (35.2) 0 (0.0) 12 (22.2) 0.1 (0.1), 52 68.4 (55.5), 52
70 52 15 (28.9) 13 (25.0) 24 (46.2) 0 (0.0) 0.4 (0.2), 52 89.0 (61.8), 52
Total 797 171 (21.5) 205 (25.7) 390 (48.9) 31 (3.9)
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Appendix 27 Log of deceased participants
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Study ID
number Centre Sex Allocation Date of death
Age at
death
(years) Cause of death Category Expectedness
3D/LTC/No
review done Relationship
u200375 Manchester F INT April 2016 70–74 Cholangitis + pancreatic sepsis Acute Unexpected 3D Unrelated
u210407 Manchester F UC September 2015 70–74 Ischaemic heart disease CVD Unexpected LTC Unrelated
u220071 Manchester M UC January 2017 80–84 Heart failure CVD Expected LTC Unrelated
u220351 Manchester M UC September 2016 85–89 CCF CVD Expected None Unrelated
u230045 Manchester M UC September 2016 80–84 Unknown Unknown Unexpected LTC Unrelated
u230176 Manchester M UC October 2015 85–89 Community-acquired pneumonia Respiratory Unexpected LTC Unrelated
u230468 Manchester M UC September 2016 85–89 Coroners inquest held September 16:
accidental death
Injury Unexpected None Unrelated
u250012 Manchester F INT May 2016 85–89 Myocardial infarction CVD Expected None Unrelated
u250181 Manchester F INT November 2015 70–74 Breast cancer Cancer Expected LTC Unrelated
u250335 Manchester F INT May 2016 60–64 1. Chronic type 2 respiratory failure
2. Obstructive sleep apnoea and COPD
3. Cerebral vascular disease
Respiratory Expected None Unrelated
u250467 Manchester M INT December 2015 90–95 1. Acute LVF
2. Severe coronary atheroma
(post mortem)
CVD Unexpected 3D Unrelated
u260070 Manchester M INT September 2016 85–89 Metastatic rectal carcinoma Cancer Expected 3D Unrelated
u260140 Manchester M INT September 2015 55–59 Acute myocardial infarction CVD Unexpected None Unrelated
u260186 Manchester M INT September 2016 80–84 Severe COPD, CKD, diabetes mellitus Multiple Expected None Unrelated
u270136 Manchester F INT January 2016 65–69 Lung cancer Cancer Expected LTC Unrelated
u270245 Manchester F INT January 2016 90–94 Ischaemic heart disease CVD Unexpected None Unrelated
u270266 Manchester M INT October 2016 85–89 Awaiting coroner’s report – collapse
natural cause of death
Old age Unexpected 3D Unrelated
u270311 Manchester F INT April 2016 80–84 Coroner’s inquest held April 2016:
natural causes
Old age Expected 3D Unrelated
u270324 Manchester F INT March 2016 80–84 Coroner’s inquest held March 2016:
died as a result of a combination of
the effects of an accident and natural
disease
Multiple Unexpected 3D Unrelated
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Study ID
number Centre Sex Allocation Date of death
Age at
death
(years) Cause of death Category Expectedness
3D/LTC/No
review done Relationship
u270369 Manchester M INT May 2016 85–89 Alzheimer’s disease/old age Old age Unexpected 3D Unrelated
u270444 Manchester M INT December 2015 85–89 COPD/community-acquired
pneumonia
Respiratory Unexpected 3D Unrelated
u280280 Manchester M UC April 2016 90–94 Hospital-acquired pneumonia Acute Unexpected LTC Unrelated
u290329 Manchester M UC July 2016 85–89 Heart failure, ischaemic heart disease CVD Expected LTC Unrelated
u300252 Manchester F INT October 2016 90–95 Septicaemia/AKI/Pneumonia Multiple Unexpected 3D Unrelated
u300441 Manchester M INT November 2016 85–89 Alzheimer’s disease Old age Expected 3D Unrelated
u310031 Manchester M UC April 2016 85–89 Malignant neoplasms of lung Cancer Expected LTC Unrelated
u310110 Manchester F UC November 2015 80–84 CVA CVD Unexpected LTC Unrelated
u310217 Manchester F UC September 2016 85–89 Sepsis and cellulitis Acute Expected LTC Unrelated
g400486 Ayrshire M INT December 2015 55–59 Head injury through accident Injury Unexpected None Unrelated
g410263 Ayrshire M UC June 2016 75–79 Bronchopneumonia secondary to
bronchogenic carcinoma
Cancer Unexpected LTC Unrelated
g410318 Ayrshire M UC July 2016 70–74 Neuropathic sepsis and cardiac failure:
non-small-cell lung cancer
Cancer LTC Unrelated
g410445 Ayrshire F UC September 2015 75–79 Hypercapnoeaic encephalopathy Respiratory Unexpected LTC Unrelated
g420060 Ayrshire F INT June 2016 70–74 Bronchial carcinoma Cancer Expected None Unrelated
g420330 Ayrshire F INT February 2016 60–64 Renal cancer/fluid in lungs Cancer Expected 3D Unrelated
g420471 Ayrshire M INT June 2016 70–74 Bladder carcinoma Cancer Expected 3D Unrelated
g450154 Ayrshire F INT August 2016 75–79 COPD (sudden death at home) Respiratory Unexpected 3D Unlikely to
be related
g450165 Ayrshire M INT September 2016 80–84 Brain tumour Cancer Unexpected LTC Unrelated
g450290 Ayrshire M INT November 2015 75–79 Adenocarcinoma Cancer Expected None Unrelated
g450411 Ayrshire F INT September 2016 80–84 Metastatic carcinoma (unknown
primary)
Cancer Expected 3D Unrelated
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Study ID
number Centre Sex Allocation Date of death
Age at
death
(years) Cause of death Category Expectedness
3D/LTC/No
review done Relationship
g450424 Ayrshire F INT May 2016 85–89 Hip fracture leading to hospital
admission and then cardiac event
Injury Unexpected None Unrelated
g450469 Ayrshire F INT June 2016 85–89 Oesophageal cancer Cancer Expected 3D Unrelated
g450545 Ayrshire F INT April 2016 60–64 Pulmonary embolism: presumed.
No post mortem
Acute Unexpected 3D Unrelated
g460119 Ayrshire F INT March 2016 60–64 Pulmonary oedema/ischaemic heart
disease
CVD Unexpected 3D nurse Unrelated
g460188 Ayrshire M INT June 2016 60–64 Accidental death Injury Unexpected 3D Unrelated
g470397 Ayrshire F UC November 2016 80–84 Hospital-acquired pneumonia,
biventricular failure, rheumatic vascular
heart disease, CKD stage 4, COPD
Multiple Unexpected LTC Unrelated
g490361 Ayrshire F UC December 2015 70–74 Death at home: unexpected
hypertensive heart disease, COPD
CVD Unexpected LTC Unrelated
g490451 Ayrshire F UC May 2016 80–84 Psychotic depression, delirium,
congestive heart failure, type 2
diabetes mellitus
Multiple Unexpected None Unrelated
b600013 Bristol F INT May 2016 80–84 Fall, broke pubic ramus and wrist.
Unknown cause of death. Coroner’s
inquest:
1. MI
2. Type 2 diabetes mellitus and COPD
CVD Unexpected 3D Unrelated
b600130 Bristol M INT February 2016 70–74 Ruptured aortic aneurysm Acute Unexpected None Unrelated
b600362 Bristol M INT March 2016 80–84 Heart failure; IHD, COPD + PE CVD Unexpected None Unrelated
b610028 Bristol M INT August 2015 65–69 Myocardial infarction CVD Unexpected None Unrelated
b610224 Bristol M INT March 2016 85–89 Post mortem done. Result not yet
available. Died in hospital. Did not
issue death certificate. Had FEV1,
subdural and deteriorated. Not sudden
Unknown Expected 3D Unrelated
b610248 Bristol F INT June 2016 80–84 Ischaemic stroke CVD Unexpected LTC Unrelated
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Study ID
number Centre Sex Allocation Date of death
Age at
death
(years) Cause of death Category Expectedness
3D/LTC/No
review done Relationship
b610403 Bristol F INT April 2016 85–89 Heart failure, renal failure CVD Expected 3D Unrelated
b620274 Bristol M UC August 2015 80–84 Bronchopneumonia, CML Cancer Unexpected LTC Unrelated
b620316 Bristol F UC February 2016 85–89 Ischaemic heart disease CVD Expected LTC Unrelated
b630174 Bristol M UC April 2016 80–84 Urosepsis Acute Expected LTC Unlikely to
be related
b630277 Bristol F UC July 2015 75–79 1. Acute left ventricular failure
2. Coronary artery atherosclerosis
CVD Unexpected None Unrelated
b630470 Bristol M UC March 2016 90–94 1. Bronchopneumonia
2. COPD
Respiratory Unexpected LTC Unrelated
b630518 Bristol F UC May 2016 85–89 1. Chest infection
2. Vascular dementia
Old age Expected None Unrelated
b640280 Bristol F UC July 2016 70–74 Infective exacerbation of
bronchiectasis
Respiratory Expected LTC Unrelated
b650284 Bristol M INT August 2016 85–89 Metastatic lung cancer Cancer Unexpected 3D Unrelated
b650307 Bristol F INT January 2016 75–79 End-stage renal failure/ischaemic
nephropathy. CCF COPD and diabetes
mellitus
Multiple Expected None Unrelated
b660068 Bristol F INT January 2016 75–79 Ruptured mycotic abdominal aortic
aneurysm. Staphylococcal bacteraemia
Acute Unexpected LTC Unrelated
b660121 Bristol M INT December 2016 75–79 Malignant glioma Cancer Expected 3D Unrelated
b670422 Bristol F UC September 2016 75–79 Subdural haemorrhage – Coroner’s
inquest:
1. Subdural haematoma
2. Fall
3. Inquest – accident
Injury Unexpected LTC Unrelated
b670524 Bristol M UC December 2016 85–89 Unknown. Had a coroner’s post
mortem. Outcome of this not received
(probable chest infection)
Unknown Expected LTC Unrelated
b680167 Bristol M UC January 2016 80–84 Aspiration pneumonia Acute Expected LTC Unrelated
b680356 Bristol F UC July 2016 85–89 Cerebrovascular disease CVD Expected LTC Unrelated
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Study ID
number Centre Sex Allocation Date of death
Age at
death
(years) Cause of death Category Expectedness
3D/LTC/No
review done Relationship
b680466 Bristol M UC July 2016 90–94 Frailty of old age Old age Expected LTC Unrelated
b680506 Bristol M UC November 2016 60–64 1. Septic shock
2. Pneumonia
Respiratory Unexpected LTC Unrelated
b690366 Bristol F INT December 2016 80–84 Bronchopneumonia Respiratory Unexpected 3D Unrelated
b700191 Bristol M INT November 2016 70–74 Metastatic cancer Cancer Expected 3D Unrelated
b700266 Bristol M INT November 2016 50–54 Sepsis and multiorgan failure –
bacterial peritonitis
Acute Expected 3D Unrelated
b700324 Bristol F INT November 2016 75–79 Unknown – coroner’s inquest:
1. Haemopericardium
2. Ruptured aortic aneurysm
CVD Unexpected 3D Unrelated
b700471 Bristol F INT May 2016 90–94 1. Lower respiratory tract infection
2. Left neck femur fracture
Injury Unexpected None Unrelated
b710236 Bristol M UC October 2016 70–74 Metastatic carcinoma Cancer Expected LTC Unrelated
b710258 Bristol M UC February 2017 75–79 Unknown (coroner) probably COPD.
Coroner’s report: COPD. No inquest
Respiratory Expected None Unrelated
AKI, acute kidney injury; CCF, congestive cardiac failure; CKD, chronic kidney disease; CML, chronic myeloid leukaemia; CVA, cerebrovascular accident; CVD, cardiovascular disease;
FEV1, forced expiratory volume in 1 second; IHD, ischaemic heart disease; INT, intervention; LTC, long-term condition; LVF, left ventricular failure; MI, myocardial infarction; PE, pulmonary
embolism; UC, usual care.
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